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1.1. A brief history of the eye and human vision
Human vision is a highly complex process with a range of physical and per­
ceptual limitations, yet it is one of the primary sources of information we obtain 
from the outside world. The human being has been surveying optical phenom­
ena and trying to explain visual perception since antiquity, reaching back to 
ancient Greek civilisation.
The Atomists, a group of ancient Greek physical philosophers, were the first 
to deliver non-religious explanations to a number of physical processes, thereby 
introducing several theories. Democritus (ca. 460 BC -  370 BC) and Epicurus 
(ca. 341 BC -  270 BC) developed different theories based on the principle that 
an object can only be perceived if it directly comes into contact with the eye.1 
Democritus believed that a reflection of an object forms a new entity called the 
air impression, which is compressed air between the object and the viewer’s 
eye. This entity of compressed air by intrinsically containing various colours 
of the object exists in the environment and eventually projects out in the eye.1,2 
Democritus also claimed that there are four basic colours: white, black, red, and 
green. The rest are produced by mixing these four basic colours.3 Epicurus pos­
tulated a theory of images, based on rays of particles continuously emanating 
from the object’s body directed into the eye, as a continuous stream.1,2
In contrast to the Atomists, Plato (ca. 427 BC -  347 BC) introduced a combi­
nation of the intromission theory that Democritus and Epicurus proposed, and 
the extramission theory which postulates that light emanated from the eye, seiz­
ing objects with its rays creating the feeling of vision. According to Plato, the 
eye contains an “inner fire” that by nature is attracted towards an “external fire” 
which has the same properties of sunlight. The attraction and subsequent fusion 
of the inner and external fire creates a constant flow of atoms, that through a 
filter mechanism in the inner eye creates an eidolon. Subsequently, the eidolon 
through the eye and the optic nerve, reaches the soul which in turn, with the 
mechanistic “collaboration” of the human body, creates an optical stimulus.1
In the second century AD Galen (ca. 133-200) supported the extramission 
theory because it corresponded well with the conception of image as a function 
of an optical pneuma which travels from the brain towards the eyes where it is 
projected. Galen defined many of the basic features of the anatomy and physiol­
ogy of the eye that until the seventeenth century remained unchanged. He also 
noted and defined principles of binocular vision. Galen paid particular attention 
to the crystalline lens, which he described as the primary instrument of vision.4,5
The eye was also a subject of special interest in medieval Islamic medicine 
and philosophy. Alhazen, one of the most prominent amongst Arab philoso­
phers, explained the modern intromission theory of vision and developed the 
laws of reflection, refraction, and transmission even if in a rather broad sense.4,6
Finally, progress in understanding the mechanism of vision was made possible 
by the detailed study of the anatomy of the eye. Until the beginning of the 17th 
century it was believed that vision is based on the anterior surface of the crystal-
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line lens. In 1583 Felix Platter, a Swiss physician, argued that the optic nerve 
was the primary organ of vision.
In 1604, Kepler offered the first theory of an image that was focused by the 
lens and projected on an inverted mode onto the retina.5,7 The latter was also 
proved by Descartes7 and served as the basis to explain phenomena which are 
studied even nowadays e.g. central visual acuity, image formation and dark ad­
aptation.
1.2. Anatomy and physiology of the human eye 
1.2.1. General anatomy of the eye
The eye and the general process o f vision
The human visual system can identify and discriminate between an incredibly 
diverse assortment of stimuli that may be chromatic or achromatic, in motion or 
not, patterned or unpatterned.
The human eye consists of three main layers, enclosing three transparent struc­
tures. The outermost layer which maintains the shape of the globe and serves as 
a protective coat is formed by the sclera and cornea, structures both containing 
connective tissue. Underneath, the middle layer consists of the choroid, ciliary 
body, and iris serving mostly as a vascular and nutritional nodal point for the 
eye. The innermost layer, which serves as the sensory part of the eye, is the 
retina (Figure 1).
ciliary body
Figure 1. Gross anatomy of the human eye (adapted from: http://webvision.med. 
utah.edu/html).
Light from an observable objects enters the eye by first passing through the 
cornea and needs to focus on the retina. The clear cornea which covers the front 
of the eye helps to focus incoming light. Subsequently light proceeds through 
the anterior chamber and the pupil, the circular opening in the centre of the co­
loured iris. Fluctuations in the intensity of the light change the size of the eye’s
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pupil diameter. Ambient bright light causes the pupil to constrict due to the pu­
pillary light response reflex. In the opposite case, when the light levels drop, it 
will expand allowing more light in the eye.
The next structure, the crystalline lens, is transparent, biconvex and along 
with the cornea, helps to refract light-beams so that they are focused in a very 
precise way onto the retina.
The retina is the light sensitive lining at the inner side of the eye. Even from 
the time of ancient Greece it has been described as a net like structure which 
subsequently was given its name by the Latin word rete which is translated as 
‘net’. The vertebrate retina plays a dual role. First, it acts as a mediator convert­
ing an optical image to electrical impulses, with the help of the rod and cone 
photoreceptors. Secondly, it wires up the human eye with the brain via the optic 
nerve, by relaying the electric potential to the visual brain cortex in the occipital 
lobes at the posterior of the brain, where our visual perception is generated. The 
outlying parts of the retina are responsible for peripheral vision while the central 
area, called the macula, is used for fine central colour vision. The very centre of 
the macula is called the fovea.
The cornea
The cornea is the clear transparent bulging surface of the most anterior surface 
of the eye that covers the iris, pupil, and anterior chamber. It is the primary re­
fractive surface of the eye with a refraction power of approximately 43 dioptres8 
rendering it the most important refractive structure of the human eye. Together 
with the lens, the cornea accounts for 65% of the eye’s total optical refractive 
power, with the remaining 35% being accounted to the aqueous humour and 
vitreous body.9 Moreover, the cornea helps to shield the rest of the eye from 
foreign particles sharing this protective task with the eyelids, the eye socket, 
tears, and the sclera. Because of its transparency, the cornea does not have blood 
vessels apart from its marginal area. It receives nutrients via diffusion from the 
tears and the aqueous humour externally, and from neurotrophins internally.
The human cornea is composed of five layers, three main and two auxiliary. 
The main layers are from anterior to posterior the epithelium, stroma and en­
dothelium. The two auxiliary layers are Bowman’s membrane, which basically 
consists of a condensed protective coat of arrayed collagen molecules located 
between the epithelium and stroma, and Descemet’s membrane, found between 
the stroma and corneal endothelium.
The corneal epithelium consists of stratified squamous cells, which function 
in corneal metabolism and serve as a foundation where many nerve endings are 
anchored. The stroma is the main corneal layer and makes up 90% of the corneal 
thickness. It is mostly composed of regularly-arranged collagen (collagen type 
I) produced by keratocytes (fibroblasts). The stroma helps the cornea to acquire 
its shape and maintain its mechanical strength or rigidness. Finally, the endothe­
lium is composed of a monolayer of mitochondria-rich cells that regulates fluid 
equilibrium in the cornea, thereby keeping it transparent.
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The anterior and posterior chambers
The anterior chamber is the space between the iris and corneal endothelium, 
whereas the posterior chamber is located between the vitreous body and the iris. 
The posterior chamber contains the lens and the suspensory ligaments. Both 
those small compartments are filled with aqueous humour which is produced by 
the ciliary body providing nourishment to the lens and cornea.
The iris
The visible shape of the coloured iris is determined by the clarity of the cor­
nea. Even if its anatomical structure is nummular, the visible iris is ovoid. It 
is a thin organ in between the cornea and the lens. In its centre it contains the 
pupil. The anatomical function of the iris is to control the size and diameter of 
the pupil, thereby regulating the amount of light shed onto the retina. The eye 
colour, or more correctly, iris colour is due to variable amounts of eumelanin 
(brown/black melanins) and pheomelanin (red/yellow melanins) produced by 
melanocytes.
The iris consists of a series of cell layers. In the outer edge, a single layer 
of flat endothelial cells which correlates with the posterior lining of the cor­
nea constitutes the surface endothelium. Another layer which is composed of a 
neatly packed network of pigmented fibrovascular tissue make is the stroma that 
displays anatomical structures such as arching ligaments, crypts and circular 
contraction folds (contraction furrows). The stroma connects to the sphincter 
papillae, a band of numerous involuntary muscles which encircle the edges of 
the papillary zone (papillary ruff) which form the boundary of the pupil. Reflex 
contraction of the muscle can decrease the size of the pupil. Posterior of the 
stroma, a layer of strong connective tissue which is used as a supportive struc­
ture, is the basement membrane. Finally, the back surface of the iris is covered 
by two rows of heavily pigmented epithelial cell layers (iris pigment epithelium) 
that are situated on the basement membrane. This pigment layer prohibits light 
from “entering” the inner dark chamber of the eyeball.
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The lens
The eye lens is also known as the aquula (Latin, a little stream, dim. of aqua, 
water) or crystalline lens. It is a biconvex, avascular, tightly packed mass of 
fibrous cells which are transparent structures enclosed by the lens capsule. The 
lens is designed to alter the refractive index of light entering the eye so that it 
focuses onto the retina. Even though it possesses less refractive power (15-17 
diopters) than the cornea, it can change its shape, with the help of the ciliary 
muscle, and therefore its refractive power.
The main molecular constituents of the lens capsule are type IV collagen and 
sulphated glycosaminoglycans (GAGs).10 The capsule is very elastic and it helps 
the lens to acquire a globular shape when it is not under the tension of the zonu­
lar fibres that connect it to the ciliary body. The lens epithelium, that is located 
in the anterior portion of the lens between the capsule and the lens fibres, is a 
simple cuboidal epithelium.10 The cells composing it, act as a major regulator 
of lens homeostasis.11 The cells forming the posterior wall of the lens are elon­
gated, thin structures firmly packed known as the lens fibres. They are enriched 
in water soluble proteins called crystallins that comprise almost 90% of the 
protein content of the lens.12 The lens fibres are arranged in sheets that form 
successive layers; the fibres run from one pole to the other, the centre of a given 
fibre being in the equatorial region forming structures called laminae. The epi­
thelium serves as the origin of the lens fibres, both during embryonic and foetal 
development, the cells of which are able to divide mitotically and elongate to 
become new fibres. Transparency of the lens is due to the structure of crystallins 
and the absence of light-scattering organelles in the mature lens fibres such as 
the nucleus or the endoplasmic reticulum.
The vitreous body
The vitreous body of the human eye is the transparent extracellular matrix 
(ECM) located between the retina and the lens, filling the vitreous cavity. It acts 
as an optically clear medium posterior to the lens, and functions in stabilising 
the volume and shape of the eye globe by keeping the retina pressed against the 
inner structures of the eye. It also mechanistically protects the content of the 
eye from shocks such as head movements. Furthermore, it constitutes one of 
the major pathways that supply the lens with nutrients (e.g. hyaloid canal) and 
it also acts as an angiogenic inhibitor.13,14 The vitreous is the largest structure 
of the human eye and is extremely hydrated as 99% of its volume is water. 
Only 1% is composed of salts and organic macromolecules such as collagens, 
and noncollagenous structural proteins (e.g. fibrillin), GAGs (e.g. hyaluronan), 
proteoglycans (e.g. versican), and glycoproteins.15-27 Most of the protein content 
of the vitreous body is found in or associated with heterotypic collagen fibrils 
that form a three-dimensional network. Those heterotypic fibril structures are 
composed of type II collagen and the quantitatively minor type XI collagens. 
In the vitreous, types II and XI collagen self-associate with type IX collagen 
molecules being aligned along their surface.
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Interestingly, the vitreous body is generally devoid of cells. However, embed­
ded in its surface, there is a population of specialised cells, the hyalocytes of 
Balazs, which participate in the metabolism of hyaluronic acid. Additionally, 
some phagocytes can also be found, which remove unwanted debris. The adult 
vitreous body contains no blood vessels.
The vitreous body is encased in a clear thin hyaloid membrane called the vit­
reous cortex.4 The vitreous cortex is situated against the internal limiting mem­
brane (ILM) of the retina. Strong vitreoretinal attachment points have been de­
scribed at the vitreous base,28 at the equator,29 over major retinal blood vessels,30 
at the optic never head,31,32 and at the macula.32
The choroid
The choroid is a richly vascularised coat located between the retina and the 
sclera. Along with the ciliary body and iris, it forms the uveal tract, the pig­
mented middle of the three concentric layers that make up the eye. The choroid 
itself displays the following strata:
a) the lamina suprachoroidea, a layer of loose connective tissue and melano­
cytes;
b) the lamina vasculosa, which consists of large and intermediate sized blood 
vessels;
c) the choriocapillaris, a layer of fenestrated capillaries;
d) the stroma, which contains loose connective tissue with numerous melano­
cytes, smooth muscle cells and collagen fibres;
and e) Bruch’s membrane or lamina vitrea, which is a thick collagenous amor­
phous hyaline membrane with a basal lamina attached to the retinal pigment 
epithelium.33-35
This dense continuous network of blood vessels and arteries is dedicated to 
supply oxygen and nutrients to the outer portion of the retina. Moreover, due to 
its melanin content the choroid limits uncontrolled light reflection within the eye 
that would potentially impair visual perception. The choroid is densely innervat­
ed by a lattice of compound origins. These innervations regulate the choroidal 
blood flow predominantly at the inner and outer vascular strata of the choroid. 
Furthermore, the different neural cell populations play a substantial role in other 
processes such as eye lens accommodation.36
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Anatomy of the retina-RPE
The retina is a very complex tissue and histologically it consists of several lay­
ers (Figure 2). The primary layer attached to the choroid is the retinal pigment 
epithelium (RPE). The RPE extends from the boundaries of the optic disc to the 
ora serrata. The uppermost layer of RPE faces the photoreceptors whereas its 
basolateral membrane (Bruch’s membrane), serves as a distinguishing border 
between the RPE and the choriocapillaris. The RPE consists of a monolayer of 
cells which are highly pigmented. This cell sheet is formed by strong physical 
interactions of the different cells at the end of their margins by the formation 
of junctional structures (maculae, zonulae adherentes and zonulae occludentes) 
that hold them together.
Figure 2. Cellular structure of the human retina.37 A) Location of the retina, the 
interior lining of the posterior part of the eye. B) Organisation of retinal neurons. Ab­
breviations used: R: rod, C: cone, B: bipolar cell; H: horizontal cell; A: amacrine cell; G: 
ganglion cell; M: Muller cell. C) Histological picture of the human retina. Abbreviations 
used: RPE: retinal pigment epithelium; OS: outer segments; IS: inner segments; ONL: 
outer nuclear layer; OPL: outer plexiform layer; INL: inner nuclear layer; IPL: inner 
plexiform layer; GCL: ganglion cell layer.
This cell-layer forms the outer blood-retinal barrier which orchestrates the 
movement of small inorganic and high molecular weight molecules between 
the subretinal space and the choriocapillaris. The physiological function of the 
RPE is multi-dimensional. Its pigmentation enables the absorption of excess 
light which is focused on the retina after its course through the eye-ball. Further­
more, it plays a key role in retinal metabolism by complementing crucial pro­
cesses such as photoreceptor excitability, visual cycle of retinal, phagocytosis of 
shed photoreceptor outer segments tips,38-40 the active transport of nutrients and 
growth factors between the choriocapillaris and subretinal space, and helping in 
the maintenance of their structural integrity. The RPE also co-ordinates immune
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response potential by regulating the secretion of immunosuppressive agents or 
factors.
The remaining layers compose the neural (sensory) retina. Moving from the 
outside to the inside these layers are: 1. the photoreceptor cell layer; 2. the exter­
nal limiting membrane; 3. the outer nuclear layer; 4. the outer plexiform layer;
5. the inner nuclear layer; 6. the inner plexiform layer; 7. the ganglion cell layer;
8. the nerve fibre layer; and 9. the internal limiting membrane. This layer pattern 
is similar across the entire retina, except in the fovea.
The macula lutea
Fovea 1.5m m
' --------------------------------------------P e rifo ve a l a r e a --------------------------------------------------
Figure 3. The positions of macula, fovea and foveola in the posterior pole of the eye.
The macula is located in the posterior retina, with a diameter of 5.5 mm and is 
identified as a yellowish region on the temporal side and slightly lower than be­
low the optic disc (Figure 3). The yellow colour is attributed to two xanthophyll 
pigments, namely lutein and zeaxanthin, which are antioxidants and serve as a 
short wavelength filter for the eye.41-43
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The fovea is the central region of the macula, with a diameter of ~1.5 mm and 
is characterised by a depression in the inner retina surface. It is surrounded by 
the parafovea belt and the perifovea outer region while its centre is called the 
foveola with a diameter of 0.35 mm. The fovea is devoid of most inner retinal 
layers and provides acute high resolution vision in the human eye. Moreover, 
it is a capillary-free zone and does not follow the ‘normal’ pattern of layers, 
found throughout the retina. It contains no rod cells, it is capillary free, and it 
is composed exclusively of cone cells in the foveola.1 Strikingly, although the 
macula comprises only 3% of the retina, approximately 50% of the nerve fibres 
in the optic nerve acquire information from the fovea due to its high and densely 
packed cone photoreceptor content.
Photoreceptors
As indicated before, the human retina possesses two types of photoreceptors, 
the rods and cones. The rods are responsible for scotopic (contrast, brightness) 
and peripheral vision, as well as motion detection. The cones are active at higher 
light levels (photopic vision), capable of colour vision and responsible for high 
spatial acuity.
A normal human retina contains close to 5 million cones and 90 million rods. 
The distribution of photoreceptors across the retina is not uniform (Figure 4). 
Their presence is highest in and near the macula and ranges according to retinal 
eccentricity. The fovea contains the highest density of cone photoreceptors in 
the retina (~160,000/mm2); however, these numbers drop sharply as eccentricity 
increases from the foveal centre.44
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Figure 4. Photoreceptor density in the retina.45 The foveal cones are drawn on a 
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Furthermore, the highest rod densities are located along an elliptical ring at the 
eccentricity of the optic disk and extend into the nasal retina. Rods are absent 
from the foveola (centre of fovea), but more abundant at the fringe of the fovea, 
in particular in the superior and nasal regions.
Although cones operate only in relatively bright light, they provide us with 
our sharpest images and enable us to see colours. Humans possess three types 
of cones. The first type which is designated as ‘L’ responds most to light of rela­
tively long wavelengths, with a peak in the yellow region (565-580 nm). The 
second type, abbreviated as ‘M’, responds most to light of medium-wavelength, 
absorbing best green light (534-545 nm). The third type are the blue (violet) 
absorbing cones, and respond better at short-wavelength light. They are abbre­
viated as ‘S’ and their peak absorption is at 440 nm. The difference in the signals 
received from the three different cone types allows the brain to perceive all pos­
sible colours.
The cone photoreceptors, as their name denotes, have a conical shape (Figure
5) and they vary in length (35-50 ^m) and diameter (0.5-4.5 ^m). Every cone 
cell possesses a synaptic terminus, and an inner and an outer segment. The inner 
segment contains various organelles (mitochondria, ribosomes, rough endoplas­
mic reticulum) and the cell nucleus, whereas the outer segments host the light 
absorbing proteins (e.g. opsins) and processes. The inner and outer segments 
communicate through the connecting cilium. The synaptic terminus serves as 
the medium of transmitting the generated electric potential to neighbouring neu­
rons (e.g. bipolar cells) by forming synapses.
The cylindrical outer segments of the cones have invaginations of their cell 
membranes that form a stack of continuous membranous discs. Embedded in the 
membranous structures are the photopigments synthesised in the inner segment. 
Like cones, rod cells are columnar cells consisting of three distinct compart­
ments (Figure 5). The synaptic terminal is the region which forms a connection 
with the neural layer of the retina and contains the nucleus and cytoplasmic 
organelles. Adjacent to the synaptic terminal, there is the inner segment which 
is rich in mitochondria and is joined to the outer segment via the connecting 
cilium. The outer segments of the rods also consist of tightly packed discs, sur­
rounded by plasma membrane. In contrast to the cones, the rod discs are sepa­
rated from the cell membrane, and provide the surface area required for the 
insertion of rhodopsin, which is the major photosensitive pigment present in the 
rods. Rhodopsin constitutes 80% of all rod outer segment proteins.
Rod and cone photoreceptor cells do not divide, but their membranous disks 
decay and are worn off at the end of the outer segment, to be consumed and 
recycled by RPE. Every night, 10% (~100) of the rod photoreceptor discs are 
processed in this way.
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Rod Cone
ribbons
Figure 5: Schematic representation of the cone and rod photoreceptor cells. 
Sensory retina
External limiting membrane -  The region between the base of photoreceptor 
inner segments and the apical processes of Müller cells, which are large glial 
neural cells, forms a thin network-like structure which appears as a membrane. 
This region is a sum of intermediate junctions (belt-desmosomes) formed be­
tween the rods’ and cones’ inner segments and synaptic endings with the Müller 
cell plasma membrane, and serves as a barrier between the inter-photoreceptor 
matrix (RPE and photoreceptors) and the subretinal space, regulating the traffic 
of several macromolecules in and out of this area.46
Outer nuclear layer -  This layer consists of the photoreceptor cell bodies 
(granules) and nuclei. Geometrically, it has a similar width in the central and 
peripheral areas of the retina. In the periphery, rod granules are more abundant 
compared to the respective cone granules, however this condition reverses in the 
central area of the retina.47 Both rod and cone granules are connected via fibrils 
with the structures of the adjacent retinal stromata.
Outer plexiform layer -  In this retinal stratum the synaptic endings of photo­
receptor inner segments located at the outer nuclear layer create neuronal con­
nections with the dendrites of horizontal and bipolar cells found in the inner 
nuclear layer. These synapses are named spherules when they refer to rods and 
are circular or ovoid, and named pedicles when they refer to cones. Both rod and 
cone synapses show special electron-dense cell organelles, called the synaptic 
ribbons and vesicles. These neural elements are perplexed and participate in the
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formation of secondary elaborate structures such as invaginating synapses (tri­
ads) and flat synapses. Their ultimate role is to transfer complex neural signals, 
generated by the action potential of the rods and cones, which must be passed to 
other neural elements of the retina for further processing.
Overall, processes in the outer plexiform layer serve as the basis of succes­
sive contrast or “ON” and “OFF” pathways, respectively, and the ‘tuning’ of 
signaling networks responsible for the establishment of gradient contrast in the 
different visual objects.
Inner nuclear layer (INL) -  This retinal layer is densely populated by five cell 
types. These are the horizontal cells, bipolar cells, interplexiform cells, Müller 
cells and amacrine cells.
The horizontal cells constitute a cell zone of interconnecting neurons closest 
to the receptor endings and are located at the outer part of the INL. The dendrites 
of three distinct types of horizontal cells (H1, H2 and H3) are joined with the 
axons of photoreceptor endings in different combinations, forming the elaborate 
structures of synaptic triads. Overall, it is thought that they integrate and regu­
late the input from multiple cone types and rods, thereby, contributing to light 
contrast, detection and colour vision.48
Bipolar cells have an oval shape and are the most abundant cell type found in 
the INL. In the human retina, 11 different bipolar cell types have been revealed 
by Golgi staining.49-52 These 11 different types of bipolar neural cells receive in­
put from both cones and rods. The signal is subsequently conveyed to ganglion 
and amacrine cells through their neural axons. Depending on their action upon 
neurotransmitter (glutamate) release by the bipolar cells, the horizontal cells 
are grouped as ON or OFF either through a metabotropic (ON) or ionotropic 
(OFF) receptor pathway.53,54 Light hyperpolarises photoreceptors which release 
less glutamate. ON bipolar cells will respond to this change by depolarising and 
OFF bipolar cells will respond by hyperpolarising.
The interplexiform cells were the most recent neurons to be recognized struc­
turally in the retina.55 They are similar in structure to the bipolar cells; however 
they are unique because of their ability to extend processes widely in both plexi­
form layers, by forming functional connections with cones, rods and bipolar 
cells.56
The Müller cells are giant glial cells that have a range of metabolic functions 
all of which are vital to the health of all the retinal neuronal cell types. They are 
involved in the structural integrity of the retina by forming intermediate con­
nections with photoreceptor inner segments.57 Their most proximal and distal 
structures form the inner and outer limiting membranes respectively as they 
traverse almost the entire neural retina.
Last, the amacrine cells are located at the inner border of the INL. There are 
more than 40 different amacrine cell types based on their morphology and neu­
rochemical content.58-60 Amacrine cells create synapses both between themselves 
and bipolar cells, and serve mostly as antagonists by releasing neuroinhibitors
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(GABA, glycine), thereby fine-tuning signal transduction from other neurons. 
Functionally, they regulate retinal image light information such as motion and 
contrast.
Inner plexiform layer -  This area of the retina consists only of cell processes 
and is made up of a dense network of fibrils and synapses formed by interlaced 
dendrites of retinal ganglion cells and other cells types of the inner nuclear layer.
Ganglion cell layer - This layer contains four different types of ganglion cells 
and bundles of optic nerve fibres. It is of note that the ganglion cell layer is made 
up of a single row of cells in the retinal periphery but within the macula there 
are several strata of ganglion cells, with the highest concentration in the parafo- 
vea.61 Ganglion cell responses define resolution of optic images, chromatic and 
spatial opponency.
Nerve fibre layer -  It comprises bundles of optic nerve projections (axons) 
which radiate towards the optic disc and eventually make up the optic nerve. 
The axons are unmyelinated before crossing the optic disc.
Inner limiting membrane -  This layer is formed by the plasma membrane of 
Müller cell endings and glial cells (astrocytes). With the help of a sheet of extra­
cellular epithelium cell matrix that lines the inner limiting membrane, it serves 
as a barrier separating the retina from the vitreous body.
Blood supply of the retina
The retina is nourished by two distinct blood supply systems that originate 
from the choroid and the central retinal artery and vein. The retina also pos­
sesses an outer and inner blood- barrier layer, formed by the RPE and the endo­
thelial membrane of the retinal blood vessels, respectively. During mammalian 
eye development, there is no inner retinal vasculature, and oxygen supply of the 
retina is sustained by choroidal and hyaloid vessels. The hyaloid vasculature is a 
complex of transient intraocular vessels comprising: the vasa hyaloidea propia,
ii) the tunica vasculosa lentis and the pupillary membrane.62 Hyaloid vessels un­
dergo progressive regression as the retinal vasculature develops on an astrocyte 
template63,64 (Figures 6 and 7).
Till now, there seems to be much debate as to whether the retinal vasculature 
forms by angiogenesis or vasculogenesis, though angiogenesis is now generally 
accepted 65-67 Regression of the hyaloid vasculature and formation of the retinal 
vasculature by angiogenesis are synchronised processes (Figure 6). Failure of 
the hyaloid vasculature to regress and is accompanied by incomplete retinal 
vascularisation, which strongly suggests that overlapping signaling networks 
simultaneously control hyaloid regression and formation of the retinal ves- 
sels.62,68-70
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Figure 6. Schematic representation of the development of the ocular vascular net­
work and progression of the retinal vascularisation in the mouse.
The primary hyaloid vasculature (hv) (A) is supplied by the hyaloid artery (ha) ending 
into the choroidal net (ch). As the retinal vasculature (B) (primary plexus) develops 
the hyaloid vasculature regresses. Eventually, (C) the deeper plexus (dp) of the retinal 
vasculature emerges from the primary plexus. Both in humans and in mice the retinal 
vasculature develops in similar patterns. In retinas of early stages such as P0 mice (D) 
the retinal vasculature is not differentiated, in contrast to later stages i.e. P4 (E-F) and 
P8 where a well patterned vasculature has developed in which arteries (red) can be 
discerned from veins (green). Moreover, in later stages (F) of development secondary 
sprouting into the deeper retinal layers can be observed in areas surrounding the veins 
(F, inset arrows of the boxed area representing higher magnification of this region) The 
progress of vascularisation is visualised using fluorescence immunohistochemistry on 
retinal whole mounts using anti-collagen type IV (red, E-F) and anti-ASMA (green, 
E-F), antibodies. Adapted from Fruttiger M., 200765 (A-C) and Fruttiger M., 200264 
(D-F).
In the mature retina, the large choroidal arteries branch into smaller blood ves­
sels that create an extensive network of capillaries called the choriocapillaris. 
This extensive capillary network is immediately adjacent to Bruch’s membrane 
in the choroid and is supported by collagen fibres. The endothelial cells compos­
ing the choriocapillaris are fenestrated. The latter allows nutrients in the form of 
serum proteins and other macromolecules to diffuse in the extracapillary space. 
Subsequently, through osmotic regulation, nutrients can passively diffuse into 
the avascular RPE and photoreceptor layers. Further diffusion is interrupted due 
to the action of the outer retinal blood barrier formed mostly by the tight junc­
tions between the RPE cells.
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Figure 7. Schematic picture of the retinal and choroidal vasculature.
The branches from the central retinal circulation form two distinct capillary plexi within 
the ganglion cell layer (the superficial capillary plexus) and in the inner nuclear layer 
(the deep capillary plexus). These two vascular plexi end as the ganglion cell and inner 
nuclear layer disappear in the foveal slope. The choroid contains a dense vascular net­
work terminating with the fenestrated choriocapillaris. Adapted from Anand-Apte and 
Hollyfield, 2010.71
The inner nuclear and ganglion retinal cell layers receive their blood flow 
through the central retinal artery. The central retinal artery is a branch of the 
ophthalmic artery that begins at a close distance (4 mm) posterior to the optic 
nerve head. The branch enters the optic nerve to become central within the optic 
nerve and divides to two main branches, each of which further splits to form 
the superior nasal and temporal and the inferior nasal and temporal arteries that 
supply the four quadrants of the retina.
The different arterial braches submerge into the retinal layers forming three 
capillary plexuses which are essential for retinal homeostasis (Figure 7). The 
first capillary network is formed by the radial pericapillary capillaries that are 
located in the inner part of the nerve fibre layer (Figure 6). The superficial cap­
illary plexus is located in the ganglion cell layer and the deep capillary plexus 
nourishes the inner nuclear layer.
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1.2.2. Physiological aspects of the human eye 
Light perception
To turn light into an electrical signal, the eye must detect and respond to the 
physical phenomenon of electromagnetic radiation in the wavelengths of the 
visible spectrum, and subsequently transform that electromagnetic energy into 
a signal the nervous system can perceive and transmit. This is performed by 
its receptor structures at the outer portions of the retina i.e. the rods and cones, 
through a process known as visual phototransduction or visual cycle. The outer 
segments of both rods and cones contain photopigments, that are composed of 
opsins (G-protein coupled receptors) bound to chromophores i.e. molecules that 
can be excited by photons. The photopigment content of photoreceptors is vari­
able. Rods contain rhodopsin as the sole visual pigment whereas cones have 
four different visual pigment groups (L-, M1-, M2- and S-groups).72 Even if the 
visual cycle is initiated in exactly the same mode for all photopigment groups, 
the action potential which triggers the phototransduction mechanism varies. The 
threshold intensity of light required to cause action is higher in cones which are 
responsible for photopic vision compared to rods which are basically used for 
light detection or scotopic vision.
Colour vision
Colour perception or colour vision is the ability of an organism to distinguish 
light of different spectral qualities. Colour vision in humans is trichromatic and 
its processing is initiated by the absorption of light by three different classes 
of cones containing pigments with different light spectral sensitivities. These 
are the short (S), medium (M) and long (L) wave sensitive cones. The absor­
bance spectra, i.e. the light emission wavelength to which the cones are sensi­
tive, highly overlap. However, their maximum absorbance rates are determined 
in different areas of the electromagnetic spectrum. Furthermore, the absolute 
numbers and the retinal topography of the three cone classes are not uniform 
rendering the intensity of signal output not being homogeneous.
Upon signal transduction, the receptor output which is based on quality (spec­
tral sensitivity) and quantity (signal intensity) is combined to form two chromat­
ic and an achromatic channel that are received by three post-receptoral neuronal 
systems i.e. yellow-blue, red-green, and luminance respectively. These neuronal 
systems deliver signals to the lateral geniculate nucleus in the brain. A series 
of very complex signal processes i.e. chromatic opponency; chromatic tuning, 
colour constancy and induction, eventually “translate” the combined output of 
cone photoreceptors output into a psychological property such as colour vision.
Binocular and stereoscopic vision
Binocular vision is the unified perception that the visual cortex produces after 
combining and fusing two separate images produced by each separate eye. For 
binocular vision to be achieved, several elements in both the retina and the visu­
al cortex have to function simultaneously in order to combine two pictures per­
ceived by both eyes at different angles (sensory fusion). Moreover, it requires
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the co-ordination of the two eyes, in order to focus on the same target (motor 
fusion). The two eyes enable stereoscopic vision and depth perception by com­
bining stimuli received from both of them, as well as from each eye separately, 
with respect to apparent size, interposition, geometric perspective and relative 
velocity of an object, eventually resulting in three-dimensional vision.
- 26 -
Chapter -1-
1.3. Clinical and genetic features of vitreoretinopathies
Hereditary vitreoretinopathies are a diverse group of diseases that may or may 
not be accompanied by systemic manifestations, mainly characterised by degen­
eration of the vitreous body. The latter may result from or may cause pathologic 
conditions in the retina, such as retinal holes and/or detachment, retinal schisis 
and retinal atrophy due to incomplete angio-vasculogenesis. Below, I will dis­
cuss clinical and genetic aspects of six vitreoretinopathies, namely Wagner dis­
ease and erosive vitreoretinopathy, Stickler syndrome, rhegmatogenous retinal 
detachment, familial exudative vitreoretinopathy and Norrie disease.
Wagner disease and erosive vitreoretinopathy (ERVR)
Wagner disease (MIM #143200) was first described in 1938 as a vitreoretinal 
disorder with an autosomal dominant pattern of inheritance in a large Swiss 
pedigree.73 The disease is fully penetrant and symptom manifestation is pro­
gressive, beginning from childhood or adolescence. Patients early in their life 
show moderate myopia (-3 - -4) diopters, with pseudostrabismus due to foveal 
ectopia74 and a complicated cataract which eventually requires lens extraction 
around the fourth decade of life.75 Moreover, affected individuals usually pres­
ent vitreal syneresis with optically empty vitreous and fibrillary condensations 
or equatorial avascular vitreous veils. Additional features include an abnormal 
central retinal vessel architecture (inverted papilla or ‘situs inversus’) (Figure 
8), perivascular pigmentation and sheathing, retinal thinning, and slowly pro­
gressive chorioretinal atrophy.
□
(
Figure 8: Composite fundus picture of the left eye of A) a patient with Wagner 
disease and B) the right eye of a healthy individual. Note the nasal dragging of the 
retinal blood vessels arcades and fovea together with the avascular regions in the far 
periphery. Adapted from Ronan et al., 2009.76
Images acquired using fluorescein angiography can clearly depict the loss of 
the choroidal capillary bed and the RPE with preservation of the large choroidal 
blood vessels. Visual fields are concentrically reduced presenting ring scotomas, 
and scotopic ERGs show reduced b-waves i.e. cone-rod loss due to the progres­
- 27 -
Chapter -l-
sive chorioretinal atrophy.77 Systemic features such as skeletal, cardiovascular 
or hearing abnormalities that are often observed in patients with other vitreo­
retinopathies, have not been reported in patients with Wagner disease73,m79 Ero­
sive vitreoretinopathy (ERVR) was described in l995 and displays an autosomal 
dominant pattern of inheritance. It shares many symptoms with Wagner disease 
but in general is more severe. It is characterised by various patterns of retinal 
detachments, together with a marked and progressive pigmentary retinal dys­
trophy.77 Patients with ERVR reveal progressive nyctalopia or night blindness, 
together with visual field constriction which initiates during early adulthood. 
Fluorescein angiography studies reveal a progressive equatorial RPE thinning 
and loss of the choriocapillaris. Retinal detachments are quite prevalent and 
can be either tractional or rhegmatogenous (i.e. occurring due to a hole, tear, or 
break in the retina). The ERG recordings clearly demonstrate rod-cone abnor­
malities because of retinal atrophy and choriocapillaris deterioration.
Linkage studies assigned the Wagner disease gene to chromosome 5ql3-ql4, 
and successive studies mapped the underlying genetic defect to a 2-cM interval 
at 5ql4.3 (Figure 9).77,S0 Linkage studies in the erosive vitreoretinopathy family 
also revealed association of a critical interval of 35 cM at 5ql3-ql4 overlapping 
the critical region for Wagner disease, suggesting that these diseases are allelic.77 
Eventually, VCAN (formerly known as CSPG2) encoding the large extracellular 
matrix proteoglycan versican was identified to be mutated in a Japanese family 
with Wagner disease.Sl
Figure 9: Linkage intervals in families with W agner disease and ERVR in four dif­
ferent studies.77,80,82,83 The overlapping linkage region is demarcated (grey background) 
and encompasses 2 Mb. “D5S’’ numbers refer to highly polymorphic markers located in 
chromosome 5, that were used in classical genetic linkage studies.
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Stickler syndrome
Stickler syndrome is a genetically heterogeneous connective tissue dysplasia 
with a broad phenotypic spectrum. In general terms, it is characterised by articu­
lar, auditory, craniofacial and ocular manifestations, first described by Stickler 
and colleagues in 1965.84 The major mode of inheritance is autosomal dominant, 
caused by mutations in COL2A1, COL11A1 or COL11A2 (Stickler syndrome 
type I [MIM 108300], Stickler syndrome type II [MIM 604841] and Stickler 
syndrome type III [MIM 184840], respectively),85-87 although an autosomal re­
cessive form of the disease has been reported in one consanguineous family 
caused by a nonsense mutation in COL9A1.88 The vast majority of families suf­
fering from Stickler syndrome harbour mutations in COL2A1.
Phenotypically, the disorder exhibits an expanded gamut of symptoms with 
the most prominent features in the eye being myopia, vitreoretinal degeneration, 
retinal holes and detachment, cataracts and glaucoma. Craniofacial involvement 
includes midface hypoplasia, broad nasal bridge, micrognathia and cleft palate. 
Audiologic findings include conductive sensorineural and mixed hearing loss. 
Musculoskeletal system alterations involve hypermobility of the joints, spon­
dyloepiphyseal dysplasia and osteoarthritis that develops typically in the third 
decade of life.
The clinical subclassification of Stickler syndrome is based on the vitreous ab­
normalities, since the systemic features are highly variable even within families, 
and not specific to any gene locus. In the most common form, i.e. STL1 caused 
by COL2A1 mutations, the majority of patients display a congenital vitreous 
abnormality consisting of a vestigial gel in the retrolental space, bounded by a 
highly folded membrane (membranous or type I vitreous). STL2 patients with 
COL11A1 mutations display a fibrillar and beaded appearance of the vitreous 
(fibrillar or type II vitreous). STL3 is the non-ocular form of Stickler syndrome, 
because COL11A2 is not expressed in the eye. Premature degenerative changes 
due to progressive vitreal liquefaction were noted in the only autosomal reces­
sive family described thus far, in which patients carried a mutation in COL9A1. 
Since the incidence of rhegmatogenous detachments among Stickler patients is 
high (50%), it is important to identify affected individuals through eye examina­
tion and direct genetic testing for confirmation of the diagnosis.
All collagen molecules consist of three polypeptide strands (a chains), each 
possessing the conformation of a left-handed helix, that twirl around each other 
into a right-handed coiled coil, a triple helix, which is stabilised by the forma­
tion of hydrogen bonds. At present, at least 40 different genes have been iden­
tified, the products of which form at least 26 different heteromeric collagen 
molecules.89
Stickler syndrome thus far seems to be caused solely by mutations affecting 
genes encoding collagen types II, IX and XI. These molecules appear to be 
distinctively present in the eye and cartilage, although expression has also been 
noted in the cochlea. Functionally, they participate in the formation and/or main­
tenance of heterotypic fibril structures by the association of type II (COL2A1)
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and the quantitatively minor type XI (COL11A1 and COL11A2) collagens. 
Anomalies in these fibrils, causing Stickler syndrome, mostly result from nucle­
otide changes spread throughout the entire COL2A1 gene which encodes the a1 
chain of procollagen II. After proteolytic processing, these precursor molecules 
assemble into mature collagen type II fibrils that exist in two distinct isoforms. 
Type IIA isoform, which is the slightly longer isoform, includes 69 amino acids 
encoded by exon 2 of COL2A1. It constitutes the most abundant form expressed 
in the vitreous body.90 Type IIB, which is the short form lacking the aminoacid 
sequence encoded by exon 2, was shown to be present in the mature cartilage. 
It is of note that the vast majority of COL2A1 Stickler-associated mutations are 
resulting in premature termination of the encoded protein and as such can be 
considered null alleles. This fact alone suggests that the main pathway in the 
disease mechanism involves type II collagen haploinsufficiency.
Autosomal dominant rhegmatogenous retinal detachment (adRRD)
Rhegmatogenous retinal detachment (RRD) refers to the occurrence of a reti­
nal break, through which fluid from the vitreous cavity enters the subretinal 
space and thereby separates the sensory retina from the RPE. RRD is often as­
sociated with (pathologic) myopia and in most cases leads to visual impairment 
or blindness if untreated.91,92
Epidemiologic studies have estimated the incidence of RRD as 1:10,000 indi­
viduals per year in Caucasians.93-97 Taken into consideration that many patients 
display recurrent RRD, it can be estimated that ~1/200 individuals suffer from 
RRD in their lifetime. It occurs predominantly between 40 and 70 years of age 
which have no family history of retinal detachment. This severely hampers the 
identification of individuals at risk, who could benefit from preventive treatment 
or improved prognosis of surgery upon early diagnosis.
Known risk factors for RRD are high myopia, lattice degeneration, posterior 
vitreous detachment and peripheral retinal degenerations. It often occurs in spe­
cific syndromes and vitreoretinopathies such as Stickler syndrome and Wagner 
disease of which the underlying genetic defects have been identified.
In the last decade, several families have been described that showed RRD with 
absent or minimal systemic features of Stickler syndrome based on Snead’s cri­
teria, i.e. a congenital vitreous anomaly (type 1: membranous, or type 2: fibril­
lar, beaded) and at least three of the following: (1) myopia with onset before 6 
years of age, (2) RRD or paravascular pigmented lattice degeneration, (3) joint 
hypermobility with abnormal Beighton score, either with or without radiologic 
evidence of joint degeneration, (4) audiometric confirmation of sensorineural 
hearing defect, and (5) midline clefts.98 These families harboured mutations in 
the COL2A1 gene,99-108 most of which are located in exon 2 of COL2A1 that 
is subject to alternative splicing. The COL2A1 mRNA transcript variant con­
taining exon 2 is specifically expressed in the vitreous, thereby explaining the 
restricted ocular phenotype of these patients. Interestingly, in one family with 
multiple affected individuals without systemic features, a p.R453X mutation in
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exon 30 of COL2A1 was found. Remarkably, the same mutation has been previ­
ously reported in a patient with full blown Stickler syndrome.66
Familial exudative vitreoretinopathy (FEVR)
Familial exudative vitreoretinopathy (FEVR; MIM 133780) is a bilateral, 
clinically and genetically heterogeneous disorder first described by Criswick 
and Schepens109 in two families in 1969. The disease is prominently character­
ised by an ischaemic retinal periphery.110-112 The abnormal retinal blood supply 
is present in the vast majority of patients, but usually causes no clinical signs.113 
An early diagnosis of FEVR is crucial for patients both in terms of genetic coun­
selling and for prevention and treatment of symptoms that predominantly start 
to occur at young age. For eye-specialists there are no clear diagnostic criteria 
since FEVR highly overlaps or resembles other disorders such as retinopathy of 
prematurity (ROP) and persistent foetal vasculature syndrome (PHPV).
The incomplete vascularisation of the retina physiologically promotes retinal 
neovascularisation and peripheral brush border anastomoses which are created 
in order to complement for the loss of blood supply in the tissue. However, the 
generation of small ‘leaky’ blood vessels is not consistent, because they are 
prone to rupture causing vitreous haemorrhage and exudation. According to the 
presence and/or extent of exudation in the patient’s eye(s), the phenotype can be 
variable. Mild symptoms include retinal traction that changes the architecture 
of the temporal retina vasculature, moderate symptoms include ectopia of the 
macula and the vessels around the optic disc, whereas the severe form displays 
retinal folds and detachment. The retinal detachment can be tractional, exuda­
tive or rhegmatogenous which is most frequently seen in affected individuals 
during the second and/or third decade of their life.112,114 Rarely, retinoschisis and 
giant retinal tears are present.
Clinically, since the description of FEVR’s pathology, several studies tried 
to establish grading systems by identifying markers that could be used as diag­
nostic tools during clinical examination. Several decades ago, contradicting re­
ports were assessing the stationary or progressive nature of the disease.112,115 The 
subsequent introduction of fluorescein angiography, combined with fundoscopy 
measurements enabled accurate stage classification of the different patients. By 
gauging parameters such as the extent of retinal vascular changes, the presence 
of an avascular zone, and morphological aspects of the posterior pole e.g. quan­
tification of macular ectopia (Figure 10), the possibilities of patient care and 
treatment have markedly increased over the past decade.
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Figure 10: Quantitation of the m acular ectopia in FEV R  A) Measurements of ana­
tomic characteristics: a1, horizontal disc diameter; a2, vertical disc diameter; b, distance 
between temporal edge of optic disc and fovea centralis. B) Left eye of a control subject: 
a normal disc-to-macula distance. C) Left eye of a patient with FEVR: an increased 
disc-to-macula distance and a stretched configuration of the vascular arcades (adapted 
from Boonstra et al. 2009).116
Management and treatment of patients includes prophylactic cryotherapy in 
order to ‘patch’ retinal holes and areas of exudation or surgical intervention 
when subjects present with retinal detachment. Fundus and ophthalmoscopic 
examination at regular intervals for individuals with a family history is required 
to evaluate the presence or progression of symptoms such as neovascularisation, 
exudation, and retinal traction.
FEVR is a very rare disorder and its prevalence has not been accurately es­
tablished even if reported cases occur across diverse ethnic groups. Non-pene­
trance can be observed in up to 25% of mutation carriers.116,117
FEVR displays all three forms of genetic inheritance i.e. autosomal domi­
nant (adFEVR, MIM# 133780),109,112,115,118 autosomal recessive (arFEVR, MIM# 
601813) or X-linked (xlFEVR, MIM# 305390),119-121 with autosomal dominant 
being the most common type of inheritance. The autosomal dominant form was 
initially localised on the long arm of chromosome 11 (EVR1 locus) through 
linkage analysis122 and subsequently was found to be associated with muta­
tions in FZD4 and LRP5, which are located on 11q14.2 and 11q13.2, respec- 
tively.123,124 Mutations in LRP5 have also been associated with arFEVR125 
whereas xlFEVR is caused by mutations in the Norrie disease/pseudoglioma 
gene (NDP) located at Xp11.3.126,127 An as yet unidentified autosomal dominant 
FEVR gene has been localised to the EVR3 locus on chromosome 11p12-p13.128
The proteins encoded by FZD4, LRP5 and NDP are components of the 
P-catenin signaling pathway(s). It has been demonstrated that P-catenin path­
ways are one of the main drivers for vascular development in the mammali­
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an eye. Consequently, mutations in these three genes cause FEVR and have a 
pathologic impact on intraretinal vasculature.
Norrie disease
Norrie disease (ND, MIM# 310600) is a severe X-linked recessive form of 
congenital blindness which in the majority of cases is accompanied by hearing 
loss and in one third by mental retardation.129,130 The pathology of the disease 
is characterised by a spectrum of fibrous and vascular changes of the retina, 
present a birth, especially in deep capillary networks and the periphery, which 
eventually progress and may result in blindness. Diagnosis of Norrie disease is 
primarily based on ophthalmologic findings, but it can also rely on extra-ocular 
features which may be recognised during a general clinical examination.131
The most severe phenotypic demonstration of Norrie disease is a grayish- 
yellow characteristic intra-ocular mass in the retina (pseudoglioma) that can 
lead to microphthalmia.132,133 The pseudogliomas are tumour-like structures and 
are considered to be classical phenotypic findings present at very early ages 
(0-3 years of age) in affected individuals. Other ocular findings include the de­
velopment of cataract, alterations in the composition of the vitreous body,134 
vitreoretinal haemorrhages, retinal folding and detachment accompanied by 
subretinal exudates135,136 which are signs bearing high phenotypic overlap with 
FEVR. At a final stage, following the demonstration of the symptoms reported 
previously, the cornea can seriously deteriorate and the globe of the eye shrinks 
(phthisis bulbi), resulting in loss of vision.137 Typical features of the disease 
include progressive sensorineural hearing loss usually not present before the 
second decade of life. Defects in the stria vascularis of the cochlea are believed 
to be responsible for the high frequency hearing loss.132 Finally, apart from the 
ocular and audiologic anomalies, almost one third of male patients suffering 
from ND are mentally retarded with behavioural abnormalities or psychotic-like 
features. Those are observed from early childhood and maybe variable within 
a family. Genetically, it is a homogeneous disease and solely caused by differ­
ent mutations in NDP126,138 (also see http://www.medmolgen.uzh.ch/research/ 
eyediseases/norriedisease/Norrinmutations.html) that almost exclusively result 
in loss of function of the wild-type protein.
Norrin has a major role as a signaling molecule in blood vessel formation and 
neural differentiation pathways.139,140 One of the most well characterised aspects 
of its function is its involvementin the P-catenin signaling pathway(s). Norrin 
possesses and binds with high affinity to the receptor FZD4, requiring LDL 
receptor-related proteins (LRPs) as co-receptors in order to activate downstream 
signaling cascades.141
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1.4 Genomics technologies and disease gene identification strate­
gies 
Genetic variation
The haploid human genome consists of ~3.2 billion bp of which an estimated 
2% contains 20,000-20,500 protein-coding genes, while researchers have con­
firmed the existence of 19,599 of them.142
The vast majority of the genetic makeup of any two unrelated individuals 
from a given species is identical. Still, on average, approximately 0.1% of the 
genome is different between two unrelated humans. Many different types of 
DNA sequence variants exist, and they can be classified in several ways,143 e.g. 
by their physical consequences, or by their effect on intrinsic protein formation 
and folding.
Two prominent classes of genetic variations are single nucleotide polymor­
phisms (SNPs) and simple sequence repeats (SSRs or microsatellites). SNPs 
are variations of single nucleotides whereas microsatellites are highly variable 
repeated sequences of 1-6 bp.144 Current estimates are that SNPs occur as fre­
quently as every 100-300 bp. This implies that in an entire human genome, there 
are approximately 10 to 30 million potential SNPs while some reports refer to a 
number close to 5.4 million have been identified and independently validated145 
(also see International HapMap project, http://snpdata.cshl.edu and Axiom™ 
Genomic Database genotyping data, http://www.affymetrix.com).
Linkage analysis
Traditionally, linkage analysis is the favoured method to identify chromosom­
al regions that either predispose to or cause disease using phenotypic observa­
tions in related individuals. In this approach, the aim is to find the approximate 
and relative location of the disease gene, compared to a genetic marker with a 
fixed position. For the latter, SNPs and microsatellite markers are frequently 
used, thereby constructing allelic configurations across a single chromosome 
(haplotypes) or the overall genetic allelic configuration (genotype) of selected 
individuals.
Genetic linkage analysis is dependent on haplotype or genotype data, and 
on the physical co-localisation of specific loci or alleles on the same chromo­
some during meiotic recombination. Using the allele calls and the known fixed 
positions of DNA markers combined with statistical tools (i.e. recombination 
frequencies occurring between two regions on a gamete), one can calculate 
the probability of a genomic region harbouring a disease-causing or disease- 
associated gene. Linkage analysis methods can be applied to major gene disor­
ders in the form of parametric linkage and in complex diseases in the form of 
model-free or non-parametric linkage. Parametric linkage is used to analyse the 
co-segregation of genetic loci in a pedigree-based manner. In order to proceed 
with this type of analysis, a model of inheritance for the disease in question 
needs to be defined and several parameters to be specified. Typically, parametric 
analysis is employed for single gene disorders. Other components essential for
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the analysis to proceed include trait allele frequency (a common/rare disease), 
the frequency of new mutations at the trait locus and the penetrance of the trait 
allele. Knowing the penetrance of the disease allele is crucial because for some 
diseases, carrying the risk genotype does not always result in an individual be­
ing affected. Rough estimates of the allele frequency and penetrance can often 
be obtained from the literature or from publically available databases, such as 
Online Mendelian Inheritance in Man (OMIM, http://www.ncbi.nlm.nih.gov/ 
omim).
Linkage is normally reported as the logarithm of the odd (LOD) score, which 
is the measure of the likelihood of two or more loci being within a measur­
able distance of each other.146 When the underlying genetic model of the trait 
is known, a statistical assessment of the likelihood of linkage can be made. 
The pedigree data are used to consider both the hypothesis of linkage between 
the disease and marker locus and non-linkage between the disease and marker 
locus. The denominator shows the likelihood of the pedigree and marker data 
calculated under the null hypothesis, which assumes free recombination (0 =
0.50) between the disease and marker loci. The numerator shows the likelihood 
of the hypothesis of linkage between the disease and marker loci. It is calculated 
at various values of 0 within the range of allowable values (0.00-0.49), repre­
senting unique sub-hypotheses of linkage between the disease and marker loci.
Essentially, a LOD score is an estimate or measure of the recombination frac­
tion 0 between disease locus and one (two-point) or more (multipoint) genetic 
marker(s) at known genomic location(s). The best (maximum likelihood) esti­
mated of 0 is the maximum LOD score. The higher the LOD score, the greater 
the evidence for linkage. When the lod score is >3.0, there is significant evi­
dence for linkage between the disease locus and the marker locus. Although a 
lod score of 3.0 is consistent with odds of 1000:1 in favour of linkage between 
the loci, it is important to note that a lod score of 3.0 is like any statistical assess­
ment and could also represent a false-positive result. The higher the lod score, 
the lower the chance of a false-positive result. Generally, when evidence for 
linkage between two loci is declared significant at a lod score of 3.0, there is a 
5% chance that it is a spurious positive result.147 In the same study, a theoretical 
value of a LOD score >3.3 was estimated to be sufficient to suggest linkage on 
a genome wide scale.
Nowadays, linkage analysis of whole genomes is routinely performed on the 
basis of microarray platforms containing between 10,000 (10k) and 1,000,000 
(1,000k) of SNPs evenly spread across the genome. Statistical processing of the 
data is dependent on fully automated linkage software packages that are becom­
ing routinely used.
Next generation sequencing
The field of DNA sequencing technology has a vast history. Initially, the major 
sequencing methods used were the Sanger enzymatic dideoxy technique and the 
Maxam and Gilbert chemical degradation method described in 1977.148,149 Since 
the early 1990s, DNA sequence analysis has almost exclusively been conducted
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using a capillary-based, semi-automated implementation of Sanger biochem- 
isty.150-152
In order to achieve high throughput using Sanger sequencing, targeted rese­
quencing has been extensively used. The principal element of this approach is 
the maximum production of template (PCR amplicon enhancement) within the 
frame of a single reaction. The template is then used for the cycle sequencing 
reaction which is a PCR based procedure, terminated by the incorporation of flu­
orescently labeled dideoxynucleotides (ddNTPs) in each individual amplicon. 
Through the mixture of end-labeled products, their separation by electropho­
resis on a capillary system and their fluorescent ‘identity’ sequence reads can 
be generated. Sanger sequencing can read up to 900 bp fragments, with an ac­
curacy of 99.9% and with material costs ranging from 8€ per kb pair in normal 
or daily applications, down to 0.40€ per kb pair in high-throughput modes.153
In daily research and routine diagnostics the widely used ABI 3730 DNA anal­
yser contain up to 96 capillaries which theoretically has a maximum output of 
80 kb per run. The high demand for low-cost sequencing has driven the devel­
opment of high-throughput next generation sequencing technologies that paral­
lelise the sequencing process, producing millions of reads (contiguous regions 
of DNA sequence) in one experiment.154,155 The spectrum of next generation 
sequencing technology includes strategies summarised in several categories i.e.
i) parallelised sequencing and sequencing by ligation e.g. the Roche 454 pyro- 
sequencing platform, or the ABI SOLiD™ System156,157 ii) microfluidic Sanger 
sequencing e.g. Apollo 100, iii) sequencing by hybridisation,158 and iv) sequenc­
ing in real time e.g. HeliScope Single Molecule Sequencer.159,160 A crucial step in 
the overall sequencing process is the generation of a library of DNA fragments 
which serves as the template for further processing. Library preparation may de­
pend on various protocols but is accomplished by random fragmentation of ge­
nomic DNA and in vitro ligation of appropriate linkers. The fragmented DNA of 
interest is captured by targeted hybridisation e.g. NimbleGen Sequence capture 
array or Agilent’s “SureSelect Target Enrichment System”, and subsequently, 
these specific DNA fragments are used to generate a pool or a library that is 
ready to be sequenced. The sequencing process is based on the sequence by 
synthesis method, in which extension of primed templates occurs either with the 
use of polymerases161,162 or ligases.157,163 Data are subsequently captured by im­
aging technology and ‘translated’ on the basis of software computer processing.
Focus on 454 pyrosequencing
The 454 technology developed by Life Sciences is based on pyrosequencing 
which is based on the “sequencing by synthesis” principle, relying on detection 
of pyrophosphate release on nucleotide incorporation.156,164-166
Initially, high molecular weight genomic DNA is fractionated into small frag­
ments (300-800 bp), and short adaptors are ligated onto their ends. The adaptors 
provide priming sequences for both amplification and sequencing of the sample- 
library fragments. After samples are enriched for the regions of interest, a sin­
gle-stranded (ss) DNA library is generated. The library is assessed for its quality
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and the optimal amount (DNA copies per bead) needed for emulsification PCR 
by titration. The ssDNA library is immobilised onto specific DNA beads. Each 
of those beads contains a single ssDNA molecule. The bead-bound library is 
emulsified with the amplification reagents in a water-in-oil mixture. Each bead 
is captured within its own micro-reactor where PCR amplification occurs. This 
results in bead-immobilised and clonally amplified DNA fragments, which are 
sequentially subjected to individual pyrosequencing reactions.
Pyrosequencing does not utilise chemically bound fluorophores to detect in­
corporated bases of DNA. Rather, a dNTP is added to a growing, primed DNA 
strand. This addition is catalysed by a DNA polymerase releasing pyrophosphate 
(PPi) in a quantity equimolar to the amount of incorporated nucleotide. The 
pyrophosphate group is converted to ATP in the presence of ATP sulfurylase, 
which when in contact with the enzyme luciferase, produces light. Addition of 
dNTPs is performed sequentially to the growing DNA molecules, in such a way 
that each trace of light is signaling the incorporation of a specific nucleotide.
This pyrosequencing reaction occurs in a massive parallel mode for all the 
copies of DNA fragments (~2 million) bound to each of the beads which are 
sequenced. The signal strength of light emission that is generated is recorded 
by the CCD camera and “translated” in the downstream analysis to provide the 
deduced nucleotide sequence (For overview of the entire process see Figure 11).
The first instrument created using this technology, 454’s GS20 instrument, 
was shown to be able to read up to 25 million bp of a bacterial genome in a sin­
gle four-hour run.156 This system could obtain average sequencing read lengths 
of 110 bp with a raw read accuracy of 96%. Improved versions of this sequencer 
include the “Titanium” GS-FLX, which is able to obtain average read lengths 
of up to 400 bp (normal range of GS-FLX series: 250 bp-400 bp) and is able to 
perform mate-paired reads. Due to an intrinsic error sequencing rate that ranges 
between 0.5% (250 bp readings) to 1% (400 bp readings), a significant coverage 
(minimum >10) is needed to accurately determine specific heterozygous calls at 
any given targeted nucleotide position.167 The GS-FLX system can produce an 
output of 500 million bp in a 7.5hr run.
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Library preparation Emulsion-PCR
Figure 11. Roche 454 platform sequencing. Template DNA is fragmented, ligated to 
adapters (A and B) and clonally amplified by emulsion PCR. After amplification the 
beads are placed into picotiter well plates where pyrosequencing is performed. Gener­
ated luminescence is captured by a CCD camera and ‘translated’ by subsequent analysis 
into nucleotide reads.
Whole genome exon sequencing
Whole genome exon (or exome) sequencing is the most recent and advanced 
strategy to selectively sequence the coding regions of the human genome in 
order to identify novel genes associated with rare and common disorders.168 The 
introduction and ongoing use of massive parallel sequencing technology has 
made it possible to sequence entire individual human genomes. However, both 
costs and capacity required to apply such an approach is still prohibitive for 
daily use. Exome sequencing targets ~1% of the human genome (human exome 
~30 Mb) which is the most functionally relevant and, in case of aberrations, 
most likely to cause disease. Ever since the first application of exome sequenc­
ing on the study of Miller syndrome,168 exome sequencing has proven successful 
at uncovering novel causative mutations in several genetic disorders e.g. Kabuki 
syndrome169 and severe brain malformations.170
Technically exome sequencing combines methods of genome capture or ‘en­
richment’ suited to current parallel sequencing platforms e.g. Roche 454 system, 
as they produce a pool of desired molecules that are separated by the paral­
lel nature of the sequencing technologies themselves. Although many differ­
ent methods of genome capture exist few have focused thus far to target the 
human exome. These include mainly array-based hybridisation and magnetic 
bead liquid-based hybridisation approaches. In the array based hybridisation, 
fragmentation of genomic DNA is used to make shotgun libraries which sub­
sequently are used to target specific exonic sequences on a microarray (Figure
12). RocheNimbleGen was the first to adapt this technology for next-generation 
sequencing using the “SeqCap/SeqCap EZ” platforms replaced by the Sequence 
Capture Human Exome 2.1M Array which captures ~180,000 coding exons,171
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and Agilent Technologies (SureSelect). In the magnetic bead liquid-based hy­
bridisation, genomic DNA undergoes fragmentation, and is hybridised against 
a pool of probes that are biotinylated. The probes are oligonucleotides con­
taining exon sequences. Following hybridization, the biotinylated probes (with 
the complementary desired genomic DNA) are bound to magnetic streptavidin 
beads and are separated from the undesired DNA by washing. After elution, 
enriched DNA can be sequenced.
Presently, exome sequencing technology is at the centre of attention and a 
very useful tool to answer a wide range of questions varying from disease gene 
identification and molecular diagnostics to evolutionary comparison of ancient 
genomes.
A _____ B
Figure 12. Illustration of different capture methods. Light grey bars represent de­
sired genomic sequence, Filled bars represent unwanted sequence.
A) Array-based hybridization. Bait probes (light grey and black) complementary to the 
desired sequence are synthesized on a microarray. Fragmented genomic DNA is ap­
plied, and the desired fragments hybridize. The array is washed, and desired fragments 
are eluted. B) Liquid-phase hybridization. Bait probes (light gray and black) comple­
mentary to the desired regions are synthesized, often using microarray technology. The 
probes are generally biotinylated (asterisk). The bait probes are mixed with fragmented 
genomic DNA, and the desired fragments hybridize to baits in solution. Streptavidin 
beads (black circles) are added to allow physical separation. The bead-bait complexes 
are washed, and desired DNA is eluted.
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1.5. Outline and aim of this thesis
The aim of the present thesis was to elucidate the molecular aetiology of vit- 
reoretinopathies. In chapter 2 we studied eight families with Wagner disease 
and ERVR, identifying three novel disease causing sequence variants in VCAN 
(also known as CSPG2), in seven of them. Moreover, we shed light and propose 
a disease mechanism possibly underlying these two diseases. Chapter 3 outlines 
the studies performed in six consanguineous families with autosomal recessive 
Stickler syndrome and the identification of one novel and one known mutation 
in COL9A1.
In chapter 4, an overview of the mutation spectrum in familial exudative vit- 
reoretinopathy and Norrie disease is presented. Moreover 21 novel variants for 
FZD4, LRP5, and NDP, are reported and the putative functional consequences 
of missense mutations is discussed.
Chapter 5 describes the identification of TSPAN12 as a novel causative gene 
for adFEVR using linkage analysis, array-based sequence capture of exon of 
338 genes of chromosome 11 and next generation sequencing technology.
In chapter 6, I report the identification of a putative novel adFEVR gene by 
combining linkage analysis and exome sequencing.
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Abstract
Purpose. Linkage intervals for erosive vitreoretinopathy (ERVR) and Wagner 
disease previously were found to overlap at 5q14.3. In a Japanese family with 
Wagner disease, a CSPG2/Versican splice site mutation (c.4004-2A>G) was re­
cently reported that resulted in a 39-nucleotide exon 8 in-frame deletion. We 
investigated whether CSPG2/Versican was mutated in six Dutch families and 
one Chinese family with Wagner disease and in a family with ERVR.
Methods. In all families, extensive ophthalmic examinations, haplotype anal­
ysis of the 5q14.3 region, and sequence analysis of CSPG2/Versican were per­
formed. The effects of splice site mutations were assessed by reverse transcrip- 
tion-polymerase chain reaction (RT-PCR) and real-time quantitative RT-PCR 
(QPCR).
Results. Three novel intron 7 sequence variants (c.4004-5T>C, c.4004-5T>A, 
c.4004-1G>A) were identified in seven families. The c.4004-5T>C variant was 
identified in four families with Wagner disease and a family with ERVR. The 
families were shown to carry the same 5q14.3 haplotype, strongly suggesting 
that this is a common Dutch founder variant. All three changes segregated with 
the disease in the respective families and were absent in 250 healthy individuals. 
In patients with the c.4004-5T>A and c.4004-1G>A variants, RT-PCR analysis 
of CSPG2/Versican showed activation of a cryptic splice site resulting in a 39-nt 
exon 8 in-frame deletion in splice variant V0. QPCR revealed a highly signifi­
cant (P < 0.0001) and consistent increase of the V2 (>38-fold) and V3 (>12- 
fold) splice variants in all patients with intron 7 nucleotide changes and in a 
Chinese Wagner disease family, in which the genetic defect remains to be found.
Conclusions. Wagner disease and ERVR are allelic disorders. Seven of the 
eight families exhibit a variant in intron 7 of CSPG2/Versican. The conspicuous 
clustering of sequence variants in the splice acceptor site of intron 7 and the 
consistent upregulation of the V2 and V3 isoforms strongly suggest that Wag­
ner disease and ERVR may belong to a largely overlooked group of diseases 
that are caused by mRNA isoform balance shifts, representing a novel disease 
mechanism.
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Introduction
Patients with Wagner disease (OMIM 143200; Online Mendelian Inheritance 
in Man; http://www.ncbi.nlm.nih.gov/Omim/ provided in the public domain by 
the National Center for Biotechnology Information, Bethesda, MD), a domi­
nantly inherited vitreoretinopathy, show vitreal syneresis with optically empty 
vitreous and equatorial avascular vitreous veils. Additional features include 
mild to moderate myopia, typical dot-like cortical cataracts, abnormal retinal 
vessel architecture (inverted papilla), ectopic fovea, perivascular pigmentation 
and sheathing, retinal thinning, and slowly progressive chorioretinal atrophy. 
Most patients under the age of 20 enjoy normal vision. However, with advanc­
ing age, cataract, retinal detachment, optic atrophy, and chorioretinal atrophy 
may cause visual loss.1-3 Erosive vitreoretinopathy (ERVR; OMIM 143200) 
was first reported as a new clinical entity in 1995.4 ERVR also displays an 
autosomal dominant pattern of inheritance and in addition to the clinical fea­
tures of Wagner disease, reveals progressive nyctalopia (night blindness), visual 
field constriction, and chorioretinal atrophy. Fluorescein angiography reveals 
a conspicuous loss of retinal pigment epithelium (RPE) and choriocapillaris. 
Electroretinography (ERG) studies show a rod-cone abnormality.4 Typically, 
systemic abnormalities are not present in Wagner disease and ERVR, in contrast 
to Stickler syndrome.
Linkage studies assigned the Wagner disease gene to a 2-cM interval at 
5q14.3,4,5 but until recently, no definite causal mutations were identified. The 
critical region for a genetic defect underlying ERVR was found to overlap the 
critical region for Wagner disease, suggesting that these diseases are allelic.4 
Recently, a heterozygous splice site change in CSPG2/Versican (c.4004-2A>G) 
was reported in a Japanese family with Wagner disease.6 This variant was shown 
to result in deletion of 13 amino acids from the beginning of the glycosamino- 
glycan (GAG)-P domain of the mature protein.6
CSPG2/Versican has been an attractive candidate for Wagner disease and 
ERVR based on its genomic location and function. It encodes a large extracellu­
lar matrix proteoglycan (chondroitin sulfate proteoglycan type 2) that is present 
in virtually every human tissue, including different parts of the eye.7 CSPG2/ 
Versican is believed to maintain the structure of the vitreous body in the human 
eye by keeping the collagen molecules apart.8 It has a tridomain structure, and 
the aminoterminal end binds to hyaluronan. The carboxyl-terminal domain has 
a C-type lectin domain adjacent to two epidermal growth factor domains and a 
complement regulatory region. The central area of CSPG2/Versican is encoded 
by two large exons (exons 7 and 8) and contains chondroitin sulfate attachment 
sites. The chondroitin sulfate chains of CSPG2/Versican are highly negatively 
charged and contribute to its anti-adhesive properties. Alternative splicing of 
these two exons results in four different isoforms of the mature protein (Figure
6). V0 contains exons 7 and 8, V1 lacks exon 7 but contains exon 8, V2 con­
tains exon 7 but lacks exon 8, and V3 lacks both these exons.7 Accordingly, the 
potential number of glycosoaminoglycan (GAG) attachment sites for each form 
are V0, 17 to 23; V1, 12 to 15; V2, 5 to 8; and V3, 0.7
- 56 -
Chapter -2-
In this study, we show that most Dutch families with Wagner disease and a 
family with ERVR share a common 5q14.3 founder haplotype and a CSPG2/ 
Versican splice site variant. In two additional unrelated families with Wagner 
disease we found two other sequence variants in the same intron 7/exon 8 splice 
junction. We found a qualitative effect on CSPG2/Versican mRNA splice iso­
forms (i.e., a 39-nt in-frame truncation, in two families with Wagner disease). 
In addition, in all families, we found a significant increase of CSPG2/Versican 
mRNA isoforms V2 and V3 which leads us to propose a novel mechanism for 
disease pathogenesis.
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Methods 
Sample collection
This study was conducted in accordance with the tenets of the Declaration of 
Helsinki. We ascertained seven multigenerational families with Wagner disease 
and one family with ERVR (Figure 1). The clinical diagnosis of Wagner disease 
or ERVR was based on detailed ophthalmic examinations, including Snellen 
visual acuity testing, slit lamp anterior segment and vitreous examinations, in­
direct funduscopy, slit lamp biomicroscopy, and color fundus photography. In 
selected cases, fluorescein angiography, kinetic and static perimetry, electroreti- 
nography, and electro-oculography were also performed.
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Figure 1. W agner disease and ERVR pedigrees and segregation of CSPG2/Versican 
sequence variants. Although the overall number of patients and nonaffected siblings 
are accurate, the pedigrees were anonymized for privacy.
EDTA-anticoagulated venous blood was collected after obtaining the in­
formed consent from the participating individuals. Genomic DNA9 and total 
RNA (Qiagen RNeasy Midi Kit; Qiagen, Venlo, The Netherlands) were iso­
lated from EDTA blood using standard procedures. A panel of 250 anonymous 
healthy Dutch control subjects was tested for the presence of intron 7/exon 8 
splice junction variants. For family W95-137, a fibroblast cell line was gener­
ated from skin biopsy of one patient. Typically, cells were grown in flasks de­
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tached to the bottom. Dulbecco’s modified Eagle’s medium was used containing 
10% fetal calf serum, penicillin (100 U/ml), and streptomycin (100 ^g/ml). The 
cells were split into two equal portions every 3 days, and RNA was isolated 
from 80% confluent cultures.
Genotyping and linkage analysis
Genotyping at the Wagner disease/ERVR locus on chromosome 5 was per­
formed by selecting 13 microsatellite markers from the Genome Database 
(www.gdb.org/ provided by RTI International, NC) covering a region of ap­
proximately 3 cM. For all the markers except D5S626, genotyping PCR was 
performed with primers with a fluorescent label and the results were analyzed 
(GeneMapper; Applied Biosystems, Inc. [ABI], IJssel, The Netherlands). For 
D5S626, 32P end-labeled primers were used. Haplotypes were constructed by 
Cyrillic 2.1 (Cyrillic Software, Wallingford, UK), and checked manually for 
confirmation of cosegregation of the marker alleles with the disease phenotype.
Sequence analysis
The open reading frame (ORF) and the exon-intron junctions of XRCC4 
was analyzed for a proband of family W95-131, as described previously.5 The 
ORF and the exon-intron junctions of the 15 exons of CSPG2/Versican were 
sequenced in a proband from each of the eight families (primer sequences avail­
able on request). Polymerase chain reaction (PCR) was performed according to 
the standard protocols.10 PCR products were purified (QiaQuick columns; Qia- 
gen), either directly or after excision from the gel and were directly sequenced 
using dye termination chemistry (model 3700; ABI).
RT-PCR and real-time quantitative RT-PCR analysis.
Total RNA was isolated from 10 ml of EDTA-anticoagulated venous blood 
within 4 hours after sampling (RNeasy minikit; Qiagen) according to the manu­
facturer’s protocol. cDNA was synthesized from 2.0 ^g total RNA using random 
hexamers (GE Healthcare, Roosendaal, The Netherlands), and M-MLV reverse 
transcriptase (Invitrogen, Groningen, The Netherlands) in a total volume of 85.0 
After the synthesis, the cDNA was purified on PCR purification columns 
(QIAquick; Qiagen) and eluted in 30 ^l sterilized water (milliQ; Millipore, Bed­
ford, MA).
RT-PCR was performed using primer pairs that specifically amplify each 
of the four mRNA splice variants (Figure 6).6 In addition, we used a common 
primer pair that amplifies all mRNA variants, termed Vt for total expression 
(Supplementary Table S1).
For QPCR, 10X dilutions of the cDNA were made and 5.0 ^l from the diluted 
stock was used for each PCR reaction. Primers were designed using Primer 3 
software (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi). Ampli- 
con lengths were typically kept between 80 to 100 bp (Supplementary Table 
S1). Quantitation was performed using relative quantification strategies (SYBR 
Green), according to the manufacturer’s protocol (Bio-Rad, Hercules, CA).
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PCR reactions were performed on a thermocycler (iCycler MyiQ Single-Color 
Real-Time Detection System; Bio-Rad). Initially, the primer conditions were 
optimized and a standard curve was determined for six different dilution points 
(10X-320X) until for each of the primers PCR efficiencies close to 100% were 
obtained. For calculation purpose all the PCR efficiencies were assumed to be 
exactly 100%. For each sample triplicate PCR reactions were performed to en­
sure reproducibility. The differences in expression between patients and con­
trols were calculated by using the 2AACt method.11,12 By definition, Ct is the re­
quired number of amplification cycles to reach the threshold fluorescence level 
(automatically determined); ACt implies the difference in the Ct between the ref­
erence gene (GUSB) and the gene of interest (CSPG2/Versican) and AACt rep­
resents the difference between two ACts. GUSB was used as a reference gene, 
because of its stable expression in lymphocytes.13,14 AACt is the difference be­
tween the mean ACt of eight control subjects and the ACt for individual patients. 
For statistical analysis of the QPCR data, the probabilities were calculated in 
the P-value calculator (www.graphpad.com/quickcalcs/PValue1.cfm/GraphPad, 
Inc., San Diego, CA) available in the public domain.
Splice-Site Score
The predicted effect of the identified intronic variants on splicing were esti­
mated at the server of the Children’s Mercy Hospitals and Clinics at the Univer­
sity of Missouri-Kansas City (https://splice.cmh.edu).15
Results
Ocular phenotypes
The clinical features of at least two patients from each of the four unrelated 
families with Wagner disease, as well as from four patients with ERVR from one 
family are summarized in Table 1. Patients from Wagner disease families W95- 
023, W95-131, W04-153, and W05-088, based on molecular genetic studies 
(see below), are considered to belong to one superfamily. Patients with ERVR, 
in addition to the features observed in patients with Wagner disease (vitreous 
abnormalities, cataract, retinal thinning, ectopia of the macula, and abnormal 
retinal blood vessel architecture), consistently show a progressive and severe 
choriocapillaris and RPE atrophy, resulting in a progressive nyctalopia and a 
marked visual field constriction.
Representative fluorescein angiography pictures are depicted in Figure 2. A 
50-year-old patient with Wagner disease (W95-131P3) showed almost no cho­
rioretinal atrophy (Figure 2A). In contrast, a patient with ERVR (W95-124P2) at 
a somewhat younger age (44 years) shows a severe midperipheral chorioretinal 
atrophy with macular sparing (Figure 2C). In a 32-year-old patient with ERVR 
(W95-124P3), the chorioretinal atrophy is restricted to the peripapillary region 
(Figure 2B).
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Table 1 . Ocular phenotypes o f Wagner disease and Erosive vitreoretinopathy patients.
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P atien ts  w ith  W agner disease
W95-038P1 (F) c.4004-5T>A 5 23
Moderate 
cortical cataract
Optically 
empty, fibrillary 
vitreous
OS ODS
Thin retina (OD),
foveal ectopia (ODS)
ODS
W95-038P2 (F) c.4004-5T>A 3 20 Clear Optically empty OD ODS ? No
W95-131P1 (F) c.4004-5T>C <19 19 Clear Optically empty No No
Peripheral pigmentations 
and retinal holes (ODS)
ODS
W95-131P2 (M) c.4004-5T>C 3 12 Clear
Optically 
empty, fibrillary 
vitreous
ODS ODS
Lattice degenerations 
and retinal holes (ODS)
OS
W95-131P3 (F) c.4004-5T>C 4 4
Posterior 
cortical cataract
Optically 
empty, fibrillary 
vitreous
ODS No
Peripheral pigmentation, peripheral retinal 
defects, vitreous ridge inferonasal (ODS)
?
W95-137P1 (M) c.4004-1G>A 11 35
Posterior
subcapsular
cataract
Optically empty, 
vitreous cords
No ODS
Lattice degeneration and peripheral 
chorioretinal atrophy (ODS), peripheral 
pigmentations (OD), end arteries ending in 
temporal midperiphery (OD), vitreous ridge 
temporal area (OD)
No
W95-137P2 (M)
c.4004-1G>A 6 6
Mild posterior 
cortical cataract
Optically empty, 
vitreous cords
ODS ODS
Vitreous ridge temporal area (ODS), lattice 
degeneration and preretinal membrane
(ODS)
No
W05-282P1 (F) Unknown 19 43
Anterior and 
posterior 
cortical cataract, 
sublaxation of 
lens
Syneresis ODS No
RP, occluded vessels on papil, sheathing 
o f vessels
No
W05-282P2 (M) Unknown 12 18
Mild posterior 
subcapsular 
cataract
Syneresis No ? Sheathing of vessels No
P a t i e n ts  w ith  e r o s iv e  v i t r e o r e t in o p a th y
W95-124P1 (M) c.4004-5T>C ? 69
Cataract 
extraction at 
45 y
Optically empty ODS No
Extensive chorioretinal atrophy with sparing 
of macular area, retinal pigmentations, 
ectopic macula (ODS)
No
W95-124P2 (M) c.4004-5T>C 34 72
Afakia (lens 
extraction) at 
51 y
Optically empty, 
vitreous cords
No No
Extensive chorioretinal atrophy, some 
pigment clumps in retina, ectopic macula
No
W95-124P3 (M) c.4004-5T>C 32 44
Cataract 
operation at
34 y
Optically empty No No
Demarcated chorioretinal atrophy, ectopic 
macula, paravascular retinal pigmentations 
ODS
No
W95-124P4 (F) c .4 0 0 4 -5 T > C 27 37
C o rtica l
o pa c itie s
O p tica lly
e m p ty
No No
D e m a rca te d  ch o rio re tin a l a tro p h y  
e c to p ic  m a cu la
No
F, Fem ale; M, Male; OD, R ight eye; OS, Left eye; ODS, Both eyes; RD, Retina l detachm ent; RP, R etinitis p igm entosa; ?, unknown.
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W95-131P3 W95-124P3 W95-124P2
Figure 2. Fluorescence angiography (FAG) pictures of patients with erosive vitreo­
retinopathy and W agner disease. A) FAG of Wagner disease patient W95-131P3, at 
the age of 50 years. B) FAG of peripapillary region of ERVR patient W95-124P3 at age 
32. C) FAG of posterior pole of Er Vr  patient W95-124P2 at age 44. Note the wide­
spread atrophy of the choriocapillaris and RPE which visualizes the larger choroidal 
blood vessels.
Identification of a founder haplotype in Dutch families with ERVR 
and Wagner disease.
We determined the 5q14.3 haplotypes in ~120 individuals ofthe families W95-
023, W95-038, W95-124, W95-131, W04-153, and W05-088, most of which 
are depicted in Figure 1, employing 13 microsatellite markers. The phenotypes 
in these families fully cosegregated with marker alleles of the 5q14 region (data 
not shown) suggesting genetic homogeneity for Wagner disease. The haplotypes 
of patients carrying critical recombinations in 5q14 are depicted in Figure 3. 
Recombinations observed in the affected individuals from families W95-023 
and W95-131 restricted the region to approximately 850 kb with D5S626 and 
D5S107 as the flanking markers. All patients from four Wagner disease families 
(W95-023, W95-131, W04-153, W05-088) and from the ERVR family (W95- 
124) showed the same haplotype for the critical region, suggesting the presence 
of a founder allele in the Netherlands.
Identification of three novel intronic mutations in CSPG2/Versican 
in patients with Wagner disease and ERVR.
The two genes present in the critical interval—namely, CSPG2/Versican and 
XRCC4—were analyzed in a patient of family W95-131. No variants were iden­
tified, except for a c.4004-5T>C change in CSPG2/Versican (Figure 4). The 
same variant was identified in the DNA of all patients from the three other ped­
igrees (W95-023, W04-153, and W05-088) belonging to the Wagner disease 
superfamily, and none of the unaffected individuals (Figure 1). In addition, we 
found a c.4004-5T>A change in the proband of family W95-038 and a c.4004- 
1G>A change in a proband from family W95-137 (Figure 4) which also showed 
cosegregation with the disease in the respective families (Figure 1).
- 62 -
Chapter -2-
W 95-023 W95-124
(E R V R )
W95-131
D5S424
D5S1501
D5S2029
D 5S 626
D5S641
D5S1347
D5S2094
CSPG2
CRTL1
D5S107
D5S428
D 5S 617
D 5S 1722
D5S1463
M bp
>2.3
>2.9
>0.2
>0.4
>0.3
>0.1
>0.4
>0.05
>0.6
>1.8
>0.7
>2.3
>1.8
122 122 122 ? 130 ? ?
96 96 110 110 106 110 ?
149 149 149 149 137 149 149
? ? 3 ? 1 ? ?
267 267 267 267 267 267 267
310 310 310 310 310 310 310
135 135 135 135 135 135 135
230 230 230 230 230 230 230
148 134 134 150 134 134 134
254 254 254 244 254 254 ?
196 188 188 188 188 188 ?
227 231 231 ? 231 ? ?
169 181 193 ? 193 ? ?
W04-153 W05-088 W95-038
136
96
129
?
269
302
135
222
152
252
196
223
177
Figure 3. Haplotype analysis of the 5q14.3 region in Dutch families with Wagner 
disease and erosive vitreoretinopathy. The disease haplotypes are shown for one or 
a few patients that show recombination events that position the critical region between 
D5S626 and D5S107. The physical distances between the markers are given as obtained 
from the UCSC genome browser. All families, except W95-038, share part of the same 
haplotype for the critical region ( ), suggesting that the c.4004-5T>C variant represents 
a founder variant in The Netherlands. Question marks: markers not tested or not scored.
Figure 4. CSPG2/Versican sequence variants at the intron 7/exon 8 junction identi­
fied in patients with W agner disease. Chromatograms showing the sequence variants 
(arrows). Box around GTC: 5' end of exon 8. PCR and sequencing primers are depicted 
in Supplementary Table S1.
As expected from the haplotype data, all patients and none of the unaffected 
individuals from the ERVR family (W95-124) showed the same T>C change as 
observed in the other related families with Wagner disease (Figure 1). Sequence 
analysis of the intron 7-exon 8 splice junction in 250 ethnically matched Dutch 
healthy individuals did not reveal any of these changes. These results strongly 
suggest the presence of a founder allele (c.4004-5T>C) in most of the Dutch 
patients with Wagner disease and in a family with ERVR, a clinically related 
phenotype. The causal variant in the Chinese family with Wagner disease has 
not yet been identified.
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Effect of intron 7 variants on CSPG2/Versican transcripts.
The c.4004-1G>A variant affects one of two completely conserved nucleo­
tides of the canonical 3' splice site of intron 7 and therefore is predicted to have 
a major effect on CSPG2/Versican splicing. The c.4004-5T>C and c.4004-5T>A 
variants are predicted to retain 64% and 14% of the original binding capac­
ity, respectively (https://splice.cmh.edu). To investigate their effect on splicing, 
both qualitative and real-time quantitative RT-PCR analyses were subsequently 
performed.
The c.4004-1G>A and c.4004-5T>A nucleotide variants result in the activa­
tion of a cryptic downstream splice acceptor site of exon 8. V0 shows the wild­
type and the 39-nt shortened cDNA fragments (Figure 5, lanes 1, 2, and 4), 
mimicking the previously described result.6 For V1, this effect is faintly visible.
Figure 5. RT-PCR results for the V0 and V1 CSPG2/Versican splice variants in 
patients with W agner disease. Total RNAs were isolated within 4 hours after veno- 
puncture, except for patient W95-137P1 (lane 1), for which RNA was isolated from 
cultured fibroblasts. Lanes 1 and 2: patient W95-137P1; lane 3: patient W95-131P1; 
lane 4: patient W95-038P1; lane 5: patient W05-282P1; and lane 6: control. The V0 
variant in patients W95-137P1 and W95-038P1 (lanes 1, 2, and 4) shows approximately 
equal quantities of wild-type and 39-nt deleted cDNA fragments; patients W05-282P1 
and W95-131P1 (lanes 3 and 5) show no or almost no deleted V0 cDNA. This effect is 
faintly visible for splice variant V1.
The c.4004-5T>C variant has only a small effect on the downstream splice 
acceptor (Figure 5, lane 3). RNA from both lymphocytes and fibroblasts show 
the same effect on V0 and V1 for c.4004-1G>A mutation (Figure 5, lanes 1 and 
2). RT-PCR analysis of RNA from a patient of the Chinese family with Wagner 
disease (W05-282) did not show an activation of the downstream cryptic splice 
acceptor site (Figure 5, lane 5). For the ERVR family the RT-PCR result was 
similar to that of W95-131 (data not shown).
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Quantitation of the CSPG2/Versican mRNA isoforms.
To quantitate the expression levels for different CSPG2/Versican isoforms in 
patients, QPCR was performed on blood cell RNA using a relative quantifi­
cation method (SYBR Green; Bio-Rad). The expression levels of each splice 
variant and the total expression (Vt) of CSPG2/Versican were analyzed for two 
patients from each of the Wagner disease families with different intron 7 se­
quence variants, as well as two patients from a Chinese family with Wagner 
disease (W05-282) and the ERVR family, and compared to the mean expression 
values obtained from eight control subjects. Initially, we used total RNAs iso­
lated from EBV-immortalized lymphocytes of control subjects and patients, but 
results were very variable (data not shown). Therefore, we collected new venous 
blood samples from controls and patients and extracted RNA within 4 hours of 
venipuncture. The total expression level of CSPG2/Versican in eight controls 
now was robust, enabling us to use the mean values for further analyses (Table
2). Table 3 and 4 show the ACt and the x-fold changes (2AACt), respectively, for 
the patients with Wagner disease and ERVR. The V2 isoform was upregulated 
between 38- and 478-fold (P < 0.0001), and the V3 isoform was upregulated 
between 12- and 52-fold (P < 0.0001). A 40-fold upregulation in patients indi­
cates that the threshold fluorescence is reached approximately five amplification 
cycles earlier than that in control subjects. The patients from family W95-131 
(Wagner disease) and W95-124 (ERVR), carrying the c.4004-5T>C change, 
showed comparable upregulation for V2 and V3 (Table 4). Patients W95-137P1 
and P2, carrying the c.4004-1G>A change, as well as the two Chinese patients 
with Wagner disease (W05-282P1 and -P2), showed the highest upregulation of 
V2 and V3. The V0 and V1 isoforms showed a tendency to be downregulated 
(Table 4).
Table 2. Real-time quantitative mRNA analysis 
of CSPG2/Versican in eight control samples.
Control Individual
Vt
CSPG2/Versican splice variant
V0 V1 V2 V3
1 3.8 -0.9 3.4 -10.1 -4.0
2 2.9 -2.2 2.7 -10.8 -4.2
3 2.8 -2.5 2.3 -11.0 -3.5
4 3.0 -1.9 2.6 -11.7 -3.8
5 3.1 -1.4 3.0 -11.2 -3.4
6 3.9 -1.3 3.4 -9.9 -2.8
7 3.3 -1.4 3.0 -10.2 -4.0
8 3.2 -1.3 2.9 -10.5 -5.0
Mean 3.2 -1.6 2.9 -10.7 -3.8
Standard deviation 0.42 0.52 0.38 0.62 0.66
ACt (CtGUSB -  CtCSPG2) for CSPG2/Versican total mRNA (Vt) and splice variants (V0- 
V3).
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Table 3. Real-time quantitative mRNA analysis of CSPG2/Versican 
in patients with Wagner disease and erosive vitreoretinopathy.
Patient Sequence Variant Vt CSPG2/Versican Splice Variant
V0 V1 V2 V3
W95-038P1 c.4004-5T>A 2.3 -2.3 1.7 -5.0 0.0
W95-038P2 c.4004-5T>A 2.9 -1.9 2.0 -5.2 0.0
W95-124P1 c.4004-5T>C 2.2 -1.6 2.3 -5.4 -0.1
W95-124P2 c.4004-5T>C 3.2 -0.6 2.9 -4.5 0.2
W95-131P1 c.4004-5T>C 2.9 -1.9 2.3 -5.2 -0.2
W95-131P2 c.4004-5T>C 3.2 -2.0 2.7 -5.4 0.1
W95-137P1 c.4004-1G>A 3.0 -1.9 2.3 -3.6 0.7
W95-137P2 c.4004-1G>A 3.4 -2.0 2.0 -2.6 1.3
W05-282P1 Unknown 3.6 -1.8 2.3 -1.8 1.9
W05-282P2 Unknown 3.7 -1.5 2.2 -1.9 1.4
ACt (CtGUSB -  CtCSPG2) for CSPG2/Versican total mRNA (Vt) and splice variants (V0- 
V3) in the patients with Wagner disease or erosive vitreoretinopathy. All the samples are 
from families with Wagner disease except W95-124, which is the family with erosive 
vitreoretinopathy.
Table 4. Relative quantities (2AACt) of CSPG2/Versican mRNA 
splice variants in patients with 
Wagner disease or Erosive vitreoretinopathy compared with control subjects.
Patient Sequence Variant Vt CSPG2/Versican Splice Variant
V0 V1 V2 V3
W95-038P1 c.4004-5T>A 0.54 0.62 0.44 52.0* 13.9*
W95-038P2 c.4004-5T>A 0.81 0.81 0.54 45.3* 13.9*
W95-124P1 c.4004-5T>C 0.49 1.02 0.64 38.3* 12.8*
W95-124P2 c.4004-5T>C 1.0 1.95 0.98 71.2* 16.3*
W95-131P1 c.4004-5T>C 0.81 0.81 0.66 45.3* 12.1*
W95-131P2 c.4004-5T>C 1.00 0.76 0.87 39.4* 14.9*
W95-137P1 c.4004-1G>A 0.87 0.81 0.66 137.2* 22.6*
W95-137P2 c.4004-1G>A 1.15 0.76 0.54 274.4* 34.3*
W05-282P1 Unknown 0.87 0.87 0.66 477.7* 52.0*
W05-282P2 Unknown 1.15 1.07 0.62 445.7* 36.8*
2AACt represents the x-fold change of the respective splice variant in the patient compared 
with the mean expression level of the splice variant in eight healthy control subjects. 
(AACt = ACt t i t  -  ACt trl ).v patient control mean'
* P < 0.0001. The probabilities were calculated in P-value calculator (http://www.graph- 
pad.com/quickcalcs/PValue1.cfm) from the Z value, based on the standard deviations 
obtained from the control group (Table 2). All the samples are from families with Wag­
ner disease except W95-124, which is the family with erosive vitreoretinopathy.
- 66 -
Chapter -2-
Discussion
In this study, we narrowed the critical region for Wagner disease to a 850-kb 
interval on 5q14.3 and also identified a founder haplotype in four large Dutch 
families with Wagner disease which, to our surprise, was also present in a fam­
ily with ERVR. Affected ancestors of these five families were traced to the 
same (southern/middle) geographical region of The Netherlands. These fami­
lies harbor >90% of all Dutch patients with Wagner disease. On identification 
of a CSPG2/Versican intron 7 sequence variant (c.4004-5T>C) in one of the 
probands we showed that this variant was present in all affected individuals of 
these four families with Wagner disease and the ERVR family. In addition, we 
found c.4004-5T>A and c.4004-1G>A variants in two unrelated families with 
Wagner disease.
Detailed RNA analysis of patients from these families, as well as from a Chi­
nese Wagner disease family in which a sequence variant was not yet found, 
revealed two putatively important effects on CSPG2/Versican mRNA isoforms. 
First, we identified a 39-nt deletion in mRNA isoform V0 in patients carrying 
c.4004-1G>A (W95-137) and c.4004-5T>A (W95-038) variants. The same 39- 
nt deletion was found previously in a Japanese family with Wagner disease, 
carrying a c.4004-2A>G mutation.6 Because the deleted 13 amino acids of V0 
do not harbor a GAG attachment site, this truncation is likely to have little or 
no effect on the function of the protein, although changes on secondary or ter­
tiary structure cannot be ruled out. The c.4004-5T>C variant in the four Dutch 
families with Wagner disease and the ERVR family and the unknown mutation 
in the Chinese family were not associated with a clear-cut structural effect on 
the V0 isoform. However, we assume that all the identified intron 7 variants 
lead to a decrease of isoforms V0 and V1. Possibly, patients with the c.4004- 
5T>C variant harbor an additional, as yet unidentified, intron 7 sequence variant 
that contributes to the skipping of exon 8. The reduction in mRNA isoforms 
V0 and V1 is difficult to quantify, but is probably reflected in the second effect 
we observed on CSPG2/Versican mRNA, a significant increase in isoforms V2 
(>38-fold) and V3 (>12-fold), which have five to eight or no GAG side chains, 
respectively.
Given the relatively low V2 and V3 splice isoform abundances in normal 
blood samples (Table 2), even a small decrease in the V1 isoform is predicted to 
have a dramatic effect on the expression of the V2 and V3 isoforms (Table 3). In 
view of the unknown absolute levels of CSPG2/Versican isoforms in different 
compartments of the human eye, it is difficult to predict the functional effect of 
the observed mRNA isoform changes. Recently, Zhao and Russell reported on 
the expression of CSPG2/Versican in human trabecular meshwork and ciliary 
muscle with V1, V0, V3, and V2 in a decreasing order of expression levels,16 
which is similar to the expression levels we found in peripheral blood and skin 
fibroblasts. Of note, as described in the ocular phenotype section, the patients 
with ERVR clearly had a more severe eye phenotype than did patients with 
Wagner disease, which suggests that other genetic factors play a role. A more 
severe retinal phenotype in patients with ERVR is not reflected in the QPCR
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results of patients with ERVR (W95-124P1 and -P2) versus Wagner disease 
patients with the same intron 7 variant (W95-131P1 and -P2; Table 4), as no 
consistent difference in upregulation of the V2 and V3 isoforms was observed. 
We hypothesize that insufficient quantities of isoforms V0 and V1 may under­
lie both Wagner disease and ERVR. Whether subtle quantitative differences of 
V0 and/or V1 isoform can explain the difference in clinical severity of Wagner 
disease and ERVR remains to be investigated. The method used is not accurate 
enough to quantitate these subtle differences. Possibly, expression levels of the 
normal CSPG2/Versican gene also play a role.
Natural variation of CSPG2/Versican isoform expression may also explain the 
relatively high upregulation we identified in the Chinese family. If the normal 
expression of CSPG2/Versican isoforms V0 and V1 in the Asian population is 
higher than in the white population, or if isoforms V2 and V3 expression levels 
are lower in the Asian population than in the white population, disruption of V0 
and V1 splicing would lead to higher relative upregulation of V2 and V3, as we 
observed. We propose that the causal variant resides in intron 7 or 8 causing 
similar balance shifts as found in the Dutch families with Wagner disease. The 
efforts to identify such variants are currently ongoing.
The absence of disease-causing mutations in the sizeable ORF (10,200 bp) 
of CSPG2/Versican in the families included in this study and in at least five 
other unrelated patients with Wagner disease (Black GCM, unpublished results, 
1999), the conspicuous clustering of putative causal variants in the splice ac­
ceptor site of intron 7 found in this study and in the previously reported Japa­
nese family,6 and the consistent V2 and V3 mRNA isoform upregulation lead 
us to believe that Wagner disease and ERVR are caused by an imbalance of the 
CSPG2/Versican isoforms, mediated by intronic variants. It is estimated that as 
much as 15% of point mutations causing human diseases affect the canonical 
splice sites,17 but this may be an underestimate. In most cases, the invariant AG 
or GT sequences of the 3' and 5' splice sites are mutated. The polypyrimidine 
stretch of 3' splice sites often harbor benign sequence variants. However, in 
a family with X-linked mental retardation, an -11C>T change of intron 1 of 
the ARHGEF6 gene resulted in skipping of the second exon.18 To the best of 
our knowledge, the only other inherited disorder that is exclusively caused by 
intronic mutations and exon skipping is autosomal dominant sensorineural deaf­
ness type 5.19
In conclusion, in this study the pathologic role of CSPG2/Versican mutations 
in Wagner disease has been significantly strengthened. We provide strong evi­
dence that, in our cohort of patients, Wagner disease is associated with CSPG2/ 
Versican intron 7 variants which result in a 39-nt truncation of isoform V0 in at 
least two of seven families. In addition, we show that Wagner disease and ERVR 
are allelic disorders and that they can be associated with the same intron7-exon 
8 splice site variant. The intron 7 variants consistently result in a dramatic up­
regulation of the V2 and V3 isoforms, most likely due to the suppression of the 
V0 and V1 mRNA isoforms (Figure 6). Both a V2/V3 overexpression model 
or a partial V0/V1 loss-of-function model could underlie Wagner disease and
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ERVR, though we favor the latter model. The pathogenic mechanism of the 
disease likely involves a reduction of chondroitin sulfate side chains of CSPG2/ 
Versican. It can be predicted that other Wagner disease mutations can be found 
deep in intronic regions, most likely introns 7 (14,697 nt) or 8 (3,268 nt). Hence, 
Wagner disease and ERVR seem to belong to a largely overlooked group of 
diseases that are caused by a novel disease mechanism based on mRNA isoform 
balance shifts. Recent studies showed how splicing modulation may restore the 
function of the cystic fibrosis transmembrane conductance regulator.20 If such 
an approach becomes feasible in a therapeutic setting, Wagner disease may be 
amenable to this treatment.
Figure 6. CSPG2/Versican splice variants and their relative quantities in healthy 
individuals versus patients with W agner disease. The four major isoforms are sche­
matically depicted. The skipping of exon 7 and/or exon 8 are shown as appropriate. The 
constitutive used exons 2 to 5 and 10 to 14 are not shown. The GAG attachment sites 
on exons 7 and 8 are indicated. At the right, the relative expression levels of different 
isoforms are shown for normal individuals versus patients with Wagner disease. Please 
note that for each isoform a different scale was used for normalization. The question 
marks indicate that the exact reductions for V0 and V1 could not be determined.
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Note Added in Proof
During the revision of this manuscript, the CSPG2/Versican defect in the orig­
inal Wagner disease was published in: Kloeckener-Gruissem B, Bartholdi D, 
Abdou MT, Zimmermann DR, Berger W. Identification of the genetic defect in 
the original Wagner syndrome family. Mol Vis. 2006;12:350-355.
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Supplementary Table SI. Primer Sequences for CSPG2/Versican.
F orward Primer ( 5 ’ -3 ’ ) Reverse Primer ( 5 ’ -3 ’ ) Region or Splice 
Variant Amplified
Product 
Size (bp)
Primers on genomic sequence
C TT GGGGT GAGAAC C C T GTAT CAGCTTAACCTGATATTTCCTCAC Exon 6-Intron 6 junction 319
C C TC A AC T GGTAAC AGT CAT GC GGAAT GAC AGGTA ATT CAT C AAC Intron 6-Exon 7 junction 405
TC C T GC TAC AC AGC C AAC AAG GC AAAAC GATTTTAGC C GT C C AC Exon 7-Intron 7 junction 565
GATT C C TT GC TT C ATTTTAAGGAC T GC AC T GGAT C T GTTT C TTC A Intron 7-Exon 8 junction 374
AGGTT GC AAC AC C AC C ATTT TTC ATC TTTTC C AT GTT GTAATT G Exon 8-Intron 8 junction 369
CAT GC C AAC TA AAT C TGC AGTAG TTCACACT GGT C TC C GC T GTA Intron 8-Exon 9 junction 406
Primers on transcript sequence (used fo r  real-time PCR)
TT C AAC C TTAATAGTAAC C C AT GC AAGGTAGGC TGAC TTTTC C AGAG CSPG2 Vt 95
C AGC AAGC AC AAAATTT C AC C CTCAAATCACTCATTCGACCTG CSPG2 VO 85
T C GTTTT GAGAAC CAGACAGG C T C AAAT CACTCATTC GAC GTT CSPG2 VI 84
C C AGC AAGC AC AAAATTT C A GTT C ATTTT GC AGC GAT C AG CSPG2 V2 90
T C GTTTT GAGAAC CAGACAGG GTT C ATTTT GC AGC GAT C AG CSPG2 V3 88
AGAGTGGTGC TGAGGATTGG CCCTCATGCTCTAGCGTGTC GUSB 80
O)
l- tIK>i
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Abstract
Purpose. To investigate COL9A1 in two families suggestive of autosomal re­
cessive Stickler syndrome and to delineate the associated phenotype.
Methods. The probands of two consanguineous autosomal recessive Stickler 
families were evaluated for homozygosity by genotyping using the GeneChip 
Genome-Wide Human SNP Array 5.0 in one and by haplotype analysis in the 
other. Subsequently, the entire COL9A1 open reading frame was analysed by 
DNA sequencing in all members from the respective families. Several family 
members were investigated for dysmorphic features as well as ophthalmologic, 
audiologic and radiologic abnormalities.
Results. We identified a novel homozygous COL9A1 mutation (p.R507X) in 
two affected Turkish sisters and the previously published mutation (p.R295X) 
in a Moroccan boy. Ophthalmic assessment revealed myopia, cataracts, distinct 
vitreous changes, progressive chorioretinal degeneration, exudative and rheg- 
matogenous detachments. All three had sensorineural hearing loss, and epiphy­
seal dysplasia. Intervertebral disk bulging was observed in one patient and in 
two heterozygous carriers of the p.R507X mutation.
Conclusions. We identified a second, novel mutation in COL9A1 causing 
autosomal recessive Stickler syndrome together with the previously described 
nucleotide change in two separate families. Although the overall phenotype was 
comparable to autosomal dominant Stickler, we were able to identify vitreous 
changes that may enable recognition of patients likely to carry mutations in 
COL9A1 and observed exudative detachment as a new finding in Stickler syn­
drome.
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Introduction
Stickler syndrome is a genetically heterogeneous connective tissue disorder 
that affects the ocular, skeletal, orofacial and auditory systems. Mutations in 
three collagen genes, COL2A1 (Stickler syndrome type I STL1 [MIM 108300]),1 
COL11A1 (Stickler syndrome type II STL2 [MIM 604841])2 and COL11A2 
(Stickler syndrome type III STL3 [MIM 184840]),3 have been shown to cause 
autosomal dominant Stickler syndrome. Yet, an autosomal recessive form of the 
disease has been reported once in a consanguineous family of Moroccan origin 
caused by a homozygous nonsense mutation in COL9A1.4
Clinical subclassification of Stickler syndrome is mainly based on vitreous 
changes, as the systemic features that can include premature osteoarthrosis, cleft 
palate, hearing impairment, and craniofacial abnormalities are highly variable 
even within families and not specific to any gene locus. The most common form 
is STL1 caused by COL2A1 mutations and the majority of these patients display 
a congenital vitreous abnormality consisting of a vestigial gel in the retrolental 
space, bounded by a highly folded membrane (membranous or type I vitreous). 
STL2 patients with COL11A1 mutations display a fibrillar and beaded appear­
ance to the vitreous (fibrillar or type II vitreous). Recently, a third, more rare 
form was added consisting of a hypoplastic vitreous that can be either caused 
by mutations in COL2A1 or COL11A1.5 STL3 is a non-ocular form of Stickler 
syndrome, because COL11A2, the gene that is mutated in STL3, is not expressed 
in the eye. Premature degenerative changes due to progressive liquefaction were 
noted in the autosomal recessive family with COL9A1 mutations.4 Since the 
incidence of rhegmatogenous detachments among Stickler patients is high, it is 
important to identify affected individuals through eye examination and direct 
genetic testing for confirmation of the diagnosis.
Here we report on two families with an autosomal recessive form of the Stick­
ler syndrome. Mutation analysis of the open reading frame (ORF) of COL9A1 
revealed one novel (c.1519C>T, p.R507X) and one previously reported non­
sense nucleotide change (c.883C>T, p.R295X). These two mutations were 
found in a homozygous state in the affected members of two families. Detailed 
clinical information of these families confirms the assumption by Van Camp 
and colleagues,4 that vitreous changes in patients with COL9A1 mutations differ 
from those described in patients with COL2A1, and COL11A1 mutations.
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Methods 
Genetic analysis
This study was approved by the ethical review boards of The Rotterdam Eye 
Hospital and the University of Antwerp, and conformed to the tenets of the 
Declaration of Helsinki. Informed consents were obtained from the participants 
before EDTA-anticoagulated venous blood was collected. Genomic DNA was 
isolated using standard procedures.6
Homozygosity mapping
Haplotyping was performed in one proband of the two consanguineous fami­
lies using five highly polymorphic microsatellite markers (D6S467, D6S254, 
D6S313, D6S1557 and D6S455) covering a 2-cM region encompassing CO- 
L9A1. Capillary electrophoresis and pattern visualization of the fluorescently 
labeled PCR products were carried out using an ABI 3130XL automatic DNA 
sequencer (Applied Biosystems Inc., Foster City, USA). Allele sizes were deter­
mined using the GeneMapper V3.7 software (Applied Biosystems Inc.).
The DNA of the proband (Family 1, II-4; Figure 1) of the other consanguine­
ous family was genotyped with the GeneChip Genome-Wide Human SNP Ar­
ray 5.0 (Affymetrix). Array experiments were conducted according to protocols 
provided by the manufacturer. Data from the SNP array analysis were genotyped 
with Genotype Console software (Affymetrix), whereas regions of homozygos­
ity were calculated with Partek Genomics Solution (Partek).
Family 1
1-1
M1/+
■o
I-2
M1/+
Family 2
1-1
M2/+
1 o o • ■
11-1 II-2 II-3 II-4 11-1
M1/M1 M1/+ M1/+ M1/M1 M2/M2
o
I-2
M2/+
Figure 1. Complete pedigrees of Families 1 and 2 with autosomal recessive Stickler 
syndrome, and the segregation of the mutations identified in these families. Black­
ened symbols represent affected individuals and white symbols represent non-affected 
individuals. M i/M i indicates homozygous carriers of the p.R507X mutation, M1/+ in­
dicates heterozygous carriers of the p.R507X mutation, M2/M2 indicates homozygous 
carriers of the p.R295X mutation, M2/+ indicates heterozygous carriers of the p.R295X 
mutation.
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Mutation analysis
The ORF and the exon-intron junctions of the 38 exons of COL9A1 were 
sequenced from forward and reverse strand initially in a proband from each of 
the two families (primer sequences available on request). Segregation studies of 
the identified mutations were performed in all available family members. Poly­
merase chain reaction (PCR) was executed according to the standard protocols. 
PCR products were purified (QiaQuick columns; Qiagen), either directly or af­
ter excision from the gel and were sequenced using an ABI 3130XL sequencer 
with the BigDyes Terminator v1.1 Cycle Sequencing Kit (Applied Biosystems 
Inc.).
Clinical diagnosis
We examined two consanguineous families with suspected autosomal reces­
sive Stickler syndrome, one of Turkish and one of Moroccan descent. Both fam­
ilies were investigated for ophthalmologic, audiologic and radiological abnor­
malities, and dysmorphic features. All available retrospective data were studied 
when possible.
In one of the two families that harboured COL9A1 mutations (Family 1), a 
more detailed ophthalmologic assessment was performed, including best cor­
rected visual acuity, biomicroscopy, ophthalmoscopy, and fundus photography. 
Fourier domain optical coherence tomography (OCT), (RTVue, Optovue Inc., 
Fremont, USA), was performed in two affected and two non-affected family 
members of Family 1. Additionally, a scan biometry (IOLMaster, Carl Zeiss 
Meditec, Germany), Goldmann perimetry, electrophysiology (ISCEV stan­
dards),7 ultrasonography, and spectral domain OCTs (Spectralis®, Heidelberg 
Engineering, Heidelberg, Germany) were obtained in the affected patients of 
Family 1.
Audiologic examination included pure-tone audiometry that was performed 
with air conduction at 125, 250, 500, 1000, 2000, 4000, and 8000 Hz, and bone 
conduction at 250, 500, 1000, 2000, and 4000 Hz in the two affected individuals 
of Family 1 and their parents, and the proband of Family 2.
Radiographic data of the hips were available for all three affected persons 
(Family 1, II-1 and II-4; Family 2, II-1), and of the hands and knees in two 
patients (Family 1, II-4; Family 2, II-1). MRIs of the cervical spine and the 
cerebrum were available for one patient (Family 1, II-4). MRI of the spine was 
obtained in the two heterozygous sisters of Family 1 (II-2, II-3).
General examination was performed by a clinical geneticist and facial features 
were documented by photographs. Individual I-1 from Family 1 died of a myo­
cardial infarction during the project.
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Results
Genetic analysis
Genome-wide SNP genotyping in patient II-4 of Family 1 (Figure 1), who is 
of Turkish descent, revealed three homozygous regions > 10 Mb. A fourth ho­
mozygous region of 5.0 Mb, was located at chromosome 6q12-q11.1 between 
SNP_A-2144407 and SNP_A-1833968, encompassing COL9A1. In patient II-1 
of Family 2, who is of Moroccan descent, haplotype analysis also displayed a 
homozygous region spanning COL9A1. Sequencing analysis revealed two CO- 
L9A1 homozygous nonsense mutations: one novel (Family 1: c.1519C>T lead­
ing to p.R507X, Table 1; Figure 1) and one known (Family 2: c.883C>T leading 
to p.R295X, Table 1; Figure 1). The two heterozygous nucleotide changes were 
also identified in the non-affected members of the two respective families.
Haplotype analysis of the Moroccan family (Family 2) also showed that it 
does not only share the same mutation with the Moroccan family previously de­
scribed, but also the identical disease haplotype in the 2-cM area encompassing 
COL9A1 (data not shown), indicating a possible relationship.
Clinical characteristics
Ophthalmologic findings
An overview of all the clinical data from Families 1 and 2 is presented in Table
1. In Family 1, individual II-1 was less severely affected than her younger sister 
(II-4). Both of them had a moderate myopia before a photorefractive keratotomy 
was performed elsewhere. From the age of 21 onwards, patient II-4 developed 
progressive epiretinal membranes with vitreoretinal traction. This led to an in­
creasing number of telangiectatic vessels with small neovascularizations over 
the years and an exudative retinal detachment with Coats’-like vasculopathy 
in the right eye on recent examination (Figure 2). The vitreous body in both af­
fected sibs was partially liquefied, and distinctly divided by membranous veils 
as seen on slit-lamp examination and ultrasound. Epiretinal membranes with 
progressive vitreo-retinal traction and retinoschisis were documented with OCT 
(Figure 2). A progressive, chorioretinal degeneration was observed in both pa­
tients leading to visual field defects, and loss of rod-cone responses on electro­
physiology. This was most pronounced in the younger sister with the exudative 
changes whose ERG was almost non-recordable (Figure 3). Except for one ab­
normal, large vitreous floater in case II-2 of Family 1, no ophthalmic abnormali­
ties were observed in the heterozygotes on ophthalmoscopy and OCT.
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Table 1 . Clinical features o f  all members in Families 1 and 2  w ith autosomal recessive Stickler syndrome.
Pa­
tie n t
A ge COL9A1
G enotype
O phthalm ology A udiogram R adio logy G eneral features M iscellaneous
VA:
RE/LEA
Refr :(D) 
RE/LE
1/1-1 65 yrs wt/R507X N/T N/T N/T SNHL 60 dB N/T Height: 1.65 m Died o f myocar­
dial infarction
1/1-2 67 yrs wt/R507X 0.7/0.5 Plano Pseudophacic, normal vitre­
ous, normal fundi
SNHL 20dB N/T Height: 1.58 m Diabetes melli­
tus, hypertension
l/II-l 43 yrs R507X/
R507X
0 .6/0 .5 -6.25/- 
8.00 (24
yrs)t
Cataract extraction (32 yrs),
axial length 25 mm  ^ , vit­
reous membranes, VR ad­
hesions, paravascular retinal 
degeneration, retinoschi- 
sisGoldmann: midperiph­
eral sensitivity loss,ERG: 
reduced responses,OCT:
VR traction, schisis
Progressive
SNHL
Coxa vara with 
short femoral necks 
& broad flattened 
femoral heads, 
thoracolumbar sco­
liosis, degenerative 
vertebral changes, 
narrow disc space 
C5-6
Height: 1.50 m,normal 
facial features,dysarthric 
speech,bilateral pes piano 
valgus,hypoplasia o f the 
lateral femoral condyles,no 
hypermobile joints
Spondy lodes is 
due to thoraco- 
lumbal sc olio - 
sis(l 5 yrs), 
cholecystectomy 
(24 yrs)
1/II-2 41 yrs wt/R507X 1 .0/ 1.0 Plano Clear lens,pronounced vit­
reous opacity (RE),normal 
fundi,OCT: normal
N/T Intervertebral disk 
bulging, S chmor 1 ’ s 
nodules
Height: 1.55 m,straightened 
lumbar lordosis, 
hypermobile joints
None
1/II-3 36 yrs wt/R507X 1 .2/ 1.2 Plano Clear lens,normal 
vitreous,normal fundi,OCT: 
normal
N/T Cervical hernia C5-6 Height: 1.60 m,no hyper- 
mobile joints
None
1/II-4 29 yrs R507X/
R507X
0.10/0.16 -6.50/-
5.75
(lS yrs)f
Anterior chamber depth 
2.5 mm, axial length 23.9
mm^, sub capsular cataracts, 
vitreous membranes,
VR traction, progres­
sive retinal degeneration, 
Coat’s-like exudative 
detachment, Go ldmann: 
constricted to 15°,ERG: 
±non-recordable,OCT: VR 
tractions, schisis
Progressive
SNHL
Coxa vara with 
short, broad femoral 
necks, normal knees 
& hands, cervical 
disc prolapse
Height: 1.54 m,nasal/dys- 
arthric speech,prominent 
supra orbital ridges,slightly 
sloping forehead, bilateral 
pes piano valgus,no hyper- 
mobile joints
Subcortical fron­
tal & temporal 
abnormalities 
CNS
2/1-1 N/A wt/R295X N/T N/T N/T N/T N/T height: 1.74 m,no visual or 
hearing problems on history
None
2/1-2 N/A wt/R295X N/T N/T N/T N/T N/T Height: 1.63 m,no visual or 
hearing problems on history
None
2/II-1 15 yrs R295X/
R295X
N/T -18.5/-17 Bilateral amblyopia,bilateral 
RRD
Progressive
SNHL
Short and squat 
metac arpals, short 
and broad femoral 
neck,irregular and 
flattened femoral 
epiphyses,small and 
squat iliac wing
Short stature (between 
3rd-10th percentile), macro- 
cephaly (60.6 cm), bilateral 
epicanthal folds, midfacial 
hypoplasia, class 3 maloc­
clusion, no hypermobile 
joints.
None
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Figure 2. Fundus pictures and optical coherence tomography (OCT) in Stickler 
patients of Family 1. A-C) Patient II-1, 43 years; A. Fundus photograph of the posterior 
pole of the left eye. Note that no abnormalities seem to exist. B. Fundus photograph 
of the periphery of the left eye. Note the retinal degeneration. C. OCT (Spectralis®) 
through the macular region of the left eye. Note the adhesion of the posterior hyaloid 
with vitreoretinal traction and schisis. D-I) Patient II-4, 29 years; D. Fundus photograph 
of the posterior pole of the right eye. Note the vascular sheathing, the epiretinal mem­
brane, and chorioretinal degeneration along the vascular arcade. E. Fundus photographs 
of the periphery of the right eye. Note the exudative detachment with hard lipids. F. 
OCT (Spectralis®) through the macular region of the right eye. Note the pronounced 
vitreoretinal traction and schisis. G-H) Fundus photographs of the periphery of the left 
eye. Note the paravascular lattice-like degenerations and the epiretinal changes. I. OCT 
(Spectralis®) superior to the macula of the left eye. Note the thickened and split epireti­
nal mebrane with retinal adhesions.
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Figure 3. Standard ISCEV ERG recordings in a normal subject and in patients 
II-1 and II-4 of Family 1. Note the recording showing reduced scotopic and photopic 
responses in II-1 (LE>RE), and almost non-recordable responses in II-4. In the 30 Hz 
flicker of II-4 an artifact is depicted due to blinking. The index case of Family 2 (II- 
1) showed bilateral amblyopia and myopia. He underwent several surgical procedures 
because of bilateral, rhegmatogenous retinal detachments making a description of the 
vitreous impossible.
Audiologic findings
The hearing loss in the three patients from the two families with COL9A1 
mutations was moderate, sensorineural, and slightly progressive over the years 
being most pronounced at higher frequencies, up to 110 dB in patient II-4 of 
Family 1 (Figure 4). The father (I-1) in Family 1 also had a sensorineural hear­
ing loss of the high tones of 60 dB at the age of 55 without a known cause. The 
mother (I-2) had a sensorineural hearing loss of 20 dB at the age of 58 years 
which is within the normal range according to her age.
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Figure 4. Audiogram with air conduction thresholds in the best ear of patients II-1 
and II-4 from Family 1 and patient II-1 from Family 2. L: Left ear, R: Right ear, air 
cond: air conduction, (1/II-1 denotes patient II-1 from Family 1, 1/II-4 denotes patient 
II-4 from Family 1, and 2/II-1 denotes patient II-1 from Patient 2).
General features and radiologic findings
In the two affected members of Family 1, several musculoskeletal alterations 
were detected, including slightly short stature, epiphyseal changes of the femo­
ral head, a short femoral neck with coxa vara, and pes plano valgus without 
hypermobility of the joints (Figure 5). X-rays of the spine showed disc space 
narrowing at C5-6 and a thoracolumbar scoliosis with degenerative changes in 
patient II-1, and herniation of the discus at C4-5 and C5-6 in patient II-4. Both 
of them had a nasal, dysarthric speech. However, they did not have a cleft pal­
ate, or micrognathia. Patient II-4 was slightly dysmorphic with round face and 
slightly low nasal bridge. At the age of 26, she had a sudden episode of headache 
with nausea, dizziness and a horizontal nystagmus. An MRI of the cerebrum 
showed aspecific subcortical abnormalities, frontal and temporal, without signs 
of cerebellar infarction.
Skeletal abnormalities were also noted in the two heterozygote sisters (II-2 
and II-3) of Family 1. Individual II-2 suffered from back pain and had a straight­
ened lumbar lordosis. MRI of the lumbosacral spine showed diffuse interverte­
bral disk bulging at T12-L1, L1-2, L4-5, and Schmorl’s nodules. Patient II-3 had 
a cervical hernia at C5-6 on MRI.
Individual II-1 from Family 2 was macrocephalic due to congenital hydro­
cephaly caused by an arachnoideal cyst with a secondary stenosis of the aque­
duct. He had a short stature, a flat midface, and bilateral epicanthal folds. There 
was a class 3 malocclusion with mild deviation of the chin to the left. His neck 
was short with a low posterior hairline and he was not hypermobile. X-rays of 
the hips showed abnormalities of the femoral head and neck. His metacarpals
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were short and squat in contrast to patient II-4 (Family 1) whose hands appeared 
normal on X-ray.
Figure 5. X-ray analysis of patient II-4 of Family 1. X-ray of the hips at the age of
21. Note the coxa vara with short, broad femoral necks as result of epiphyseal dysplasia.
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Discussion
This study is the second report so far on the occurrence of autosomal recessive 
Stickler syndrome caused by COL9A1 mutations. A novel, homozygous non­
sense mutation (p.R507X) was detected in two Turkish sisters, and a previously 
reported nonsense homozygous mutation (p.R295X) was found in a Moroccan 
boy.
Stickler syndrome thus far seems to be caused solely by mutations affecting 
genes encoding the collagen types II, XI and IX. In our families, we searched 
for characteristics that potentially could distinguish autosomal recessive Stick­
ler patients with COL9A1 mutations from patients with mutations in the genes 
causing the autosomal dominant form ofthe disease i.e. COL2A1, COL11A1 and 
COL11A2. The most important finding was the confirmation4 that the vitreous 
structure does not match the Stickler type I and II phenotypes, and the recently 
reported hypoplastic vitreous that are described in the dominant forms.2,8-11 The 
vitreous in two of our patients contained membranous structures throughout its 
cavity as seen in age-related degeneration. Furthermore, we documented vit- 
reoretinal adhesions with progressive traction leading to chorioretinal degen­
eration, retinoschisis in the periphery and in the macular area, and exudative 
and rhegmatogenous retinal detachment. Coats’-like exudative detachment in 
Stickler syndrome has not been reported in autosomal dominant cases. Rheg- 
matogenous detachments, on the other hand, may occur in up to 73% of STL1 
patients who did not have prophylactic retinopexy,12 and in up to 42% of patients 
with STL2.8
Type IX collagen was the first member to be identified in a subgroup of col- 
lagens called FACITs (fibril-associated collagen with interrupted triples helices) 
and is encoded by COL9A1, COL9A2 and COL9A3. In the human vitreous, type 
IX collagen possesses a glycosoaminoglycan (GAG) side chain covalently at­
tached to its collagenous protein core13 which renders it a proteoglycan. This 
side chain may play an important role stereochemically, in the maintenance of 
structure and spacing of adjacent collagen fibrils,14,15 but also in the formation 
of the vitreous gel. Fibrillar collagens such as type II or type XI, tend to ag­
gregate or fuse when they interact, and it was shown that type IX collagen acts 
as a shield.13 With aging, type IX collagen is progressively lost, minimising the 
shielding effect and thus increasing the propensity of vitreous collagen fibrils to 
fuse leading to synchisis as in our patients.
The non-ocular symptoms in our families were very diverse, but all affected 
individuals had sensorineural hearing loss, epiphyseal dysplasia of the femoral 
heads with short femoral necks, and spinal abnormalities similar or even identi­
cal to the ones observed in autosomal dominant Stickler syndrome.11,16 It is of 
note that, heterozygous mutation carriers (Family 1: II-2 and II-3), were also 
symptomatic. None of the patients in our two families or in the one previously 
described4 had a palatal cleft.
The overall clinical picture of our patients suggests that only the vitreous de­
fects differ from those harboring mutations in COL2A1 or COL11A1, and might
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be used as a diagnostic criterion. Caution is required, though, since the vitre­
ous phenotype is not always conclusive for involvement of a particular colla- 
gen,5,17,18 and we could study the vitreous in only two siblings.
In the present families, homozygosity for a null mutation in COL9A1 is as­
sociated with a full-blown Stickler phenotype whereas the heterozygotes have 
milder skeletal phenotypes consistent with a mild effect of haploinsufficiency. 
Due to a putative lower allele dosage, potentially producing a ‘collateral’ less 
severe clinical picture e.g. skeletal problems, the latter could possibly give an 
insight on the molecular aetiology of the phenotype of the two heterozygous 
sisters. COL9A1 is involved in the formation of macromolecular complexes 
via a helical co-operative mechanism which is not progressing unless collagen 
concentration, at least in vitro, does not reach a critical threshold.19 Haploinsuf- 
ficiency in the COL9A1 mutation carriers could explain a marginal or mediocre 
assembly of collagen molecules to form the heterotrimeric fibrils, possibly re­
sulting in a ‘partial’ phenotype. Mild clinical expression in heterozygous carri­
ers of a recessive disease or of patients carrying two autosomal dominant muta­
tions for a dominant trait being more severely affected, has been described.20
Heterozygous splice site mutations leading to in-frame exon skipping in CO- 
L9A1 and other COL9 genes have been associated with multiple epiphyseal dys­
plasia (MED), a clinically highly heterogeneous disease.21 The exon skipping 
(exon 8 and/or 10 in COL9A1, exon 3 COL9A2/COL9A3)22'21 and subsequent 
deletion of several amino acids in the third collagenous domain COL3 is com­
patible with a dominant-negative effect. Interestingly the epiphyseal changes 
in COL9 associated MED result in more severe involvement of the knees with 
relative sparing of the hips, while in our patients the hips are involved with spar­
ing of the knees. In addition, COL9A2 and COL9A3 have been associated with 
intervertebral disc degeneration,28 whereas the spinal changes in Family 1 may 
also provide some indications for a possible role of COL9A1 in intervertebral 
disc degeneration.
In summary, we identified a second novel mutation in COL9A1 causing auto­
somal recessive Stickler syndrome together with the previously described mu­
tation in two separate families. Although their complete clinical picture was 
comparable to autosomal dominant Stickler, we were able to identify distinct 
phenotypic elements such as vitreous changes that might enable recognition of 
other patients likely to carry mutations in the COL9A1 gene. Furthermore, we 
have added exudative retinal detachment to the spectrum of features character­
ising the disease and indications that mutations in COL9A1 may be associated 
with intervertebral disc degeneration.
Thus, patients with symptoms suggestive of autosomal recessive Stickler syn­
drome should be routinely checked for COL9A1 changes, both for an accurate 
diagnosis and prognosis as well as for genetic counseling purposes.
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Abstract
Wnt signaling is a crucial component of the cell machinery orchestrating a 
series of physiological processes such as cell survival, proliferation, and migra­
tion. Among the plethora of roles that Wnt signaling plays, its canonical branch 
regulates eye organogenesis and angiogenesis. Mutations in the genes encoding 
the low density lipoprotein receptor protein 5 (LRP5) and frizzled 4 (FZD4), 
acting as coreceptors for Wnt ligands, cause familial exudative vitreoretinopa- 
thy (FEVR). Moreover, mutations in the gene encoding NDP, a ligand for these 
Wnt receptors, cause Norrie disease and FEVR. Both FEVR and Norrie disease 
share similar phenotypic characteristics, including abnormal vascularisation of 
the peripheral retina and formation of fibrovascular masses in the eye that can 
lead to blindness. In this mutation update, we report 21 novel variants for FZD4, 
LRP5, and NDP, and discuss the putative functional consequences of missense 
mutations. In addition, we provide a comprehensive overview of all previously 
published variants in the aforementioned genes and summarize the phenotypic 
characteristics in mouse models carrying mutations in the orthologous genes. 
The increasing molecular understanding of Wnt signaling, related to ocular de­
velopment and blood supply, offers more tools for accurate disease diagnosis 
that may be important in the development of therapeutic interventions.
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Introduction
Familial exudative vitreoretinopathy (FEVR; MIM# 133780) and Norrie dis­
ease (ND; MIM# 310600) are two inherited retinal disorders with highly over­
lapping ocular manifestations that are caused by alterations in the Wnt signaling 
network. FEVR and ND share an abnormal vascularization of the peripheral 
retina with the formation of retinal folds, retinal detachment, and in many cases 
the creation of a fibrovascular membrane located behind the lens.1-4 Genetic 
analyses have thus far identified three causative genes for the two disorders, 
that is, frizzled 4 (FZD4, located on 11q14.2; MIM# 604579), low-density li­
poprotein 5 (LRP5, located on 11q13.2; MIM# 603506), and Norrin (NDP, lo­
cated on Xp11.3; MIM# 300658). Those genes encode proteins involved in the 
evolutionary highly conserved Wnt signaling network that plays an important 
role in eye development and angiogenesis. FEVR is a genetically heterogeneous 
disease and is inherited in an autosomal dominant (adFEVR; MIM# 133780),4-8 
autosomal recessive (arFEVR; MIM# 601813) or an X-linked recessive mode 
(MIM# 305390),1,9,10 with autosomal dominant being the most prominent mode 
of inheritance. Mutations in FZD4 and LRP5, which are located on 11q14.2 and 
11q13.2, respectively, are associated with autosomal dominant FEVR.11,12 In ad­
dition, one family has been found to link to the EVR3 locus on chromosome 
11p12—p13.13 Mutations in LRP5 have also been associated with arFEVR,14 
whereas X-linked recessive FEVR is caused by mutations in the Norrie disease 
gene (NDP) located on Xp11.3.9,15 The pathologic features of the disease initiate 
from the abnormal retinal development due to the incomplete vascularization 
of the peripheral retina and/or retinal blood vessel differentiation.16 The result­
ing avascular peripheral retinal zone2-4,15,17 is the hallmark of the disease and 
in many mildly affected patients may be FEVR’s only manifestation. In more 
severe cases, retinal complications such as the formation of holes and tears, neo­
vascularization, exudation, vitreous haemorrhage, macular ectopia, falciform 
folds, and retinal detachment, can result in blindness.
Norrie disease (MIM# 310600) is a severe X-linked recessive form of con­
genital blindness, which in about one-third of the cases is accompanied by men­
tal retardation and deafness.18,19 A characteristic intraocular mass in the retina 
(pseudoglioma) can lead to microphthalmia.20,21 Other ocular findings include 
the development of cataract, alterations in the composition of the vitreous body,22 
vitreoretinal hemorrhages, creation and deposition of retrolental fibrovascular 
tissue, retinal folding and detachment, accompanied by subretinal exudates,23,24 
which are signs bearing high phenotypic overlap with FEVR.4 ND is genetically 
homogeneous, and is caused by mutations in NDP.15,25
In addition to causing FEVR, defects in LRP5 have also been associated with 
two groups of bone abnormalities. The first group includes osteoporosis-pseu- 
doglioma syndrome (OPPG; MIM# 259770), a rare autosomal recessive condi­
tion that initiates during early childhood. The major symptoms of OPPG include 
visual loss due to several vitreoretinal dysplasias and bone weakness that re­
sults in multiple fractures and deformities as the bone mass reduces. Carriers of 
OPPG-associated LRP5 mutations are often found to have reduced bone mass
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density. The second group of diseases comprises endosteal hyperostosis (MIM# 
144750), osteosclerosis (MIM# 144750), osteopetrosis (MIM# 607634), van 
Buchem disease type 2 (VBCH2; MIM# 607636), and highbone- mass trait 
(HBM; MIM# 601884). The aforementioned conditions are all characterized 
by a high-bone-mass phenotype and are inherited in autosomal dominant mode.
FZD4, LRP5, and NDP are components of the Norrin-induced FZD4/LRP5/P- 
catenin signaling pathway. It has been demonstrated that Wnt signaling path­
ways are one of the main drivers for vascular development in the mammalian 
eye. Consequently, mutations in these three genes cause FEVR and ND that 
have an almost identical pathologic impact on intraretinal vasculature.
Recently a series of dedicated experiments revealed that a new gene, TSPAN12 
(located on 7q31.31; MIM# 613138) plays a key role in Norrin-induced 
P-catenin signaling transduction and regulation (Figure 1). TSPAN12 is a mem­
ber of the tetraspanin family that share certain specific structural features that 
distinguishes them from other proteins that pass the membrane four times. The 
protein was postulated to act via a mechanism that enhances FZD4 multimeriza- 
tion and clustering by binding to Norrin multimers, a crucial step for induction 
of physiological levels of signaling.26
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Wnt signaling and eye vasculature: Brief overview
The Wnt signaling transduction network influences cell survival, differentia­
tion, proliferation, and migration by a highly orchestrated transcriptional regu­
lation of target genes. The network can be roughly categorized in two broad 
branches: the canonical or Wnt/p-catenin pathway and the noncanonical path­
way, which includes the Wnt/calcium signaling and planar cell polarity path­
ways. Wnt genes encode a family of soluble, secreted cysteine-rich proteins 
that are often glycosylated and/or palmitoylated. Wnts can act as ligands for 
Frizzled receptors that, in concert with LRP5/6 coreceptors, form a ternary com­
plex27 and subsequently initiate Wnt canonical signaling. Canonical Wnt signal­
ing regulates the amount of P-catenin that reaches the nucleus via the action of 
Disheveled proteins that block its phosphorylation by GSK-328 and proteolytic 
degradation in the proteosome.29 Presence of P-catenin inside the nucleus pro­
motes transcription of several genes implicated in different processes. Wnts are 
expressed in a wide variety of tissues, and the specific type of Wnt-Frizzled in­
duced signaling is determined mostly by the nature of the different interactions 
and the locations in which these occur. FZD4 has been shown to act also in the 
noncanonical Wnt signaling pathway11 by regulating components belonging to 
the Wnt/calcium signaling network.
Wnt signaling also plays an important role in eye organogenesis and angio- 
genesis. Beta-catenin regulation is present in critical steps of ophthalmogenesis 
such as anterior neural tissue definition from the remaining brain compartments, 
eye field formation, and fine definition of the neural retina.30 In addition, ocu­
lar blood vessel formation during development initiates with the formation of 
a provisional blood vessel system in the extraretinal hyaloid region called the 
hyaloids vascular system (HVS). This system is responsible for the supply of 
nutrients to the early vitreal structure and the retina. When the intraretinal vas­
culature develops, the HVS recedes in the maturing eye.
Retinal angiogenesis is dependent on TSPAN12, FZD4, and LRP5 to initiate 
the P-catenin signaling cascade upon NDP binding (Figure 1).
Mutations in FZD4
FZD4 is a member of the Frizzled gene family and encodes a protein of 537 
amino acids. Similar to the other members of the Frizzled family it is composed 
of a seven pass transmembrane helix and an extracellular Frizzled (FZ) domain 
(Supporting Figure S1).
To date, a total of 32 different mutations have been reported for FZD4 (Sup­
porting Table S1). Ten mutations result in a premature stop codon, 21 are mis- 
sense changes and one is an in-frame deletion of two amino acids (p.M493_ 
W494del). No splice mutations have been reported for FZD4 and mutations 
are not clustering in a specific ‘‘hotspot”. All patients with FZD4 mutations 
are heterozygous carriers, except for a 5-month-old baby carrying a homozy­
gous change (p.R417Q) for which both parents harboring the same mutation 
heterozygously exhibited mild phenotypes,31 suggesting an autosomal dominant 
mode of inheritance. The effect of a few FZD4 nucleotide variants has been
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assayed functionally. Robitaille et al. (2002)11 measured the FZD4-dependent 
induction of P-catenin signaling upon activation of the receptor. They found that 
p.M493_494del and p.L501SfsX533 mutant proteins did not exert any detect­
able activity. Two additional studies, using Norrin dependent signaling reporter 
assays, showed the reduced activity of FZD4 mutants (p.M105V, p.M157V, 
p.W319X, and p.R417Q) ranging from ~30 to 95% of the wild-type levels.32,33
In this study we report five novel variants in FZD4, one of which is located in 
exon 1 (p.E40Q) and the other four in exon 2 (p.C204Y, p.E286X, p.D428SfsX2, 
and p.G525R). Because FZD4 contains only two exons, protein truncating muta­
tions in exon 2 likely do not result in complete nonsense mediated decay (NMD) 
but rather in a nonfunctional protein.
Nucleus
Figure 1. Schematic representation of the activation of the Norrin/p-catenin ca­
nonical signaling pathway from TSPAN12/FZD4/LRP5 coreceptors upon activa­
tion by NDP. Mutations in the corresponding genes have been associated with impaired 
activation of the pathway and result in FEVR and Norrie disease, two conditions that not 
only share common molecular aetiologies but to a high extent show phenotypic overlap.
The FZD4 proteins containing the two protein-truncating mutations p.E286X, 
p.D428SfsX2 (Table 1, Supporting Table S1) are predicted to lack the conserved 
KTXXXW domain and PDZ binding motif (Supporting Figure S1). The absence 
of these elements probably abolishes the ability of FZD4 to induce the down­
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stream P-catenin signaling pathway. The KTXXXW domain is located directly 
after the seventh transmembrane (TM) helix at the C-terminus, and is essential 
for generation of FZD4-mediated signal transduction.34 Moreover, a truncated 
protein (p.L501SfsX33) that contained the KTXXXW domain but lacked the 
PDZ binding motif was shown to be defective. The mutated protein was absent 
from the plasma membrane, probably due to impaired oligomerization of the 
wild type protein with the mutant form, which lead to the retention of FZD4 in 
the endoplasmic reticulum.35
Table 1. Novel FZD4 sequence variants that are likely to cause 
familial exudative vitreoretinopathy.
Effect Exon
Occurrence 
in patients 
(probands)
Occurrence in 
control alleles Segregation
Truncating changes
c.856G>T p.E286X 2 1/16 0/100 Yes
c.1282_1285del p.D428SfsX2 2 1/16 0/100 Yes
Missense changes
c.118G>CA p.E40Q 1 1/16 0/100 Simplex
c.611G>A p.C204Y 2 1/16 0/100 Simplex
c.1573G>C p.G525R 2 1/16 0/100 Yes
Nucleotide numbering reflects cDNA numbering with +1 corresponding to the A of the 
ATG translation initiation codon in the reference sequence (GenBank NM_012193.2), 
according to journal guidelines (www.hgvs.org/mutnomen). The translation initiation 
codon is codon 1 (GenBank NP_036325.2).
AThis patient also carries a splice site mutation in LRP5 (c.4489-1G>A), see Table 2.
In addition to the two protein-truncating mutations we also identified three 
novel missense changes. Variant p.E40Q was found in one sporadic patient (Ta­
ble 1). The wild type glutamic acid residue is located at the N-terminus, directly 
following the putative signal peptide at the FZ domain (Supporting Figure. S1). 
According to the secondary structure prediction,36 this residue is located at a 
coiled domain on the surface of the protein where interactions might occur. The 
function of the FZ domain is not fully elucidated, although mutagenesis and 
crystal structure studies suggest that it may be important for interaction with 
other proteins such as Wnts or NDP.37 Glutamic acid is a negatively charged 
amino acid and is often involved in ionic interactions. The mutant glutamine 
has the same molecular structure except for the negatively charged oxygen. The 
pathogenic effect of this change is therefore likely due to the loss of ionic inter­
actions of the FZ domain with other proteins or by itself. In addition, the same 
patient carries a second nucleotide variant in LRP5, the splice site mutation 
c.4489-1G>A. To better assess the disease-causing potential of the two afore­
mentioned changes, the affected mother was also included in the study. She 
was found to carry both variants, that is, FZD4 p.E40Q and LRP5 splice site 
mutation c.4489-1G>A, which does not exclude a digenic mode of inheritance.
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Notably, previous studies have also provided some evidence that FEVR may 
not exclusively rely on a monogenic model of inheritance. Shastry and Trese 
(2004)38 reported that a factor V change co-segregated with the FZD4 mutation 
in a patient with autosomal dominant FEVR.
The p.C204Y variant (Table 1, Supporting Table S2) is located in a stretch 
of residues that connects the FZ domain with the first TM domain of FZD4. 
Using the PHDacc-server39 (accessible via ‘‘Project HOPE,’’ http://www.cmbi. 
ru.nl/hope/), secondary structure prediction indicates that the mutated cysteine 
is placed in a large coiled region, buried in the core of the protein preceding 
the first TM helix. Mutation of a cysteine residue, possibly employed to form a 
disulfide bond, into a tyrosine, a hydrophilic amino acid with a large bulky side 
chain, is expected to lead to destabilization or even unfolding of the domain. 
In family W06-237 we identified the p.G525R variant in FZD4 (Table 1, Sup­
porting Table S1). This missense change affects an amino acid located in the 
intracellular C-terminal tail of FZD4, in a stretch of residues predicted to form 
a coil (Supporting Figure S1). This residue is partly exposed to the solvent and 
partly buried. The two following residues (tryptophan and valine) are predicted 
to be completely buried in the core of the protein and by being hydrophobic, 
they are probably important forming the core of the C-terminal domain. Glycine 
residues are known for their flexibility, as no other residue can make the same 
backbone angles. It seems possible that the residues preceding tryptophan and 
valine form a typical structure that is needed to locate the hydrophobic trypto­
phan and valine in their correct position. This is underlined by the fact that the 
glycine residue at position 525 is preceded by an asparagine (a residue often 
present in structural turns) and by another flexible glycine. The p.G525R variant 
changes the flexible glycine into a less flexible arginine, thereby disturbing the 
putative backbone structure that is needed for the positions of tryptophan and 
valine. This potentially could affect the normal function of KTXXXW and PDZ 
binding in the Wnt/p-catenin pathway, thereby impeding the action of FZD4 
receptor complex. All the changed residues are highly conserved among several 
FZD4 orthologues (Supporting Figure S2). We have summarized the clinical 
data of five FEVR patients with FZD4 variants in Supporting Table S2. Their 
visual acuity ranges from normal to complete blindness. Macular ectopia is fre­
quently observed.
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Mutations in LRP5
LRP5 is a composite cell surface receptor protein that consists of 1,615 amino 
acids and belongs to the low-density lipoprotein receptor (LDLR) superfamily. 
Its function is associated with the process of receptor-mediated endocytosis of 
a wide spectrum of ligands. Upon ligand binding, LRP5 can act synergistically 
with FZD4 or other members of the Frizzled family by activating the canoni­
cal Wnt and/or Norrin/p-catenin pathway and induce the transcription of target 
genes.40-42
LRP5 consists of four extracellular domains, each of which is composed of 
six segments. Those segments form a P-propeller structure that is followed by 
an EGF-like domain (Figure 2A). Five of those segments are YWTD LDL-class 
B repeats, whereas the sixth does not contain the required YWTD motif to be 
recognized as a LDL-class B repeat. The first two propeller domains were sug­
gested to be important for interaction with the Wnt/Frizzled complex.43 The 
four propeller domains are followed by three LDL-class A repeats (also known 
as LDL receptor like ligand binding domains), one TM domain, and a cyto­
plasmic region with one or multiple short signals for receptor internalization 
through coated pits. LRP5 is highly expressed in many tissues including bone, 
liver, heart, retina, skin, and pancreas during various stages of development. 
Moreover, although part of a very potent and diverse signaling network such as 
the P-catenin pathway, LRP5 is a major player in morphological development, 
sugar and lipid metabolism.
Thus far, 86 different mutations have been reported for LRP5, of which 26 
introduce premature stop codons, 56 mutations are missense changes, and four 
changes affect splicing (Supporting Table S3). Whereas LRP5 mutations that 
are associated with FEVR are scattered throughout the gene, other mutations in 
LRP5 that seem to be clustered locally cause different phenotypes. Individuals 
suffering from a group of disorders demonstrating high bone mass and scleros­
ing bone dysplasias, show autosomal dominant missense variants clustered in 
exons 2 to 5 that encode the first ‘‘P-propeller’’ domain of LRP5. These changes 
are hypothesized to act in a dominant negative way. The mutant LRP5 proteins 
are impaired from binding to Wnt pathway antagonists, for example, SOST or 
DKK-1, because of defective receptor action or cell trafficking, thereby promot­
ing abnormal growth in bone-forming cells.44-46
LRP5 variants have also been associated with OPPG, a rare autosomal reces­
sive condition for which the vast majority of loss of-function mutations identi­
fied are located in the second and third ‘‘P-propeller’’ domain and the following 
LDL repeats of LRP5. Of the FEVR-causing mutations, four mutations result in 
premature stop codons, whereas at least six missense changes have been associ­
ated with the autosomal dominant form of the disease. In addition, 11 missense 
variants (of which, three homozygous and two compound heterozygous) have 
been associated with autosomal recessive or sporadic FEVR cases. All these 
changes seem to result in a reduced or lost interaction with FZD4 and NDP and 
thus disturbing the normal Wnt signaling cascade that regulates retinal vessel 
formation.
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Figure 2. Schematic representation of LRP5 and 3D modelling of LRP5 missense 
changes. A) Schematic overview of LRP5 and its different domains. B) Overview of 
the second P-propeller domain of LRP5 and a close-up of the p.E441K change in the 
second P-propeller domain. The side chain of the wild-type residue (glutamic acid) in 
position 441 is shown in green, whereas the mutant lysine is shown in red. Two neigh­
bouring arginines are coloured blue. C) Overview of one of the EGF-like domains and 
the p.C1253F change. Pair of cysteines forming disulfide bridges are shown in yellow. 
One of these cysteines is mutated into a phenylalanine, depicted in red.
Functional characterization of nucleotide changes in LRP5 has been per­
formed by various groups. Gong et al. (2001)47 studied the effect of p.Q853X 
and p.E1270RfsX169 by transiently transfecting COS-7 cells with mammalian 
expression constructs containing either the wild-type or mutant LRP5 sequenc­
es. They demonstrated that even if the mutant proteins were synthesized they 
were not able to be secreted, due to impaired cell trafficking, adding evidence 
to the assumption that OPPG results from loss-of function mutations. Boyden 
et al. (2002)47 studied the effects of p.G171V by performing in vitro and in vivo 
experiments measuring Wnt signaling output. They used a luciferase activity 
assay, which was responsive to LRP5 by cotransfection experiments in NIH3T3 
cells and by measuring fibronectin levels in affected individuals with the high 
bone mass phenotype. The p.G171V variant did not influence normal Wnt sig­
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naling in the absence of Wnt antagonists. However, when such an antagonist 
(e.g., Dkk-1) was present, the mutant LRP5 construct was able to reduce its in­
hibitory action. Zhang et al. (2004)46 showed that the p.G171V mutation seemed 
to disrupt the Mesd-mediated recruitment of LRP5 to the surface of osteoblasts, 
which occurs via the first P-propeller domain. They proposed that paracrine 
Dkk-1, which is produced by osteoclasts and binds to the third ‘‘P-propeller’’ 
domain of LRP5, has limited target availability, that is, minimal antagoniz­
ing potential, boosting autocrine Wnt action in the osteoblasts. Adding to the 
complexity of events that act synergistically for high bone mass phenotype, it 
was also postulated that p.G171V was able to directly reduce binding ability 
of a bone specific LRP5 antagonist, SOST, to the first P-propeller structure, 
potentially affecting bone mass regulation.45 Ai et al. (2005)48 designed a se­
ries of expression constructs containing OPPG-associated mutations (p.S356L, 
p.T390K, p.G404R, p.D434N, p.G520V, and p.G610R) and FEVR-associated 
mutations (p.T173M, p.R570Q, p.Y1168H, p.C1361G, and p.E1367K) along 
with wild-type LRP5 and transiently transfected HEK293T cells in an ex vivo 
reporter assay for Wnt and Norrin signal transduction. With the exception of 
p.S356L and p.G520V, OPPG-associated LRP5 mutations, which affected the 
first or second P-propeller domain, resulted in impaired subcellular trafficking 
of mutant LRP5. However, there was no clear-cut correlation between assay 
activity and phenotypes. When FEVR-associated mutations were tested in the 
same assay they showed variable results. The p.Y1168H missense variant that 
causes autosomal dominant FEVR almost completely abolished Wnt and Nor- 
rin signal transduction, whereas p.T173M had no significant impact. A similar 
effect was shown for two other mutations associated with autosomal recessive 
FEVR (p.R570Q and p.E1367K). Finally, it was demonstrated in concordance 
with all the previous experiments, that LRP5 mutants p.R444C and p.A522T 
exhibited a variable reduction in the Norrin-dependent Wnt signaling (45 and 
26%, respectively) that correlated with the mild phenotype observed in the pa­
tients who carry these changes.32
In this study, we report two new missense (p.E441K, p.C1253F), one new 
nonsense variant (p.W993X), and one novel splice site (c.4489-1G>A) change. 
The p.E441K variant has been identified in one sporadic FEVR patient (Table
2, Supporting Table S3). It is located in the second ‘‘P-propeller’’ domain of the 
protein, at an evolutionary highly conserved position (Supporting Figure S3). 
As our structure prediction model (Figure 2B) points out, the negatively charged 
and hydrophilic glutamic acid creates ionic interactions with two positively 
charged arginine residues in its close proximity (residues indicated in blue), 
thereby stabilizing and formulating the local structure of the whole domain. 
Introduction of an additional positive residue such as lysine is likely to disturb 
the ionic interactions, potentially destabilizing the whole domain structure and 
therefore impeding its normal function. This could have an effect on its potential 
interaction with NDP, which is also supported by the aforementioned functional 
analysis of p.R444C. More interestingly a different mutation, p.D434N, which 
was also characterized by decreased Wnt signaling potential, was associated 
with OPPG. The second variant, p.C1253F, is located in the EGF-like domain
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following the third ‘‘P-propeller’’ module of LRP5 (Figure 2C), and also af­
fects a well-conserved residue (Supporting Figure S3). The role of this domain 
is unclear. The third ‘‘P-propeller’’ structure and the three LDL-class A repeats 
play a role in binding of ligands such as Dkk-1. The EGF-like domains in gen­
eral are stabilized by three disulfide bridges (Figure 2C). The introduction of a 
phenylalanine at the position of cysteine residue is predicted to disturb one of 
the existing disulfide bridges. Moreover, phenylalanine has a much bulkier side 
chain when compared with cysteine and might exert steric hindrance effects. 
Interestingly, the same person carrying the p.C1253F variant was found to carry 
a second LRP5 missense variant, p.G610R, previously reported to be associated 
with FEVR (in a compound heterozygous mode) and with OPPG (Supporting 
Table S3 and Supporting Table S4). The p.G610R variant, when present het­
erozygously, was shown in at least one case to result in low bone mass density. 
The father of the proband was found to carry the p.C1253F variant, whereas the 
mother was carrying the p.G610R. Based on the clinical picture of this family 
(Supporting Table S2) and mutation segregation data an autosomal recessive 
mode of inheritance can be suggested, although autosomal dominant inheritance 
cannot be totally excluded.
Furthermore, a nonsense change (p.W993X) was found in one sporadic pa­
tient with FEVR that results in a premature stop codon in exon 13 likely caus­
ing NMD and thus leading to LRP5 haploinsufficiency (Table 2, Supporting 
Table S3). Finally, we identified a splice-acceptor mutation, c.4489-1G>A, in 
the same person that harbors the FZD4 p.E40Q variant. The effect of this muta­
tion is predicted to be skipping of exon 22 and the subsequent in frame deletion 
of 20 amino acids. No RNA was available to test the effect of the splice site 
change. We summarized the clinical data for three patients with LRP5 variants 
in Supporting Table S2.
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Table 2. Novel LRP5 sequence variants that are likely to cause 
familial exudative vitreoretinopathy.
Nucleotide variant Effect Exon
Occurrence 
in patients 
(probands)
Occurrence in
control alleles Segregation
Truncating changes
c.2978G>A p.W993X 13 1/16 0/100 Simplex
Missense changes
c.1321G>A p.E441K 6 1/16 0/100 Yes
c.3758G>TB p.C1253F 17 1/16 0/100 Simplex
c.4489-1G>AA Splice defect 22 1/16 0/100 Simplex
Nucleotide numbering reflects cDNA numbering with +1 corresponding to the A of the 
ATG translation initiation codon in the reference sequence (GenBank NM_002335.2), 
according to journal guidelines (www.hgvs.org/mutnomen). The translation initiation 
codon is codon 1 (GenBank NP_002326.2).
AThis patient also carries a second missense variant in FZD4 p.E40Q (c.118G>C), see 
Table 1.
BThis patient also carries a second missense variant in LRP5 p.G610R (c.1828G>A).
LRP5 polymorphisms
Many groups have tried to find associations between LRP5 polymorphisms 
and osteoporosis, low bone mass index, hypercholesterolemia, obesity, and in­
creased body mass index. The non synonymous p.A1330V (rs3736228:C>T) 
SNP in exon 18 has been in the center of attention in a large number of studies. 
This polymorphism was linked with low bone mass determination at the lum­
bar spine, femoral neck and total hip.49 Subsequently, at least six more groups 
reported putative association of p.A1330V alone or synergistically with other 
polymorphisms in LRP5 or other genes, with bone mass determination and hy- 
percholesterolemia.50-55
Qin et al. (2008),32 utilizing a Norrin-dependent reporter, demonstrated an 
unexpected decrease in Wnt signaling activity in the case of SNPs p.Q89R 
(rs41494349:A>G) and p.A1330V. These variants may play a role in the wide 
phenotypic heterogeneity observed in people that harbor the same pathogenic 
nucleotide variants in LRP5.
NDP mutations
The NDP gene encodes Norrin, a small secreted and cysteine rich protein that 
consists of 133 amino acids with weak homology to the transforming growth 
factor (TGF)-P family of ligands.56-59 Norrin consists of two major parts: a signal 
peptide at the amino-terminus of the protein that directs its localization and a re­
gion containing a typical motif of six cysteines forming a cysteine-knot that pro­
vides the structural conformation required for receptor binding and subsequent 
signal transduction.59 Our 3D model of NDP agrees with structures previously 
described60 and contains two antiparallel P-sheets and one a-helical structure 
(Figure 3A).
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Figure 3. 3D modeling of NDP missense changes. A) Ribbon model of NDP. The 
protein is colored in gray, the cysteine side chains that participate in forming disulfide 
bonds and creating the critical knot motif are shown in yellow. The wild-type and mu­
tant residues are depicted in green and red, respectively. B) Close-up of the p.C55R mis­
sense change. The wild-type cysteine creates a bond with the neighboring cysteine. The 
arginine residue at position 55 disrupts the disulfide bond. C) Close-up of the cysteine 
knot in NDP and missense change p.G67R. The cysteines forming the typical knot motif 
are indicated. NDP contains an additional cysteine bond that is shown in gray. Addition- 
aly, assumptions on the effect of p.G67E on the cysteine knot motif can be drawn from 
the same figure as the stereochemical structure of glutamic acid is very similar to argi­
nine. D) Close-up of the p.F89L missense change. The side chains of phenylalanine and 
leucine are shown in green and red, respectively. E) Close-up of the p.S92P missense 
change. The mutation precedes one of the important bonding cysteines in the protein 
disturbing the creation of the disulfide bond and possibly affecting the local structure 
of NDP. F) Close-up of the missense change p.P98L. The change is located close to the 
last cysteine in the cysteine knot motif and to the unbound cysteine that is needed to 
form dimers. Conversion of proline to leucine will probably have an impact on the local 
structure of the protein averting its normal function.
Although Norrin is not structurally related to the Wnt family of proteins, it 
resembles their function by binding with high affinity to the receptor Frizzled-4, 
requiring LDL receptor-related protein (LRP) as a coreceptor and by activating 
the FZD4/LRP5/p-catenin signaling pathway Wnt signaling pathway.33 One of
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the multiple routes that this pathway is involved in, is the transcriptional control 
and regulation of genes that are under the influence of TCF/Lef binding sites. 
NDP, together with FZD4 and LRP5, effectively plays a role in the development 
of the cells in the retinal neural epithelium by setting off the retreat of the HVS 
and in parallel by patterning the external and deep retinal vasculature, which is 
necessary for retinal function.61
Ninety-five nucleotide variants have been reported for NDP (Supporting Ta­
ble S5). Twenty-four mutations result in the introduction of a premature stop 
codon, 58 are missense changes, six changes affect splice sites and for seven 
variants their effect is different or unknown. Most of the mutations result in 
Norrie disease and a smaller percentage in X-linked FEVR. Five NDP changes 
(p.R41S, p.Y44X, p.C96W, p.L108P, and p.R121W) have been suggested to be 
associated with persistent fetal vasculature syndrome, Coats disease, and reti­
nopathy of prematurity (ROP). These distinct clinical entities share some com­
mon pathological features such as abnormal retinal blood vessel growth that 
may result in scarring and retinal detachment.
Two groups have performed functional assays for NDP variants. Xu et al. 
(2004),33 using a cotransfection signaling assay in STF cells in parallel with 
immunoblotting, assessed total protein production, secretion efficiency to the 
extracellular matrix and potency for signaling transduction. They analysed 18 
NDP mutations associated with FEVR or ROP. All missense mutants but one 
(p.L13R), showed no production or secretion efficiency aberrations; all but one 
(p.K58N) resulted in a 20 to 80% decreased Wnt signaling potential. Moreover, 
Qin et al. (2008),32 after testing two groups of NDP missense variants associated 
with either F e V r (p.R41K, p.K54N, p.R115L, and p.R121W) or Norrie dis­
ease (p.K58N, p.A63D, p.R97P, and p.R121W), in a similar way showed 17 to 
96% reduced signaling potential. Only p.K58N, in agreement with the previous 
study, resulted in increased signaling ability. Interestingly, the authors suggested 
that mutants p.K54N, p.K58N, and p.R115L disturb binding of Norrin with oth­
er factors possibly related to Norrin’s physiological function. Finally, no mutant 
was observed to have any impact on the integrity of the protein.
Here, we report 12 novel nucleotide variants in NDP associated with Nor­
rie disease or X-linked FEVR. These include six missense variants (p.C55R 
p.G67E, p.G67R, p.F89L, p.S92P, and p.P98L), one nonsense (p.SlllX ), three 
frameshift (p.H4RfsX21, p.S9PfsX4, and p.Y44MfsX60), and two splice site 
mutations (c.-208+2T>G, c.-208+5G>A). The missense change p.C55R influ­
ences a cysteine residue located on the ‘‘top’’ of one of the antiparallel b-sheets 
forming a disulphide bridge with a cysteine on the top of the other p-sheet (Fig­
ure 3B). The exact function of this bond is unclear, but it could be speculated 
that it might be necessary to stabilize the conformation of the two p-sheet do­
mains that contain hydrophobic residues that can interact with another NDP 
monomer. Without the disulfide bridges the two sheets will have more freedom 
to move, thereby making it difficult to form the correct structure for dimeriza­
tion. Moreover, this disulfide bridge and amino acid location was shown to be 
evolutionary conserved (Supporting Figure S4).59
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The glycine residue at position 67 is highly conserved among many NDP or- 
thologues (Supporting Figure S4) and the p.G67E and p.G67R variants change 
a small and flexible glycine into either a glutamic acid (negatively charged) or 
into an arginine (positively charged). Glycine is ‘‘required’’ at this position for 
the protein to adopt a typical backbone conformation crucial for formation of 
the cysteine knot (Figure 3C). No other residue can make the correct backbone 
angles, and therefore, mutation of the glycine will disturb cysteine knot forma­
tion and the structure of the protein.
The missense change p.F89L is located in a highly conserved domain (Sup­
porting Figure S4) that adopts an a-helical structure. This amino acid is pre­
dicted to be one of the residues that participate in the dimerization of NDP.59 
The hydrophobic phenylalanine interacts with other hydrophobic residues on 
the other monomer. Leucine is also hydrophobic, but has a smaller side chain 
(Figure 3D). It seems possible that this leucine could make the same type of 
interactions, but because of altered stereospecificity the dimer formation could 
be less strong and stable.
The missense change p.S92P affects a serine that precedes a cysteine in the 
cysteine knot motif, and was identified in a simplex Norrie disease patient (Ta­
ble 3 and Supporting Table S2). As a ‘‘consensus’’ it is very critical that the 
cysteines are placed correctly in NDP, as they are crucial for its structure. The 
missense change introduces proline (Figure 3E), which is known to be a very 
rigid residue that often forces the backbone to bend and thereby might disturb 
the formation of the disulfide bridge and thus the conformation of NDP. Finally, 
p.P98L is located close to the last cysteine in the knot motif and to the unbound 
cysteine that is needed to form dimers (Figure 3F). The local backbone structure 
that is created by proline, might be necessary for the correct positioning of cys­
teines. A leucine will cause more flexibility in the backbone that might result in 
difficulties during dimerization and/or formation of the cysteine knot. Another 
possibility is that the hydrophobic side chain of proline might be needed for 
interactions with another monomer.
- 109 -
Chapter -4-
Table 3. Novel NDP sequence variants that are likely to cause Norrie Disease.
Nucleotide variant Effect Exon Occurrence 
in patients 
(probands)
Occurrence in 
control alleles
Segregation
Truncating changes
c.11_12del p.H4RfsX21 2 1/46 0/100 Simplex
c.25_40del p.S9PfsX4 2 1/46 0/100 Simplex
c.129delC p.Y44MfsX60 2 1/46 0/100 Simplex
c.332C>A p.S111X 3 1/46 0/100 Simplex
Missense changes
c.163T>C p.C55R 2 1/46 0/100 Simplex
c.199G>A p.G67R 3 1/46 0/100 Simplex
c.200G>A p.G67E 3 1/46 0/100 Simplex
c.267C>A p.FS9L 3 1/46 0/100 Simplex
c.274T>C p.S92P 3 1/46 0/100 Simplex
c.293C>T p.P9SL 3 1/46 0/100 Simplex
Splice-site changes
c.-20S+2T>G Splice defect 1 1/46 0/100 Simplex
c.-20S+5G>A Splice defect 1 1/46 0/100 Yes
Nucleotide numbering reflects cDNA numbering with +1 corresponding to the A of the 
ATG translation initiation codon in the reference sequence (GenBank NM_000266.3), 
according to journal guidelines (www.hgvs.org/mutnomen). The translation initiation 
codon is codon 1 (GenBank NP_000257.1)
The four novel protein truncating mutations likely result in NMD of the RNA 
or a truncated protein and thereby in a reduction or absence of NDP activity. 
Moreover, the two novel splice mutations, c.-208+2T>G and c.-208+5G>A, af­
fect the highly conserved splice donor site of exon 1. The two most likely ef­
fects are that either intron 1 is retained in the mature mRNA or that exon 2 is 
not spliced into the mRNA. In the latter case, the mRNA would lack the ATG 
residing in exon 2, as well as the 58 most N-terminal amino acids. Inclusion of 
intron 1 may have an effect on the stability of the mRNA. The c.-208+5G>A 
variant segregates with the disease phenotype in the family as it is present in 
two affected males. The clinical information of one ND patient is presented in 
Supporting Table S2.
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Animal models
Several mouse models have been made that either have no or partially func­
tional Fzd4, Lrp5, and Ndph (Norrie disease pseudoglioma mouse homologue), 
to shed more light on the biochemical properties of these proteins and under­
stand the pathology of the associated diseases.
Gene disruption in murine Fzd4 using a Fzd4-lacZ knock-in reporter allele 
assessed by X-gal staining provided in-depth analysis of its expression. During 
littermate development, Fzd4 seemed to be transiently present in a wide variety 
of tissues. In mature Fzd4+'~ mice, expression was observed in the Purkinje cells 
of the cerebellum, in the retina, in the inner hair cells in the organ of Corti, and 
in the sensory epithelium of the otolith organs.62 Moreover, a prominent Fzd4 
expression throughout development was also demonstrated in the ovary, with 
high prevalence in the corpus luteum.63 Fzd4~'~ mice are viable, although they 
are subject to high mortality rates (~50%) and impaired growth, beginning in 
the second postnatal week.62 The Fzd4~'~ mice also displayed progressive hear­
ing loss and an inoperative swollen esophagus around P8.62 Xu et al. (2004)33 
demonstrated that young adult mice show compromised intraretinal vascula­
ture. Problematic blood supply of the retina especially in the nerve fiber layer 
(NFL) and outer plexiform layer (OPL) was noted. No significant differences 
in anatomic and/or phenotypic characteristics were noticed between Fzd4+/+ and 
Fzd4~'~ mice.
Similar to Fzd4, Lrp5 was found to be expressed in many tissues in the mouse. 
However, its expression was most abundant in central nervous system neurons, 
the islets of Langerhans, liver, osteoblasts, and ocular macrophages.64,65 In an 
effort to replicate the phenotypic manifestation of OPPG, Lrp5~'~ mice were gen­
erated by disrupting exon 6 of the gene with the insertion of an IRES-LacZ- 
Neomycin cassette and thus resulting in a prematurely truncated protein.65 These 
Lrp5~'~ mice were viable and fertile; however, a fraction of them died prema­
turely because of bone fractures. The mice displayed low bone mass phenotype 
from 2 weeks and decreased bone volume and mineral content of the ECM sur­
rounding osteoblasts. In 70% of Lrp5~'~ mice hyaloid vessels regression was de­
layed at 6 months of age. This was postulated to result from failed macrophage- 
mediated apoptosis. Lrp5+'~ mice displayed the same bone phenotype to a lesser 
extent and had no eye-related abnormalities. Moreover, Fujino et al. (2003)66 
generated Lrp5~'~ mice by disrupting a ligand binding repeat in exon 18. All mice 
appeared normal until the sixth month of their life when parietal bone weakness 
was noted in 70% of Lrp5~'~ of the female population. The Lrp5~'~ mice also dis­
played impaired chylomicron clearance, hepatic uptake, and glucose-induced 
insulin secretion. The authors did not report on eye-related abnormalities. Two 
other studies67,68 described transgenic mice with the p.G171V mutation, which 
is associated with the human high bone mass phenotype. The LRP5G171V mice 
showed greater bone mass, density, structure, and strength. Finally, Xia et al. 
(2008)69 identified a ENU-induced recessive mouse mutant line that bears many 
similarities with the eye pathology that FEVR shows in humans. The mutant r18 
mouse carries a frameshift mutation that causes a premature stop at codon 1596
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and the replacement of the 39 most C-terminal amino acids by 20 different ones. 
In Lrp5r18/r18 mice, the retina appeared hypopigmented and the retinal arteries 
weak. Moreover, early in their growth, the mice developed retinal hemorrhage. 
The retinal vasculature was disorganized, immature, and leaky, with less and 
smaller blood vessels. Meagre retinal blood supply was postulated to be a con­
sequence of defective capillary lumen formation.
Ndph mutant mice replicate most of the symptoms associated with Norrie 
disease and partially that of FEVR, both in terms of eye/retinal symptomatol­
ogy and auditorial defects. The mutant mice display retrolental structures in the 
vitreous body and a perturbed ganglion cell layer along with the formation of 
pseudogliomas in the posterior vitreal chamber.70,71 All the different cell lay­
ers of the retina were reduced along with the photoreceptors, but specific seg­
ments of the retina such as the OPL could completely disappear.70,72 Moreover, 
the Ndph knockout mice developed severe structural irregularities of the retinal 
vascular system formation. The hyaloid blood vessels delayed to regress,61,71,73 
and both superficial and intraretinal vasculature was severely impaired because 
a large number of blood vessels or capillaries was defective or even absent. The 
lack of normal blood supply that nourishes the different retinal cell layers results 
in local hypoxic conditions, especially in the inner retina. This was associated 
with increased expression of vasodilatation indicators such as eNOS and VEGF, 
and increased permeability of retinal blood vessels.61,74 Defects in the cochlear 
stria vascularis of Ndphy/- animals resulted in progressive hearing loss, leading 
to deafness, similar to the human phenotype.75 Adding to that, more light was 
shed on the biochemical role of NDP by overexpressing it transgenically in the 
eyes of Ndphy/- mice under the control of a lens-specific promoter.73 Ectopically 
expressed Norrin surprisingly restored the normal retinal vasculature, while re­
specting the normal local architecture of the blood vessels. Recently, the fact 
that vascular changes occur in the cerebellum of hemizygous Ndphy/- animals 
was noted as the first evidence of a brain phenotype in mice that could be cor­
related with the mental retardation seen in one-third of human Norrie disease 
patients.76 Finally, Schafer et al. (2009)77 provided further evidence about the 
multidimensional role of NDP during retinal angiogenesis. They postulated that 
the function of NDP may not only be limited to transcriptional regulation of 
p-catenin target genes that, for example, regulate blood vessel formation and in­
tegrity, but also play a role in the transcription of other targets like Plvap.78,79 The 
latter would expand Norrin’s functional spectrum, which might provide us with 
an insight into the phenotypic heterogeneity observed even in individuals of the 
same family suffering from FEVR or ND. The parallel contribution of other ge­
netic determinants could affect the severity of disease symptoms by putatively 
altering target gene expression, something that potentially could be explored as 
a diagnostic or prognostic tool regarding the phenotypic severity of patients.
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Clinical, diagnostic, biological relevance and future prospects
With the present study on FZD4, LRP5, and NDP, we have attempted to pro­
vide a comprehensive summary of mutations that have been reported to affect 
these genes, with a focus on FEVR and Norrie disease. The three proteins coop­
erate in the Wnt/p-catenin and/or Norrin/p-catenin signaling pathway, by regu­
lating angiogenesis and maintaining blood vessel integrity in the retina. Patients 
suffering from FEVR and to a lesser degree, Norrie disease, are often difficult 
to diagnose. Nonpenetrance in FEVR can be observed in up to 25% of mutation 
carriers80,81 and genotype-phenotype correlations are often not accurate enough. 
Wu et al. (2007),82 have suggested that NDP mutations affecting cysteine resi­
dues that play a firm role in the formation of the cysteine knot motif resulted 
in severe retinal dysgenesis and were diagnosed as Norrie disease. Nucleotide 
variants that affected noncysteine residues were associated with FEVR-like 
phenotypes. Furthermore, it was also postulated that mutations in LRP5 found 
in patients with FEVR or OPPG can result both in ocular and bone abnormali­
ties, classifying both diseases under the same phenotypic spectrum.83 The rela­
tively small number of 28 exons and 32 amplicons that need to be analyzed for 
theses three genes renders Sanger sequence analysis cost effective. Molecular 
testing is important for diagnostic and prognostic purposes in individuals sus­
pected to suffer from FEVR or ND, especially when coupled with a detailed 
family history. At least 40% of patients with FEVR do not carry mutations in 
FZD4 or LRP5,80,83,84 so we are pursuing the identification of additional FEVR 
genes. Recently, in a cohort of eleven Dutch families that were tested negative 
for mutations in the ORF of FZD4, LRP5, and NDP, respectively; we identified 
TSPAN12 as a gene causative for autosomal dominant FEVR.85 The gene was 
mutated in 5 out of the 11 Dutch families tested, rendering it a relative frequent 
cause of FEVR. In parallel, Poulter et al. (2010)86 identified the involvemen- 
tof TSPAN12 in FEVR by identifying seven novel mutations in this gene in 
a cohort of 70 FEVR patients in whom known FEVR genes had already been 
excluded. Our emerging understanding of Wnt signaling offers hope that phar­
maceutical agents that selectively target this pathway will be developed to treat 
some phenotypic characteristics of these diseases in the future.
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Patients and Methods
The tenets of the Declaration of Helsinki were followed and informed consent 
was obtained from all patients who participated in this study prior to donation 
of a blood sample. These studies were approved by the local medical ethical 
commission.
For mutation analysis of the probands, DNA was isolated from blood leuko­
cytes by an automated procedure with the magnetic bead platform from Chema- 
gen AG (Baeswider, Germany). The FZD4 (2 exons, 6 amplicons), LRP5 (23 
exons, 23 amplicons), and NDP (3 exons, 3 amplicons) genes were scanned for 
mutations by using standard sequencing methodologies on a genetic analyzer 
(model 3730; ABI) with primers flanking the coding exons and the adjacent 
splice sites. Primers and PCR conditions are available on request.
In this study we analysed probands from 16 different FEVR families. From 
those families, 11 were sporadic cases and five had two or more affected indi­
viduals. In total those families comprise 20 affected and six not-affected indi­
viduals. In the 16 families we identified four probands harboring aberrant nucle­
otide changes in FZD4, three in LRP5, and one harboring changes in both FZD4 
and LRP5. In seven families we did not identify any variants in those genes. 
We also analysed 29 sporadic cases and 17 families with two or more affected 
individuals with ND or ND-like features. Our screening identified 27 probands 
harboring aberrant nucleotide changes in the NDP ORF and four female index- 
patients being carriers of such changes. Probands of 15 families were tested 
negative for NDP changes and seven of those did not contain changes in the 
ORF of FZD4 and LRP5.
In families in which a genetic variant in one of the genes was identified, DNA 
of all available affected and non affected family members was analyzed for 
segregation of the specific variant by analysis of the relevant exons using the 
same conditions when this applicable. All novel variants in FZD4 and LRP5 
were absent among 100 control alleles tested, or 100 X chromosomes in case of 
novel variants in NDP.
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Supporting information (Figures and Tables)
Supporting Figure S1: Topology of the Frizzled 4 receptor and the position of novel 
missense variants. The 7 transmembrane domains are shown as dark grey cylindrical 
columns numbered 1 through 7. The FZ-domain was modelled using the mouse Fzd8 
homolog, which is 40% identical with human FZD4. Amino acids connecting the trans­
membrane domains are shown as grey lines; no structure could be predicted for these 
residues. The putative signal peptide is shown as a dashed line. The KTXXXW and PDZ 
binding motifs located in the C-terminal tail are indicated with arrows.
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A. Missense variant
Homo sapiens 
Mus musculus 
Bos taurus 
Canis familiaris 
Macaca mulatta 
Pan troglodytes 
Xenopus laevis 
Gallus gallus
B. Missense variant
Homo sapiens 
Mus musculus 
Bos taurus 
Canis familiaris 
Macaca mulatta 
Pan troglodytes 
Xenopus laevis 
Gallus gallus
C. Missense variant
Homo sapiens 
Mus musculus 
Bos taurus 
Canis familiaris 
Macaca mulatta 
Pan troglodytes 
Xenopus laevis 
Gallus gallus
P.E40Q
30 LLGPARGFGDEEERRCDPIRI 50 
jpfflGFGDEEERRCDPIRI 50 
SpJr g f g d e e e r r c d p i r i 50 
35 LLgPARGFGDEEERRCDPIRI 55 
30 LLGPARGFGDEEERRCDPIRI 50 
30 Bl g p a r g f g d e e e r r c d p i r i 50 
16 ^BgW ^ gfgISeeerScdpiri 36 
18 LLGPARGFGDEEERRCDPIRI 38
p .C204Y
194 VKRSLNCVLKCGYDAGLYSRS 
194 VKRSLNCVLKCGYDAGLYSRS 
194 VKRSLNCVLKCGYDAGLYSRS 
198 VKRSLNCVLKCGYDAGLYSRS 
194 VKRSLNCVLKCGYDAGLYSRS 
194 VKRSLNCVLKCGYDAGLYSRS 
180 VKRSjJjNCVLKCGYD@GLYjJ]R0 
182 VKRSLNCVLKCGYDAGLYSRS
p .G525R 
515 GKVKREKRGNGWVKPGKGNET 
515 GKVKREKRGNGWVKPGKGNET 
515 GKVKREKRGNGWVKPGKGNET 
519 GKVKREKRGNGWVKPGKGNET 
515 GKVKREKRGNGWVKPGKGNET 
515 GKVKREKRGNGWVKPGKGNET
501 gkvkrBkrBBgwvkpgkgnet
503 GKVKREKR
^E
r^BgWVKPGKGNET
214
214
214
218
214
214
200
202
535
533
533
539
535
535
521
523
Supporting Figure S2: Amino acid sequence alignment of human FZD4 with or- 
thologous proteins from, rhesus monkey, mouse, cow, opossum, chicken, frog, and
stickleback. Ten upstream and 10 downstream amino acids of the missense variants 
p.E40Q (panel A), p.C204Y (panel B) and p.G525R (panel C) are depicted. Residues 
identical across all sequences are black on a white background whereas similar amino 
acids are indicated in white on a gray background. Non similar and weakly similar 
amino acids are indicated in white on a black background. The amino acid residue at the 
position of the missense change is indicated in bold. GenBank and/or Ensembl protein 
ID numbers for FZD4 amino acid alignment: Homo sapiens NP_036325.2; Macaca 
mulatta XP_001103927.1; M us musculus NP_032081.3; Bos taurus XP_ 874584.2; 
Monodelphis domestica XP_001376661.1; Gallus gallus NP_989430.1; Xenopus laevis 
NP 001083922.1;. Gastrosteus aculeatus ENSGACP00000010666.
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A. Missense variant 
Homo sapiens 
Mus musculus 
Bos taurus 
Papio anubis 
Pan troglodytes 
Gallus gallus 
Xenopus laevis 
Danio rerio 
Drosophila arrow
p .E441K
431 YWTDTGTDRIEVTRLNGTSRK 451 
430 YWTDTGTDRIEVTRLNGTSRK 450
618 YWTDTGTDRIEVTRLNGTSRK 638
428 YWTDTGTDRIEVTRLNGTSRK 448
517 YWTDTGTDRIEVTRLNGTSRK 537 
430 YWTDTGTDRIEVTRLNGTSRK 450
421 YWTDTGTDRIEVTRLNGTSRK 441
408 YWTDTGTDRIEVTRLNGTSRK 428
492 YWTDTBTDRIEvgRLjjGTgRK 512
B. Missense variant
Homo sapiens 1243 
Mus musculus 1242 
Bos taurus 1430 
Papio anubis 1240 
Pan troglodytes 1329 
Gallus gallus 1244 
Xenopus laevis 1235 
Danio rerio 1217 
Drosophila arrow 1303
p .C1253F
HLVLLQNLLTCGEPPTCSPDQ 
HLVLLQNLLTCGEPPTCSPDQ 
HLVLLQNLLTCGEPPTCSPDQ 
HLVLLQNLLTCGEPPTCSPDQ 
HLVLLQNLLTCGEPPTCSPDQ 
h l v l l q0 l l t c g e p p t c s p[3 
h l v l l q n l lSc g e p p t c s I 
h l v l l q n l lSc g e p p t c s
h l IJl l e d k e m
aQ
gpDH
Supporting Figure S3: Amino acid sequence alignment of human LRP5 with or- 
thologous proteins from chimpanzee, mouse, cow, chicken, lizard, frog, zebra fish 
and fruit fly. Ten amino acids in the vicinity of missense changes p.E441K (panel A) and 
p.C1253F (panel B) are depicted. Residues identical across all sequences are black on 
a white background whereas similar amino acids are indicated in white on a gray back­
ground. Non similar and weakly similar amino acids are indicated in white on a black 
background. The amino acid residue at the position of the missense change is bolded. 
GenBank and/or Ensembl protein ID numbers for LRP5 amino acid alignment: Homo 
sapiens NP_002326.2; Pan troglodytes XP_508605.2; M us musculus NP_032539.1; 
Bos taurus XP_ 614220.3; Gallus gallus NP_001012915.1; Anolis carolinensis EN- 
SACAP00000014430; Xenopus laevis NP_001079163.1; Danio rerio XP_696943.3; 
Drosophila arrow NP_524737.2.
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p.C55R
p.G67E 
p .G67R
p . S 9 2 P
1 I
p . F 8 9 L p .P98L
n  I
VDSISHPLYKCSSKMVLLARCEGHCSQASRSEPLVSFSTVLKQPFRSSCHCCRPQTSKLKALRL 108 
VDSISHPLYKCSSKMVLLARCEGHCSQASRSEPLVSFSTVLKQPFRSSCHCCRPQTSKLKALRL 106 
VDSISHPLYKCSSKMVLLARCEGHCSQASRSEPLVSFSTVLKQPFRSSCHCCRPQTSKLKALRL 108 
VDSISHPLYKCSSKMVLLARCEGHCSQASRSEPLVSFSTVLKQPFRSSCHCCRPQTSKLKALRL 108 
VDSISHPLYKCSSKMVLLARCEGHCSQASRSEPLVSFSTVLKQPFRSSCHCCRPQTSKLKALRL 108 
VDSISHPLYKCSSKMVLLARCEGjCSQBSRSEPgVSFSTVLKQPFRSgCHCCRPQTSKLKAjRL 108 
VDSISHPLYKCSSKMVLLARCEGHCSQASRSEPLVSFSTVLKQPFRSSCHCCRPQTSKLKALRL 108
V@BiraHPnYKCBSKMVLLARCEGHCSHSRSjPL0SFS@VLKQPF|^C||CCRP|jjTSKLKABRL 114 
VDSllHPgSKCÈKMVLLARCEGScS^SRsEPLVSFSTVLKQPFRSüCHCCRPQTSKLKABRL 107
Homo sapiens 45 
Mus musculus 43 
Bos taurus 45 
Canis familiaris 45 
Pan troglodytes 45 
Gallus gallus 45 
Sus scrofa 45 
Danio rerio 51 
Xenopus laevis 44
Supporting Figure S4: Protein sequence alignment of human NDP with orthologues 
from chimpanzee, mouse, pig, cow, dog, tenrec, chicken, lizard, frog and zebrafish.
Residues identical across all sequences are black on a white background whereas similar 
amino acids are indicated in white on a gray background. Non similar and weakly similar 
amino acids are indicated in white on a black background. The amino acid residue at 
the position of the missense change is bolded. GenBank and/or Ensembl protein ID 
numbers for NDP amino acid alignment: Homo sapiens NP_000257.1; Pan troglodytes 
XP_528948.1; M us musculus NP_035013.1; Sus scrofa NP_001106528; Bos taurus 
NP_001039555.1; Canisfamiliaris XP_855261.1; Echinops telfairi ENSP00000367301; 
Gallus gallus XP_416765.1; Anolis carolinensis ENsAcAP00000017627; Xenopus 
laevis NP_000257.1; Danio rerio XP  001338820.
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Supporting Table S1. FZD4 sequence variants that are ikely to be pathogenic.
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T runca ting  changes
c.244_251delins27 p.F82AfsX53 1 1/53 0/200 Yes FEVR Nallathambi et al., 200687
c.856G>T p.E286X 2 1/8 0/10 0 Yes FEVR This study
c.957delG p.W319CfsX5 2 1/40 0/200 Simplex FEVR Toomes et al., 2004b84
c.957G>A p.W 319X 2 5/20,
1/24
0/80,
0/300
Yes,
De novo
FEVR,
FEVR
Kondo et al., 2003;31 
Boonstra et al., 200931, 80
c.1282_1285del p.D428SfsX2 2 1/8 0/10 0 Yes FEVR This study
c.1286_1290del p.K429RfsX28 2 1/2 l N/A Yes FEVR M uller et al., 200888
c.1488G>A p.W 496X 2 1/20 0/80 Yes FEVR Boonstra et al., 20 0980
c.1498delA p.T500LfsX13 2 1/40 0/200 Simplex FEVR Toomes et al., 2004b84
c.1501_1502del p.L501SfsX33 2 1/2 ,
1/40
0/306,
0/200
Yes,
Yes
FEVR,
FEVR
Robitaille et al., 2002 ;11 
Toomes et al., 2004b84
c.1513C>T p.Q505X 2 1/40 0/200 Yes FEVR Toomes et al., 2004b84
M issense changes
c.107G>A p.G36D 1 1/40 0/400 Simplex FEVR Toomes et al., 2004b84
c.118G>C p.E40Q 1 1/8 0/10 0 Simplex FEVR This studyA
c.313A>G p.M 105V 2 1/24 0/300 Yes FEVR Kondo et al., 200331
c.314T>C p.M 105T 2 1/40 0/400 Simplex FEVR Toomes et al., 2004b84
c.341T>C p.I114T 2 1/2 N/A Yes FEVR Robitaille et al., 200989
c.469A>G p.M 157V 2 1/40 0/400 Yes FEVR Toomes et al., 2004b84
c.541T>C p.C181R 2 1/2 0/240 Yes FEVR Omoto et al., 20 0490
c.609G>C p.K203N 2 1/104 0/346 Yes ROP Ells et al., 20 1091
c.611G>A p.C204Y 2 1/8 0/10 0 Simplex FEVR This study
c.612T>C p.C204R 2 1/53 0/200 Yes FEVR Nallathambi et al., 200687
c.6 6 8T>A p.M 223K 2 1/20 0/80 Yes FEVR Boonstra et al., 20 0980
c.766A>G p.I256V 2 1/20 0/200 Simplex FEVR M acDonald et al., 200 592
c.1005G>C p.W 335C 2 1/56 0/300 Yes FEVR Qin et al., 200583
c.1024A>G p.M 342V 2 1/ 1,
1/56
0/ 120 ,
0/300
Yes,
Simplex
FEVR,
FEVR
Yoshida et al., 2004;93 
Qin et al., 200583
c.1109C>G p.A370G 2 1/104 0/346 Simplex ROP Ells et al., 20 1091
c.1250G>A p.R417Q 2 2/24 0/300 Yes FEVR Kondo et al., 200331
c.1333A>C p.T445P 2 1/20 0/80 Yes FEVR Boonstra et al., 20 0980
c.1463G>A p.G488D 2 1/24 0/300 Yes FEVR Kondo et al., 200331
c.1474G>C p.G492R 2 1/2 N/A Yes FEVR M uller et al., 200888
c.1490C>T p.S497F 2 1/40 0/400 Simplex FEVR Toomes et al., 2004b84
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Supporting Table S1. FZD4 sequence variants that are ikely to be pathogenic.
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M iscellaneous chan ges
c.1479_1484del p.M493
W 494del 0
1/2 0/306 Yes FEVR Robitaille et al., 200211
Nucleotide numbering reflects cDNA numbering with +1 corresponding to the A of the 
ATG translation initiation codon in the reference sequence (GenBank NM_012193.2), ac­
cording to journal guidelines (www.hgvs.org/mutnomen). The translation initiation codon 
is codon 1 (GenBank NP_036325.2).
AThis patient also carries a splice site mutation in LRP5 (c.4489-1G>A), see Supporting 
Table S2.
FEVR, familial exudative vitreoretinopathy (autosomal dominant); ROP, retinopathy of 
prematurity; N/A, information not available or screening was not performed.
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Supporting Table S2. Summary of clinical data of several FE VR or Norrie disease patients harboring novel mutations in FZD4, LRP5  or NDP
Family Patient Gene M utation Gender Age at 
investigation
Visual acuity Miscellaneous ocular features Non-ocular features
LE RE
W05-
214
11:1 F Z D 4 p.E286X M 6 years ? 6/6 Equatorial zone with avascular peripheral fundus. LE: RD 
surgery (8  years), no vision.
Not present
1:1 F Z D 4 p.E286X F 53 years 6/6 6/6 RE: Few abnormal temporal retinal branches. Not present
W06-
241
11:1 F Z D 4 p.D428SfsX2 F 5 years N/A N/A M acular ectopia. Haemorrhagic and exudative areas present in 
the retina.
Premature delivery
W05-
213
IV:2 F Z D 4 p.C204Y M 3 years 6/60 No LP RE: Vitreous haemorrhage and formation o f fibrovascular m em­
brane. Total RD LE: Deformation o f posterior retina, ectopia o f 
the macula, stretched retinal vessels, preretinal membranes
Juvenile
osteochondrosis
15 years 20 /200 No LP LE: Scleral buckling procedure w ith cryocoagulation.
17 years 2/60 No LP LE: Lensectomy and vitrectomy.
19 years 1/300 No LP LE: Vitreous haemorrhage, vitreoretinal traction and secondary 
uveitis.
W06-
237
11:2 F Z D 4 p.G525R M At birth N/A N/A Congenital falciform retinal fold from ciliary body to posterior 
papilla.
Not present
26 years LP 20 /100 M acular ectopia and peripheral RD.
W05-
204
11:1 L R P 5 p.W993X M 6 months N/A N/A LE/RE: Leucocoria. Persistent hyperplastic primary vitreous. Severe developmental delay and 
learning difficulties; plagiocephaly; 
autistic features and seizures (8 
years).
W06-
920
11:2 L R P 5 p.E441K F 6 years 0 6 /12 RE: Falciform retinal fold.LE:RD Not present
18 years 0 CF RE: Cataract, lens aspiration, secondary glaucoma.
26 years 0 CF LE: pupillary block, glaucoma, iridectomy
53 years 0 0 Enucleation o f both eyes because o f recurrent pain
W05-
205
11:2 L R P 5 p.G610R/
p.C1253F
M 1 year N/A N/A LE: RD. LE/RE: Ectopic macula and fibrovascular ridge in the 
temporal periphery
Reduced BMI (0.62gr/cm2),
8 years 0 N/A LE: Total RD.
OS-
2645
N D P p.S92P M 3 weeks N/A N/A Conjunctival inflammation. Irregular pupils due to presence of 
synechiae in the anterior chamber.
Moderate bilateral hearing loss (2 
years); skeletal abnormality affect­
ing cervical spine and forearms (24 
years).
7 months N/A N/A Inflammatory bilateral pseudoglioma.
For FZD4 the translation initiation codon is codon 1 (GenBank NP 036325.2). For LRP5 the translation initiation codon is codon 1 (GenBank NP 002326.2). For NDP, the transla­
tion initiation codon is codon 1 (GenBank NP 000257.1). BMI: Bone mass index, LE: Left eye, LP: light perception, N/A: Not available, RD: Retinal detachment, RE: Right eye.
C
hapter 
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Suporting Table S3. LRP5 sequence variants that are likely to be pathogenic.
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Truncating changes
c.29G>A p.W10X 1 1/28,
1/37
0/50,
N/A
Yes,
Yes
OPPG,
OPPG
Gong et al., 2001;47 
Ai et al., 200548
c.209_210TC>AA p.F70X 2 1/37 N/A Yes OPPG Ai et al., 200548
c.765G>A p.W255X 4 1/37 N/A Yes OPPG Ai et al., 200548
c.789C>A p.C263X 4 1/37 N/A Yes OPPG Ai et al., 200548
c.803_812del p.G269RfsX4 4 1/56 0/362 Simplex arFEVR Qin et al., 200583
c.1000_1004dup p.C336GfsX50 5 1/37 N/A Yes OPPG Ai et al., 200548
c.1275G>A p.R425X 3/3 N/A Yes OPPG Streeten et al., 200894
c.1282C>T p.R428X 6 1/28,
1/37
0/50,
N/A
Yes,
Yes
OPPG,
OPPG
Gong et al., 2001;47 
Ai et al., 200548
c.1453G>T p.E485X 7 1/28,
1/37
0/50,
N/A
Yes,
Yes
OPPG,
OPPG
Gong et al., 2001;47 
Ai et al., 200548
c.1468delG p.D490MfsX40 7 1/28,
1/37
0/50,
N/A
Yes,
Yes
OPPG,
OPPG
Gong et al., 2001;47 
Ai et al., 200548
c.1750C>T p.Q584X 8 1/37 N/A Yes OPPG Ai et al., 200548
c.2151dupT p.D718X 10 1/28,
1/37
0/50,
N/A
Yes,
Yes
OPPG,
OPPG
Gong et al., 2001;47 
Ai et al., 200548
c.2202G>A p.W734X 10 1/28,
1/37
0/50,
N/A
Yes,
Yes
OPPG,
OPPG
Gong et al., 2001;47 
Ai et al., 200548
c.2247delG p.Q750SfsX48 10 2/37 N/A Yes OPPG Ai et al., 200548
c.2305delG p.D769IfsX29 10 1/27 0/50 Yes OPPG Gong et al., 200147
c.2409_2503+79del174 p.G804 G835delf- 
s49X
11 1/37 N/A Yes OPPG Ai et al., 200548
c.2557C>T p.Q853X 12 1/28,
1/37
0/50,
N/A
Yes,
Yes
OPPG,
OPPG
Gong et al., 2001;47 
Ai et al., 200548
c.2718_2721del p.M907TfsX52 12 1/37 N/A Yes OPPG Ai et al., 200548
c.2737dupT p.C913LfsX73 12 1/37,
1/20
N/A,
0/246
Yes,
Yes
Primary
osteo­
porosis,
OPPG
Ai et al., 2005;48 
Hartikka et al., 200595
c.2978G>A p.W993X 13 1/8 0/100 Simplex FEVR This study
c.3232C>T p.R1078X 14 1/37 N/A Yes OPPG Ai et al., 200548
c.3804delA p.E1270RfsX169 18 1/28 0/50,
0/400,
N/A
Yes,
Simplex,
Yes
OPPG,
FEVR,
OPPG
Gong et al., 2001;47 
Toomes et al., 2004a;12 
Ai et al., 200548
c.4105_4106del p.M1369VfsX2 19 1/37 N/A Yes OPPG Ai et al., 200548
c.4119dupC p.L1374QfsX176 20 1/32 0/400 Yes FEVR Toomes et al., 2004a12
c.4512 4517 
delinsTGTACAACAT
p.A1505VfsX46 22 1/37 N/A Yes OPPG Ai et al., 200548
c.4600C>T p.R1534X 23 1/37 N/A Yes OPPG Ai et al., 200548
Missense changes
c.85G>A p.A29T 1 1/20 0/246 Yes Pri­
mary
osteo­
porosis
Hartikka et al., 200595
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Suporting Table S3. LRP5 sequence variants that are likely to be pathogenic.
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c.331G>T p.D111Y 2 1/10 0/100 Yes HBM van Wesenbeeck et al., 
200396
c.433C>T p.L145F 2 1/56 0/362 Yes FEVR Qin et al., 200583
c.461G>T p.R154M 2 1/1 1/544 Yes HBM Rickels et al., 200597
c.511G>C p.G171R 3 1/10 0/100 Yes HBM van Wesenbeeck et al., 
200396
c.511G>T p.G171V 3 1/1,
1/1
0/420,
0/2000
Yes,
Yes
HBM,
HBM
Boyden et al., 2002;44 
Little et al., 20 0298
c.518C>T p.T173M 3 1/32 0/400 Simplex FEVR Toomes et al., 2004a12
c.607G>A p.D203N 3 1/32 N/A Yes OPPG Ai et al., 200548
c.640G>A p.A214T 3 1/10 0/100 Yes HBM van Wesenbeeck et al., 
200396
c.641C>T p.A214V 3 1/10 0/100 Simplex HBM van Wesenbeeck et al., 
200396
c.724G>A p.A242T 4 4/10 0/100 Yes HBM van Wesenbeeck et al., 
200396
c.731C>T p.T244M 4 1/37 N/A Yes OPPG Ai et al., 200548
c.758C>T p.T253I 4 2/10 0/100 Yes HBM van Wesenbeeck et al., 
200396
c.844A>G p.M282V 4 1/1 0/100 Simplex HBM Balemans et al., 200799
c.920C>T p.S307F 5 1/37 N/A Yes OPPG Ai et al., 200548
c.1042C>T p.R348W 6 1/37 N/A Yes OPPG Ai et al., 200548
c.1058G>A p.R353Q 6 1/37 N/A Yes OPPG Ai et al., 200548
c.1067C>T p.S356L 6 1/66 0/390 Yes Idio­
pathic
osteo­
porosis
Crabbe et al., 2005100
c.1169C>A p.T390K 6 1/37 N/A Yes OPPG Ai et al., 200548
c.1199C>A p.A400E 6 1/37 N/A Yes OPPG Ai et al., 200548
c.1210G>A p.G404R 6 1/37 N/A Yes OPPG Ai et al., 200548
c.1225A>G p.T409A 6 1/3 N/A Yes OPPG Streeten et al., 200894
c.1300G>A p.D434N 6 1/37 N/A Yes OPPG Ai et al., 200548
c.1321G>A p.E441K 6 1/8 0/100 Yes FEVR This study
c.1330C>T p.R444C 6 1/56 0/362 Yes FEVR Qin et al., 200583
c.1364C>T p.S455L 6 1/66 0/390 Yes Idio­
pathic
osteo­
porosis
Crabbe et al., 2005100
c.1378G>A p.E460K 6 1/32 N/A Yes OPPG Ai et al., 200548
c.1432T>A p.W478R 7 1/1 0/200 Yes OPPG Cheung et al., 2006101
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c.1481G>A p.R494Q 7 1/28,
1/37
0/50,
N/A
Yes,
Yes
OPPG,
OPPG
Gong et al., 2001;47 
Ai et al., 200548
c.1513G>T p.W504C 7 1/1 0/200 Yes OPPG Cheung et al., 2006101
c.1532A>C p.D511A 7 1/20 0/80 Yes FEVR Boonstra et al., 20 0980
c.1559G>T p.G520V 7 1/37 N/A Yes OPPG Ai et al., 200548
c.1564G>A p.A522T 7 1/56 0/362 Yes FEVR Qin et al., 200583
c.1592A>T p.N531I 8 1/1 N/A Yes OPPG Barros et al., 2007102
c.1604C>T p.T535M 8 1/56 0/362 Simplex arFE-
VR
Qin et al., 200583
c.1648G>A p.G550R 8 1/1 0/120 Yes arFE-
VR
Downey et al., 200613
c.1708C>T p.R570W 8 1/28,
2/37
0/50,
N/A
Yes,
Yes
OPPG,
OPPG
Gong et al., 2001;47 
Ai et al., 200548
1709G>A p.R570Q 8 1/3 0/200 Yes arFE-
VR
Jiao et al., 200414
c.1828G>A p.G610R 9 1/37,
1/56
N/A,
0/362
Yes,
Simplex
OPPG,
arFE-
VR
Ai et al., 2005;48 
Qin et al., 200583
c.1850T>G p.F617C 9 1/56 0/362 Simplex arFE-
VR
Qin et al., 200583
c.1999G>A p.V667M 9 1/28 0/50 Yes OPPG Gong et al., 200147
c.2047G>A p.D683N 9 1/37 N/A Yes OPPG Ai et al., 200548
c.2197T>C p.Y733H 10 1/37 N/A Yes OPPG Ai et al., 200548
c.2302C>G p.R752G 19 1/3 0/200 Yes arFE-
VR
Jiao et al., 200414
c.2392A>G p.T798A 11 1/56 0/362 Yes FEVR Qin et al., 200583
c.2413C>T p.R805W 11 1/20 0/80 Yes FEVR Boonstra et al., 20 0980
c.3107G>A p.R1036Q 14 1/20 0/246 Yes Pri­
mary
osteo­
porosis
Hartikka et al., 20 0 595
c.3295G>T p.D1099Y 15 1/37 N/A Yes OPPG Ai et al., 200548
c.3337C>T p.R1113C 15 1/37 N/A Yes OPPG Ai et al., 200548
c.3361A>G p.N1121D 15 1/56 0/362 Yes FEVR Qin et al., 200583
c.3502T>C p.Y1168H 16 1/32 0/400 Yes FEVR Toomes et al., 2004a12
c.3758G>T p.C1253F 17 1/8 0/100 Simplex FEVR This studyB
c.4081T>G p.C1361G 19 1/32 0/400 Simplex FEVR Toomes et al., 2004a12
c.4147G>A p.E1367K 20 1/3 0/200 Yes arFE-
VR
Jiao et al., 200414
c.4202G>A p.G1401D 20 1/37 N/A Yes OPPG Ai et al., 200548
c.4609G>A p.A1537T 23 1/66 0/390 Yes Idio­
pathic
osteo­
porosis
Crabbe et al., 2005100
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Splice-site changes
c.3763+2T>C Splice defect 17 1/37 N/A Yes OPPG Ai et al., 20 0 548
c.4488+2T>G Splice defect 21 1/32 0/400 Yes FEVR Toomes et al., 2004a12
c.4489-1G>A Splice defect 22 1/8 0/100 Simplex FEVR This studyA
c.4588+2T>C Splice defect 22 1/37 N/A Yes OPPG Ai et al., 20 0 548
Nucleotide numbering reflects cDNA numbering with +1 corresponding to the A of the ATG 
translation initiation codon in the reference sequence (GenBank NM_002335.2), according to 
journal guidelines (www.hgvs.org/mutnomen). The translation initiation codon is codon 1 (Gen­
Bank NP_002326.2).
AThis patient also carries a second missense variant in FZD4 p.E40Q (c.118G>C), see Supporting 
Table S1.
BThis patient also carries a second missense variant in LRP5 p.G610R (c.1828G>A). 
arFEVR, autosomal recessive familial exudative vitreoretinopathy; HBM, high-bone-mass; 
OPPG, osteoporosis-pseudoglioma syndrome; N/A, information not available or screening was 
not performed.
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osteoporosis-pseudoglioma syndrome and ar familial exudative vitreoretinopathy.
Disease Allele 1 Allele 2 Reference
OPPG c.29G>A p.W10X c.29G>A p.W10X Gong et al., 
2001;47
Ai et al., 200548
OPPG c.209_210TC>AA p.F70X c.1378G>A p.E460K Ai et al., 200548
OPPG c.607G>A p.D203N c.1199C>A p.A400E Ai et al., 200548
OPPG c.731C>T p.T244M c.3763+2T>C Splice defect Ai et al., 200548
OPPG c.765G>A p.W255X c.1067C>T p.S356L Ai et al., 200548
OPPG c.789C>A p.C263X c.2202G>A p.W734X Ai et al., 200548
OPPG c.920C>T p.S307F c.920C>T p.S307F Ai et al., 200548
OPPG c.1000_1004dup p.C336Gfsx50 c.1000_1004dup p.C336GfsX50 Ai et al., 200548
OPPG c.1042C>T; 2047G>A; 
3337C>T
p.R348W; 
D683N; R1113C
+ + Ai et al., 200548
OPPG c.1058G>A p.R353Q c.1058G>A p.R353Q Ai et al., 200548
OPPG c.1169C>A p.T390K + + Ai et al., 200548
OPPG c.1210G>A p.G404E c.2718_2721del p.M907TfsX52 Ai et al., 200548
OPPG c.1225A>G p.T409A c.1275G>A p.W425X Streeten et al., 
200894
OPPG c.1275G>A p.W425X c.1275G>A p.W425X Streeten et al., 
200894
OPPG c.1282C>T p.R428X c.1282C>T p.R428X Gong et al., 
2001;47
Ai et al., 200548
OPPG c.1300G>A p.D434N c.1559G>T p.G520V Ai et al., 200548
OPPG c.1432T>A p.W478R c.1513G>T p.W504C Cheung et al., 
2006
OPPG c.1453G>T p.E485X c.4600C>T p.R1534X Gong et al., 
2001;47
Ai et al., 200548
OPPG c.1468delG p.D490MfsX40 c.1468delG p.D490MfsX40 Gong et al., 
2001;47
Ai et al., 200548
OPPG c.1481G>A p.R494Q c.1481G>A p.R494Q Gong et al., 
2001;47
Ai et al., 200548
OPPG c.1592A>T p.N531I c.1592A>T p.N531I Barros et al., 
2007102
OPPG c.1708C>T p.R570W c.1708C>T p.R570W Gong et al., 
2001;47
Ai et al., 200548
arFEVR c.1709G>A p.R570Q c.1709G>A p.R570Q Jiao et al., 
200414
OPPG c.1750C>T p.Q584X c.4512 4517 
delinsTGTA- 
CAACAT
p.A1505VfsX46 Ai et al., 200548
OPPG c.1828G>C p.G610R + + Ai et al., 200548
arFEVR c.1828G>C p.G610R c.3758G>T p.C1253F This study
OPPG c.1999G>A p.V667M c.1999G>A p.V667M Gong et al., 
200147
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osteoporosis-pseudoglioma syndrome and ar familial exudative vitreoretinopathy.
Disease Allele 1 Allele 2 Reference
OPPG c.2151dupT p.D718X c.2151dupT p.D718X Gong et al., 
2001;47
Ai et al., 200548
OPPG c.2197T>C p.Y733H c.2247delG p.Q749fsX797 Ai et al., 200548
OPPG c.2202G>A p.W734X + + Gong et al., 
200147
OPPG c.2247delG p.Q750SfsX48 c.2738dupT p.C913LfsX73 Ai et al., 200548
arFEVR c.2302C>G p.R752G c.2302C>G p.R752G Jiao et al., 
200414
OPPG c.2305del p.D769IfsX29 + + Gong et al., 
200147
OPPG c.2409_2503+79del174 p.G804
G835delfsX49
c.3232C>T p.R1078X Ai et al., 200548
OPPG c.2557C>T p.Q853X c.2557C>T p.Q853X Ai et al., 200548
OPPG c.3295G>T p.D1099Y + + Gong et al., 
2001;47
Ai et al., 200548
OPPG c.3804delA p.E1270RfsX169 c.3804delA p.E1270RfsX169 Gong et al., 
2001;47
Ai et al., 200548
OPPG c.4105_4106del p.M1369VfsX2 + + Ai et al., 200548
arFEVR c.4147G>A p.E1367K c.4147G>A p.E1367K Jiao et al., 
200414
OPPG c.4202G>A p.G1401D c.4588+2T Splice defect Ai et al., 200548
Nucleotide numbering reflects cDNA numbering with +1 corresponding to the A of the ATG 
translation initiation codon in the reference sequence (GenBank NM_002335.2), according 
to journal guidelines (www.hgvs.org/mutnomen). The translation initiation codon is codon 1 
(GenBank NP_002326.2).
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Truncating changes
c.11_12del p.H4RfsX21 2 1/13 0/100 Simplex ND This study
c.24 27dup p.F10IfsX17 2 1/17 0/22A Simplex ND Berger et al., 1992b15
c.25_40del p.S9PfsX4 2 1/13 0/100 Simplex ND This study
c.50dupT p.I18DfsX8 2 1/3 N/A Yes ND Gal et al., 1996103
c.65delC p.T22KfsX10 2 1/26 0/100 Yes ND Schuback et al., 1995104
c.86C>G p.S29X 2 1/6 0/20 Simplex ND Meindl et al., 199258
c.109C>T p.R37X 2 1/1 N/A Yes ND Ott et al., 2000105
c.128dupA p.H43QfsX14 2 N/A N/A N/A ND Caballero et al., 1996106
c.129delC p.Y44MfsX60 2 1/13 0/100 Simplex ND This study
c.131dupA p.Y44X 2 1/1 0/150 Yes ROP Hatsukawa et al., 2002107
c.136delG p.D46IfsX58 2 1/26 0/100 Yes ND Schuback et al., 1995104
c.170C>G p.S57X 1/17 0/22A Simplex ND Berger et al., 1992b15
c.205delT p.C69AfsX35 3 1/26 0/100 Yes ND Schuback et al., 1995104
c.218C>A p.S73X 3 1/2 0/60 Yes ND Walker et al., 1997108
c.236_240del p.S80QfsX67 3 1/5 0/75 De novo ND Riveiro-Alvarez et al.,
200581
c.285C>A p.C95X 3 2/5 0/81A Yes ND Wu et al., 20 0782
c.291delG p.Q99RfsX5 3 1/17 0/22A Simplex ND Berger et al., 1992b15
c.325C>T p.R109X 3 1/2,
2/26
0/200,
0/100
Yes,
Yes
ND,
ND
Schuback et al., 1995;104 
Mintz-Hittner et al.,
1996109
c.330C>A p.C110X 3 2/17 0/22A Simplex ND Berger et al., 1992b15
c.332C>A p.S111X 3 1/13 0/100 Simplex ND This study
c.360C>A p.Y120X 3 1/5 0/75 Yes ND Riveiro-Alvarez et al.,
200581
c.378T>A p.C126X 3 1/5,
1/2
0/60,
N/A
Simplex,
Yes
ND,
Ocular phe­
notypes
Fuchs et al., 1996;110 
Kellner et al., 1996111
c.383_384delinsAA p.C128X 3 1/1 0/4 Yes ND Wong et al., 1993112
c.384C>A p.C128X 3 1/26 0/100 Yes ND Schuback et al., 1995104
Missense changes
c.38T>G p.L13R 2 1/1 0/78 Yes ND Fuchs et al., 1996110
c.47T>C p.L16P 2 1/2 0/50 Yes ND Yamada et al., 2001112, 113
c.53T>A p.I18K 2 1/65 0/360 Simplex xlFEVR Kondo et al., 2007114
c.112C>T p.R38C 2 1/21,
2/5
0/75,
0/75
Simplex,
Yes
xlFEVR,
ND
Royer et al., 2003;115 
Riveiro-Alvarez et al.,
200581
c.115T>C p.C39R 2 1/1,
1/52
0/100, 
0/81A
Yes,
Simplex
ND, ND Joos et al., 1994;116 Wu 
et al., 20 0782
c.122G>A p.R41K 2 1/5 0/54A Simplex xlFEVR Shastry et al., 1997a117
c.123G>C p.R41S 2 1/15 0/81A Simplex PFVS Wu et al., 20 0782
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c.125A>G p.H42R 2 2/5,
1/13,
1/52
0/54A
0/130,
0/81A
Yes,
Simplex,
Simplex
xlFEVR,
ND,
xlFEVR
Shastry et al., 1997a;117 
Dickinson et al., 2006;118 
Wu et al., 20 0782
c.129C>G p.H43Q 2 1/21 0/75 Yes ND Royer et al., 2003115
c.131A>G p.Y44C 2 1/6,
1/21
0/20,
0/75
Simplex,
Simplex
ND,
ND
Meindl et al., 1992;58 
Royer et al., 2003115
c.133G>A p.V45M 2 1/21 0/75 Simplex ND Royer et al., 2003115
c.134T>A p.V45E 2 1/1 N/A Simplex ND Lev et al., 2007119
c.162G>C p.K54N 2 2/65,
1/20
0/360,
0/60A
Yes,
Simplex
xlFEVR,
ND
Kondo et al., 2007;114 
Boonstra et al., 20 0980
c.163T>C p.C55R 2 1/13 0/100 Simplex ND This study
c.174G>T p.K58N 2 1/2,
1/5
0/45A,
0/54A
Yes,
Simplex
ND,
xlFEVR,
Fuentes et al., 1993;120 
Shastry et al., 1997a117
c.179T>A p.V60E 3 1/6 0/20 Simplex ND Meindl et al., 199258
c.181C>A p.L61I 3 1/52 0/81A Simplex xlFEVR Wu et al., 20 0782
c.181C>T p.L61F 3 1/17,
1/1
0/22A,
0/115
Simplex,
Yes
ND,
ND
Berger et al., 1992b;15 
Rehm et al., 1997121
c.182T>C p.L61P 3 1/26 0/100 Yes ND Schuback et al., 1995104
c.188C>A p.A63D 3
3
1/26,
1/1
0/100,
N/A
Yes,
Yes
ND,
ND
Schuback et al., 1995;104 
Zaremba et al., 1998122
c.194C>G p.C65W 3 1/26 0/100 Yes ND Schuback et al., 1995104
c.194G>A p.C65Y 3 1/1,
1/5
0/45,
0/81A
Yes,
Simplex
ND,
ND
Strasberg et al., 1995; 
Wu et al., 20 0782
c.199G>A p.G67R 3 1/13 0/100 Simplex ND This study
c.200G>A p.G67E 3 1/13 0/100 Simplex ND This study
c.206G>C p.C69S 3 1/1 0/60 Yes ND Chen et al., 1993b25
c.220C>T p.R74C 3 1/17,
1/2,
1/5
0/22A,
0/60,
0/144A
Simplex, 
De novo, 
Yes
ND
ND
ND
Berger et al., 1992b;15 
Fuchs et al., 1996;110 
Allen et al., 2006123
c.223T>C p.S75P 3 1/2 0/50 Yes ND Yamada et al., 2001113
c.224C>G p.S75C 3 1/17 0/22A Simplex ND Berger et al., 1992b15
c.267C>A p.F89L 3 1/13 0/100 Simplex ND This study
c.268C>T p.R90C 3 2/21 0/75 Yes,
De novo
ND Royer et al., 2003115
c.269G>C p.R90P 3 1/17 0/22A Simplex ND Berger et al., 1992b15
c.274T>C p.S92P 3 1/13 0/100 Simplex ND This study
c.283T>C p.C95R 3 1/1 0/60 Yes ND Isashiki et al., 1995124
c.284G>T p.C95F 3 1/1 N/A Yes ND Khan et al., 2004125
c.287G>A p.C96Y 3 1/17,
1/6,
1/2
0/22A,
0/20,
0/174
Simplex, 
Simplex, 
De novo
ND,
ND,
xlFEVR
Berger et al., 1992b;15 
Meindl et al., 1992;58 
Shastry et al., 1999126
c.288C>G p.C96W 3 1/1 0/60 Yes Coats’
disease
Black et al., 1999127
c.289C>G p.R97P 3 1/2 0/98 Yes ND Rivera-Vega et al.,
2005128
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c.290G>C p.R97P 3 1/65 0/360 Simplex ND Kondo et al., 2007114
c.293C>T p.P98L 3 1/13 0/100 Simplex ND This study
c.302C>T p.S101F 3 1/2 0/60 Yes ND Walker et al., 1997108
c.307C>G p.L103V 3 1/13 0/130 Simplex xlFEVR Dickinson et al., 2006118
c.310A>C p.K104Q 3 1/4 0/75 Yes ND Meindl et al., 199558
c.312G>T p.K104N 3 1/1 0/100 Yes ND Riveiro-Alvarez et al.,
2006129
c.313G>A p.A105T 3 1/2 0/52A Yes ND Torrente et al., 1997130
c.323T>C p.L108P 3 1/13 0/75A Simplex ROP Shastry et al., 1997b131
c.328T>G p.C110G 3 1/2 0/45A Yes xlFEVR Torrente et al., 1997130
c.328T>C p.C110R 3 1/5 0/60 De novo ND Fuchs et al., 1996110
c.335G>A p.G112E 3 1/2 0/144A Yes ND Allen et al., 2006123
c.344G>T p.R115L 3 1/65 0/360 Simplex xlFEVR Kondo et al., 2007114
c.353C>A p.A118D 3 1/2 0/174 Yes ND Shastry et al., 1999126
c.359A>G p.Y120C 3 1/5 0/54A Simplex xlFEVR Shastry et al., 1997a117
c.361C>T p.R121W 3 1/4,
1/2,
2/13,
1/52
0/75,
N/A,
0/75A,
0/81A
Yes,
Yes,
Yes,
Simplex
ND,
ND,
ROP,
xlFEVR
Meindl et al., 1995;58 
Kellner et al., 1996;111 
Shastry et al., 1997b;131 
Wu et al., 200782
c.362G>T p.R121L 3 1/2 0/100 Yes xlFEVR Mintz-Hittner et al., 
1996109
c.362G>A p.R121Q 3 1/2,
1/4,
1/15,
1/20
0/75A
0/75,
0/75,
0/60
Yes,
Yes,
Yes,
Simplex
ND,
xlFEVR,
ND,
ND
Fuentes et al., 1993;120 
Meindl et al., 1995;58 
Riveiro-Alvarez et al., 
2005;81 Boonstra et al.,
200980
c.368T>A p.I123N 3 2/26,
1/1
0/100,
N/A
Yes,
Yes
ND,
ND
Schuback et al., 1995;104 
Sims et al., 1997132
c.370C>T p.L124F 3 1/1 0/60 Yes xlFEVR Chen et al., 1993a9
c.377G>C p.C126S 3 1/2 N/A Yes ND Gal et al., 1996103
c.382T>C p.C128R 3 1/21 0/75 Simplex ND Royer et al., 2003115
Splice-site changes
c.-208+1G>A Splice mutation 1/5 0/60 Simplex ND Fuchs et al., 1996110
c.-208+2T>G Splice mutation 1/13 0/100 Simplex ND This study
c.-208+5G>A Splice mutation 2/13 0/100 Simplex, ND This study
c.62+1G>C Splice mutation 1/5 0/60 Simplex ND Fuchs et al., 1996110
c.62+1G>A Splice mutation 1/65 0/360 Simplex ND Kondo et al., 2007114
c.62-1G>C Splice mutation 1/21 0/75 Yes ND Royer et al., 2003115
Miscellaneous changes
c.1A>G p.M1? 2 2/2,
1/3,
1/21
0/60A
N/A,
0/75
Yes,
Yes,
Simplex
ND,
ND,
ND
Isashiki et al., 1995;124 
Gal et al., 1996;103 
Royer et al., 2003115
c.2T>G p.M1? 2 1/26 0/100 Yes ND Schuback et al., 1995104
c.2 3del p.M1? 2 N/A N/A N/A ND Caballero et al., 1996106
c.282C>A; in- 
s285CTC; 286T>G
p.H94delinsQC 3 1/26 0/100 Yes ND Schuback et al., 1995104
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c.360_368del p.R121_I123del 3 1/26 0/100 Yes ND Schuback et al., 1995104
c.397delT p.S133PfsX129 3 1/17 0/22A Simplex ND Berger et al., 1992b15
c.399delC p.X134EextX127 3 1/1 N/A Simplex ND Riveiro-Alvarez et al.,
2008133
Nucleotide numbering reflects cDNA numbering with +1 corresponding to the A of the 
ATG translation initiation codon in the reference sequence (GenBank NM_000266.3), ac­
cording to journal guidelines (www.hgvs.org/mutnomen). The initiation is codon 1 (Gen­
Bank NP_000257.1)
ANumber of alleles is estimated on the basis of equal distribution of control individuals 
between males and females as this is not specified in the original paper.
ND, Norrie disease; xlFEVR, X-linked familial exudative vitreoretinopathy; ROP, reti­
nopathy of prematurity; N/A, information not available or screening was not performed.
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Abstract
Familial exudative vitreoretinopathy (FEVR) is a genetically heterogeneous 
retinal disorder characterised by abnormal vascularisation of the peripheral ret­
ina, often accompanied by retinal detachment. To date, mutations in three genes 
(FZD4, LRP5 and NDP) have been shown to be causative for FEVR. In two 
large Dutch pedigrees segregating autosomal dominant FEVR, genome-wide 
SNP analysis identified a FEVR locus o f ~40 Mb on chromosome 7. Microsat­
ellite marker analysis suggested similar at risk haplotypes in patients o f both 
families. To identify the causative gene, we applied next-generation sequencing 
in the proband of one o f the families, by analyzing all exons and intron-exon 
boundaries o f338 genes, in addition to microRNAs, non-coding RNAs and other 
highly conserved genomic regions in the 40-Mb linkage interval. After detailed 
bio-informatic analysis o f the sequence data, prioritization of all detected se­
quence variants led to three candidates to be considered as the causative genetic 
defect in this family. One of these variants was an alanine to proline substitution 
in the transmembrane 4 superfamily member 12 protein, encoded by TSPAN12. 
This protein has very recently been implicated in regulating the development 
of retinal vasculature, together with the proteins encoded by FZD4, LRP5 and 
NDP. Sequence analysis o f TSPAN12 in total revealed two mutations segregat­
ing in five out o f eleven FEVR families, indicating that mutations in TSPAN12 
are a relatively frequent cause o f FEVR. Furthermore, we demonstrate as one of 
the first groups, the power o f targeted next-generation sequencing technology to 
identify novel disease genes in linkage intervals.
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Main text
Familial exudative vitreoretinopathy (FEVR) is a well-characterized heredi­
tary ocular disorder that was first described by Criswick and Schepens.1 The 
pathologic features o f the disease initiate from the abnormal retinal develop­
ment due to the incomplete vascularization of the peripheral retina and/or reti­
nal blood vessel differentiation.2 The latter can lead to various complications, 
such as retinal neovascularization and exudates, vitreous haemorrhage, ectopia 
of the macula, retinal folds, and retinal detachment.3 FEVR is genetically het­
erogeneous and shows autosomal-dominant, autosomal-recessive, and X-linked 
recessive modes o f inheritance.1,4-9 Mutations in the genes coding for frizzled
4 (FZD4, located on 11q14.2 [MIM *604579]) and low-density lipoprotein 5 
(LRP5, located on 11qi3.2 [MIM *603506]), which act as Wnt coreceptors, 
and Norrin (NDP, located on Xp11.3 [MIM *300658]), a ligand for these Wnt 
receptors, have been shown to result in FEVR. A consistent feature is the aber­
rant retinal vascular development caused by the impaired action of the Ndp/p- 
catenin signaling pathway, which, among others, orchestrates eye organogen­
esis and blood supply.7,10-13
To unravel the genetic causes underlying FEVR, we included patients and 
their relatives in our study. Informed consent was obtained from all patients and 
their participating relatives in adherence to the tenets o f the Declaration o f Hel­
sinki. In 11 families with autosomal-dominant FEVR, we excluded mutations 
in FZD4 and LRP5 via sequence analysis o f all coding exons and intron-exon 
boundaries (unpublished data). In those families in which X-linked inheritance 
could not be excluded on the basis o f the pattern o f inheritance, mutations in 
NDP were excluded via sequence analysis. In the two largest families (fami­
lies A and B) that did not carry exonic mutations in FZD4 and LRP5, detailed 
analysis o f microsatellite markers surrounding these two genes excluded them 
as causative for FEVR. Patients in both families invariably show a peripheral 
avascular area, the most typical feature in FEVR (Figure 1). The visual acuity 
varies considerably (normal to light perception) as a result o f secondary defects 
such as retinal detachment and retinal exudates. Subsequently, eight individuals 
from family A and 15 individuals from family B (Figure 2A) were genotyped on 
the Infinium II HumanLinkage-12 Panel (Illumina, San Diego, CA, USA) that 
contains 6090 SNP markers. Genome-wide linkage analysis via the GeneHunter 
2.1r5 program in the easyLinkage v5.052beta software package14 revealed a 40.5 
Mb genomic region on chromosome 7 suggestive for linkage (LOD score 2.34) 
in family A (Figure 2B, left panel), whereas in family B, a significant LOD score 
of 3.31 was obtained for a 16.7 Mb genomic region on chromosome 7 (Figure 
2B, right panel), completely contained within the 40.5 Mb region detected in 
family A (Figure 3A). Moreover, the affected individuals in both families shared 
the same SNP and microsatellite alleles for a region o f at least 10 Mb. These 
results strongly suggested that the region on chromosome 7 is likely to contain 
a gene causative for FEVR. Two obvious candidate genes within the shared 
linkage intervals were WNT2 (MIM *147870) and WNT16 (MIM *606267), 
since the canonical Wnt signaling pathway has been implicated in regulating 
the formation of intraretinal capillaries.15 Sequence analysis o f the exons and
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intron-exon boundaries o f these two genes in probands III-7 (family A) and II-5 
(family B) did not, however, reveal any sequence variant causative for FEVR.
Family A: individual IV:2
Figure 1. Fundus photograph showing part of the avascular periphery of patient 
IV:2 from Family A. Temporal periphery of the left fundus in patient IV:2 from family 
A (numbering according to the pedigree presented in Figure 2A). The retinal vasculature 
(at the left side) ends in small aberrant ramifications in the equatorial area of the fundus. 
The peripheral retina (at the right side) is avascular; only choroidal vessels are present 
in this area.
Given the high number of genes in the region, as well as the lack of other 
obvious candidate genes, we decided to apply array-based sequence capture fol­
lowed by next-generation sequencing to simultaneously analyze all genes in the 
region. The complete 40.5 Mb region on chromosome 7, suggestive for linkage 
in family A (Figure 3A, upper panel), was used for sequence capture. The array 
design included all known exons, untranslated regions (UTRs), microRNAs, 
and highly conserved regions (PhastCons Conserved Elements, 28-way Mam­
mal Multiz Alignment, LOD score > 100), complemented with the complete 
genomic sequence o f WNT2 and WNT16. For all exons, an additional 30 base 
pairs (bp) were added at each side for the detection o f splice-site mutations. 
Targets smaller than 250 bp, which is, based upon our experience, the minimum
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size for the DNA-capture protocol, were enlarged by extending both ends o f the 
region. In total, 3048 exons from 338 RefSeq genes and 313 UCSC genes (see 
Web Resources), as well as 14 microRNAs and 23 noncoding RNAs, were tar­
geted (Figure S1, available online). Together with the UTRs and regions o f high 
conservation, 2,366,514 bp were selected. For reasons o f efficiency, the array 
included targets for another linkage region representing 352 Kb on chromosome
17. After stringent probe selection by NimbleGen (Roche NimbleGen, Madison, 
WI, USA) (uniqueness tested by Sequence Search and Alignment by Hashing 
Algorithm-SSAHA),16 a total o f 2,528,988 bases were represented on an array, 
with 385,000 oligonucleotide probes targeting the region of interest as well as 
the additional region on chromosome 17.
Figure 2. Pedigree structure and genome-wide linkage analysis for FEVR Families
A and B. A) Pedigree structure of those parts of families A and B that were selected 
for Illumina 6K SNP genotyping analysis. Individuals of whom the clinical status is 
uncertain are depicted in gray. Probands are indicated with an arrow. Eight members of 
family A and 15 individuals of family B, indicated with asterisks, were genotyped. B) 
Genome-wide LOD score calculations, with the use of the 6K SNP array genotyping 
data. In family A, two peaks are visible, on chromosomes 7 and 8, respectively. In fam­
ily B, only one clear peak is visible, on chromosome 7, with a genome-wide-significant 
LOD score of 3.31. Interestingly, the two peaks on chromosome 7 in families A and B, 
indicated by arrows, represent the same genomic region.
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Figure 3. Genomic structure, next-generation sequencing, and mutation analysis 
of TSPAN12. A) Upper panel, part of chromosome 7 showing the linkage intervals 
and the corresponding flanking SNPs for FEVR families A and B. The linkage inter­
val from family A was enriched for targeted next-generation sequencing technology. 
The TSPAN12 gene is located in the shared interval between families A and B. Lower 
panel, overview of the genomic structure of the TSPAN12 gene, showing all introns 
and exons. For all exons, as well as a highly conserved region between exons 7 and 8, 
the sequence coverage histograms are presented. B) Overview of all patient reads for 
exon 8 of TSPAN12. In total, more than 30 reads were representing parts of this exon. 
C) Sequence traces for the twenty unique reads covering the TSPAN12 heterozygous 
G-to-C mutation. For these 20 reads, ten were representing the reference allele and ten 
were showing the mutant allele. At the protein level, the G-to-C transition results in the 
substitution of a proline for an alanine residue (c.709G>C [p.Ala237Pro]). D) Topol­
ogy of TSPAN12 and the positions of the missense mutions identified in the FEVR 
families. TSPAN12 shows the characteristic domain structure of tetraspanins, including
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four transmembrane (TM) domains (in green). A cysteine residue preceding TM domain 
1 (C9) and another following TM domain 2 (C83) are probably palmitoylated (bright 
green wavy lines). The second extracellular loop (EC2) contains three a  helices (boxes), 
the typical C-C-G motif characteristic for all tetraspanin proteins, followed by one pair 
and two single cysteine residues. These six cysteines are predicted to form disulphide 
bonds (stippled lines). The glycine residue that is mutated into an arginine (G188) pre­
cedes one of these cysteines. The alanine residue that is mutated into a proline (A237) 
resides within an a-helical structure within the fourth TM region. E) Sequence compari­
son of a number of vertebrate TSPAN12 proteins. Depicted are parts of TSPAN12 that 
harbor the amino acid residues that are mutated. Both the glycine residue at position 188 
(upper panel) and the alanine residue at position 237 (lower panel) are completely con­
served throughout vertebrate evolution. Residues identical in all sequences are black on 
a white background, whereas similar amino acids are black on a light gray background. 
Nonconservative changes are indicated in white on a black background. UniProt ac­
cession number of the protein sequences used for sequence comparison are as follows: 
human TSPAN12, O95859; bovine TSPAN12, Q29RH7; mouse TSPAN12, Q8BKT6; 
chicken TSPAN12, Q5ZIF5; zebrafish TSPAN12, Q7T2G0.
Sequence capture was performed in accordance with the manufacturer's in­
structions (Roche NimbleGen). In brief, 20 o f genomic DNA of the FEVR 
proband from family A was used in the preparation o f DNA for sequence-cap- 
ture hybridization. A final amount o f 5 ^g DNA was hybridized to the custom­
ized array, subsequently eluted and amplified by ligation-mediated PCR. Three 
micrograms of amplified enriched DNA was used as input for generating an 
ssDNA library for massive parallel sequencing, with the use o f a Roche 454 GS 
FLX sequencer with Titanium series reagents. The sample was sequenced by 
using one quarter lane o f a Roche sequencing run, yielding 48.6 Mb o f sequence 
data. Approximately 94.5% of the sequence data mapped back to unique regions 
of the human genome (hg18, NCBI Build 36.1), with the use o f the Roche New- 
bler software (version 2.0.01.12). Of all mapped reads, 90.5% was located on or 
near the targeted regions (i.e., within 500 bp proximity). This was sufficient to 
reach an average o f 13.2-fold coverage of all target regions and, more specifi­
cally, an average o f 14.7-fold coverage o f the targeted exons on chromosome 7. 
For the region of interest, only 5.2% (112,319 bp) o f all targeted sequences were 
not covered, whereas 39.2% (1,099,873 bp) o f the target sequence was covered 
less than ten times (Table S1).
The Roche software detected a total o f 1915 variants on chromosome 7. We 
used a custom-made data analysis pipeline to annotate detected variants with 
various kinds o f information, including known SNPs, amino acid consequenc­
es, genomic location, and evolutionary conservation. With this analysis, 1749 
variants were found to correspond to known SNPs or to overlap with a known 
polymorphic region (dbSNP130). After we excluded nonexonic (145), synony­
mous (4), and putative homozygous variants (variation percentage > 80%) (3), 
14 variants remained (Table 1). From these, three promising candidates were 
selected (in the PTCD1, ZAN [MIM *602372], and TSPAN12 [MIM *613138] 
genes) because they were detected in at least four nonduplicate reads and had a 
high score for evolutionary conservation (vertebrate PhyloP).17-19
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Table 1. Overview of all non-synonymous sequence variants not present in dbSNP.
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92570705 T C 7 3 43 D G SAMD9 1.56
98870495 G A 26 16 62 R C PTCD1 3.06
99835402 C T 13 6 46 P L PILRA 1.75
100122289 - CCT 5 3 60 EQ ERQ GIGYF1 3.98
100209410 G A 15 8 53 R H Z A N 1.81
100473466 A G 38 13 34 T A MUC17 0.60
105066159 TC - 19 3 16 E X ATXN7L1 4.92
113306419 C T 15 6 40 S N PPP1R3A 1.05
115411632 C T 14 5 36 D N TFEC -0.45
119702880 T C 29 3 10 C R KCND2 5.00
120216091 C G 20 10 50 A P TSPAN12 5.32
120555712 T C 10 3 30 L S C7orf58 3.00
128099699 C G 7 5 71 I M FAM71F2 0.42
128221650 T C 13 3 23 L P CCDC136 1.26
After initial filtering of the 1,915 variants based upon overlap with dbSNP (build 130) 
and amino acid consequences, only 14 candidate variants remained. Variants marked in 
bold and indicated with an arrow were selected after further prioritization based upon 
the number of variant reads and evolutionary conservation. The position of the reference 
nucleotide is based on UCSC genome build hg18. The table lists the reference allele and 
the variant allele for that position, the total number of high confident sequence reads for 
this position, and the number of times a variant was read. The percentage of variation 
indicates how often a variant was read compared to the total number of reads. The amino 
acid of the reference and mutant alleles are indicated as well as the gene in which the 
variant was detected. In the right column, the vertebrate PhyloP score for evolutionary 
conservation is presented.17-19
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The missense variant detected in PTCD1 changes an arginine to a cysteine, 
whereas the variant in ZAN  alters an arginine to a histidine residue. Both arginine 
residues are not completely conserved throughout vertebrate evolution. In addi­
tion, the presumed physiological roles o f the proteins encoded by PTCD1 and 
ZAN, namely controlling leucine tRNA levels in mitochondria20 and regulating 
the adhesion o f sperm cells to the zona pellucida,21 respectively, do not support 
an involvement in causing FEVR. Finally, PTCD1 and ZAN  are both located 
outside the smaller linkage interval in family B and will therefore definitely not 
be causative for FEVR in that family. The TSPAN12 gene, however, is located 
within the shared linkage interval, and the variant detected via next-generation 
sequencing technology substitutes a proline residue for a highly conserved ala­
nine residue, with the highest PhyloP conservation score (Table 1). In addition, 
very recently, TSPAN12 was found to regulate retinal vascular development in 
cooperation with the proteins encoded by FZD4, LRP5, and N D P 22 Therefore, 
the variant detected in TSPAN12 was considered to be the mutation causative for 
FEVR in family A.
TSPAN12 contains eight exons, for which exons 2-8 are protein coding, plus 
an alternative noncoding exon for a different isoform (Figure 3A). All exons of 
TSPAN12 were covered by sequence reads from the targeted next-generation 
sequencing experiment (Figure 3A). The missense variant that was detected by 
this approach (c.709G>C [p.Ala237Pro]) is located in exon 8. This exon was 
covered by more than 30 sequence reads (Figure 3B). The mutated nucleotide 
(at position 120,216,091) was covered by 20 unique sequence reads. In ten of 
the reads, the reference allele was detected, whereas in the other ten reads, the 
mutant allele was observed (Figure 3C), indicating that the mutation is present 
in a heterozygous state.
Conventional Sanger sequencing confirmed the mutation to be present in the 
proband o f family A, as well as in the proband of family B who shared the at- 
risk haplotype for the region containing TSPAN12. Furthermore, the mutation 
was present in all relatives that were clearly affected with FEVR in both families 
(Figure S2). In three other relatives o f whom the clinical status was uncertain 
(III:1 in family A, III:15 and IV:2 in family B) and in one healthy individual 
(III:8 in family B), the mutation was also present, which points to nonpene­
trance, a feature that is also often observed in FEVR families with mutations in 
FZD4, LRP5, and NDP.3
To determine the prevalence o f TSPAN12 mutations as a cause o f FEVR, we 
selected nine additional FEVR probands from unrelated families for sequence 
analysis o f the complete gene (primer sequences are listed in Table S2). In two 
of these nine families, the same p.Ala237Pro change was detected as segregat­
ing with the phenotype (families C and D; Figure S2). Microsatellite marker 
analysis surrounding TSPAN12 showed that the affected individuals o f all four 
families showed a shared at-risk haplotype of at least 5.8 Mb (data not shown). 
In addition, a second variant was detected in the proband of family E, substitut­
ing an arginine residue for a glycine residue (c.562G>C [p.Gly188Arg]). This 
change was also present in his affected brother (Figure S2). Both changes were
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not detected in 140 ethnically matched control individuals (data not shown), 
nor were they present in a database containing more than two million variants 
from various in-house and published next-generation sequencing projects.23-25 
An overview of the mutations that were identified is presented in Table 2.
<N§ Overview of the missense mutations identified in TSPAN12
Fa
m
ily
Pr
ob
an
d
No
. 
of 
af
fe
ct
ed
 
re
la
tiv
es
 
w
ith
 
m
ut
at
io
n
No
. 
of 
un
af
­
fe
cte
d 
re
la
tiv
es
 
wi
th 
m
ut
at
io
n
M
ut
at
io
n
(cD
NA
 
le
ve
l)
M
ut
ati
on
 
(p
ro
­
tei
n 
le
ve
l)
Fr
eq
ue
nc
y 
in
 
co
nt
ro
l 
al
le
le
s
Family A III-7 3 0 c.709G>C p.Ala237Pro 0/280
Family B II-5 7 1 c.709G>C p.Ala237Pro 0/280
Family C II-2 0 0 c.709G>C p.Ala237Pro 0/280
Family D III-2 3 0 c.709G>C p.Ala237Pro 0/280
Family E II-1 1 0 c.562G>C p.Gly188Arg 0/280
Five families have been identified that carry a dominant missense mutation in TSPAN12. 
The proband corresponds to the pedigrees depicted in Supplemental figure 2. For each 
family, the number of affected relatives that carry the mutation is listed. In family B, one 
healthy individual also carried the mutation, suggesting non-penetrance. None of the 
two variants was detected in over 280 ethnically matched control alleles.
The TSPAN12 protein is a member of the tetraspanin family, whose members 
share certain specific structural features that distinguish them from other pro­
teins that pass the membrane four times.26 The glycine residue at position 188 
is located in the extracellular loop between the third and the fourth transmem­
brane region and is completely conserved throughout vertebrate evolution (Fig­
ures 3D and 3E). The arginine residue substituting the glycine has a bulky side 
chain that is positively charged. In addition, this small and flexible glycine resi­
due precedes a cysteine residue that is involved in the formation of disulphide 
bridges (Figure 3D) and is highly conserved in the complete tetraspanin protein 
family.27 Therefore, the substitution of an arginine for this glycine residue is 
likely to affect TSPAN12 function. The alanine at position 237 resides within 
the fourth transmembrane region and is also completely conserved throughout 
vertebrate evolution (Figures 3D and 3E). A proline residue has the intrinsic 
property to induce bends in the three-dimensional protein structure. Therefore, 
a proline residue at position 237 is predicted to disrupt the helical structure of 
the transmembrane region, which would result in a TSPAN12 protein with a 
defective confirmation that might even be subject to proteolytic degradation. 
The p.Ala237Pro mutation was detected in four unrelated Dutch families. Ge­
nealogical analysis revealed, however, that the ancestors o f families A, B, and C 
were born in the same region in the eastern part o f The Netherlands, with those 
of families B and C even being born in the same village. These data, combined 
with the microsatellite marker analysis that showed a shared haplotype among 
all families, suggest that the p.Ala237Pro mutation is a regional founder muta­
tion.
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The TSPAN12 protein has recently been identified to play a crucial role in the 
regulation of the development o f the retinal vasculature.22 Mice lacking Tspan12 
show a primary vascular defect in the developing retina between postnatal days
5 and 11, similar to the phenotypes described for Fzd4, Lrp5, and Ndph mutant 
mice, genes for which mutations in the human orthologs also cause FEVR.13,28,29 
In addition, whereas heterozygous Tspan12, Lrp5, and Ndph single-mutant mice 
did not show any abnormalities, Tspan12/Lrp5 and Tspan12/Ndph double-het­
erozygous mice demonstrated a retinal vascular phenotype, indicating that these 
proteins act in a similar pathway. A series o f dedicated experiments revealed 
that TSPAN12 is required for Norrin-induced P-catenin signaling, by promoting 
FZD4 multimerization and clustering o f FZD4 via binding to Norrin multim- 
ers.22
A question that remains is how the heterozygous FEVR-mutations described 
in this study affect the function o f TSPAN12 and the complex that it is associ­
ated with. The glycine residue at position 188 precedes a highly conserved cys­
teine among tetraspanin family members involved in the formation of disulfide 
bridges and is located in the large extracellular loop (EC2) between the third and 
fourth transmembrane region (Figure 3D). This extracellular loop is known to 
harbor most o f the protein-protein interaction sites described for tetraspanins.30 
As such, the substitution of an arginine residue for the glycine at position 188 
might disrupt one o f these interactions; for instance, the interaction with the 
Fzd4/Lrp5/Norrin protein complex. The alanine-to-proline change at position 
237 is likely to disrupt the three-dimensional structure o f TSPAN12. Both hap­
loinsufficiency and a dominant-negative effect of the mutant TSPAN12 on the 
wild-type protein should be considered as the underlying disease mechanism.
Tetraspanins are suggested to form so-called tetraspanin-enriched microdo­
mains that act as specific signaling compartments within the membrane and 
might form homomultimers, as well as protein complexes, with nontetraspanin 
membrane proteins.30,31 In the case that TSPAN12 indeed forms homomultim­
ers, the two missense mutations that cause FEVR might impair multimerization 
of the protein and, as such, act in a dominant-negative fashion. This would be in 
line with the absence o f any abnormalities in the heterozygous Tspan12 mutant 
mice.22 Recessive loss-of-function mutations in genes encoding other tetraspa­
nins, such as TM4SF2 (MIM *300096) and CD151 (MIM *602243), causing 
X-linked mental retardation and kidney malfunctions, respectively, would fa­
vor a dominant-negative mechanism instead of haploinsufficiency.32,33 On the 
other hand, heterozygous loss-of-function mutations in the PRPH2 gene [MIM 
179605], encoding the tetraspanin peripherin, cause autosomal-dominant retinal 
photoreceptor degeneration, favoring a model for haploinsufficiency.34,35 Addi­
tional functional studies are needed to determine the effect o f the two missense 
mutations described here, in order to unravel the pathological mechanism in 
which dominant mutations in TSPAN12 are causative for FEVR.
This study shows the power o f next-generation sequencing after initial iden­
tification of a disease-gene locus. So far, the only other example o f this ap­
proach has been reported on by Brkanac et al., which led to the identification
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of IFRD1 (MIM *603502) as a candidate gene for autosomal-dominant sensory 
and motor neuropathy with ataxia (MIM %607458).36 This targeted resequenc­
ing approach may be an attractive alternative to whole-genome or -exome rese­
quencing in those families for which disease loci have been defined. Recently, 
unbiased genome-wide resequencing o f the whole human exome led to the first 
disease-gene identification in patients with Miller syndrome.37 The number of 
potential protein-truncating variants in their study was, however, approximately 
three orders o f magnitude higher than those identified by our study. Such a ge­
nome-wide approach requires multiple affected individuals to limit the amount 
of potential candidate genes, especially when operating under an autosomal­
dominant disease model.
In conclusion, we have identified TSPAN12 as a gene causative for autosomal­
dominant FEVR. TSPAN12 is only the third autosomal gene described to be 
causative for FEVR and is mutated in five o f the 11 Dutch families studied. On 
the basis o f the function o f TSPAN12 in regulating the development o f the reti­
nal vascular system, it is expected that mutations in TSPAN12 will also be caus­
ative in FEVR patients from different populations and, as such, will facilitate 
genetic diagnostics for FEVR. Moreover, we have proven the enormous power 
of next-generation sequencing technology in combination with array-based se­
quence capture, by identifying a single causative base-pair substitution within 
a 40 Mb region containing more than 300 genes. Given that for many inherited 
disorders, several loci have been published for which the causative gene still 
awaits discovery, applying this technology will be instrumental in identifying 
many disease genes in the near future.
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Figure SI. Coverage histogram for the complete 40.5-Mb FEVR locus (part 1). Coverage histogram for the whole region targeted 
for next-generation sequencing, displayed in 6 panels. This figure shows a UCSC genome browser view with genomic position, 
custom tracks representing the sequence coverage that was obtained, the target region (e.g. regions covered on the enrichment 
array), and the UCSC gene track. The array design included all known exons, untranslated regions, microRNAs and highly con­
served regions complemented with the complete genomic sequence of the candidate genes WNT2 and WNT16. The positions of the 
genes IVNT2, WNT16 and TSPAN12 are indicated with a black arrowhead. In total, 3,048 exons from 338 RefSeq genes and 313 
UCSC genes as well as 14 microRNAs and 23 non coding RNAs were targeted.
Supplem
ental data
Figure SI. Coverage histogram for the complete 40.5-Mb FEVR locus (part 2). Coverage histogram for the whole region targeted for 
next-generation sequencing, displayed in 6 panels. This figure shows a UCSC genome browser view with genomic position, custom 
tracks representing the sequence coverage that was obtained, the target region (e.g. regions covered on the enrichment array), and the 
UCSC gene track. The array design included all known exons, untranslated regions, microRNAs and highly conserved regions comple­
mented with the complete genomic sequence of the candidate genes WNT2 and WNT16. The positions of the genes WXT2. WNT16 and 
TSPAN12 are indicated with a black arrowhead. In total, 3,048 exons from 338 RefSeq genes and 313 UCSC genes as well as 14 microR­
NAs and 23 non coding RNAs were targeted.
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Figure S2. Pedigree structure and mutation segregation in all families with 
TSPAN12 mutations. A) Complete pedigrees for families A to E, and the segregation 
of the mutations identified in these families. M1/+ indicates heterozygous carriers of 
the p.Ala273Pro mutation, M2/+ heterozygous carriers of the p.Gly188Arg mutation, 
whereas +/+ indicates individuals with two wild-type alleles. All affected individuals 
in the families carry the respective causative mutations. In family A, the clinical status 
of individual III:1 was uncertain, as well as for individual III:15 and IV:2 in family B 
(indicated in grey). These three individuals all carried the mutation, as did the healthy 
individual III:8 in family B, suggesting non-penetrance. Probands in each family are in­
dicated with an arrow. B) Sequence chromatograms for the two mutations in TSPAN12. 
The upper two chromatograms show the heterozygous mutations, whereas the lower 
two indicate the sequences detected in controls. The corresponding amino acids are in­
dicated above the sequence traces. M1 and M2 correspond to the mutations as described 
in panel A
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Supplemental Table 1. General statistics of the sequencing run.
Coverage statistics Variant statistics
Number of bases 
sequenced
51,440,891 Number of variants detected 1,915
% bases mapped 94.4% Known SNPs (dbSNP130) 1,749
% bases mapped to or near 
(500bp) targets
90.5% Unknown variants in genes 106
Average coverage of the 
targets
13.2x Unknown variants in exons 21
Unknown missense variants 17
% targets covered at least 1x 94.8% Unknown variants in splice sites 2
% targets covered at least 5x 79.8% Unknown substitutions 139
% targets covered at least 10x 56.5% Unknown indels 27
% targets covered at least 20x 20.9%
Left side: statistics on the target sequence coverage for the complete run. Right side: sta­
tistics on the detected variants in the region on chromosome 7 by the Roche 454 software.
Supplemental Table 2. Primer sequences of TSPAN12.
Exon Forward (5’>3) Reverse (5’>3’) Amplicon Length (bp)
1A ggagggcaacaaagcaataa cagctgcacaaactctcagc 397
1B ctgggtgagagggacaagaa gtcattcaaaccccgcttc 645
2 gatgaggcgatgtctcgaat gtggctgcagaaaaccagag 332
3 ttcaagatgcagcaaatggt ccaaaagatcaaggaagagca 307
4 tgctatgtcttgggtgcatt tcactgctccctaatcttgtga 291
5 caagtctgtctttgaggagccta gcggagtgaaaatgaactaaca 230
5’ cgaagagagtcatttggcaat ccagagacagggagaaaatatga 393
6 tgcagttgcttcaaagagca caggcttaatttttcagcacag 631
7 gccatggtgttcctttactaca ggccttttacatttagacagagaag 430
8 tctcatcagctttccctgaga tgtccaggtggtgacttatgac 646
Primers used for amplification and sequence analysis of human TSPAN12.
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Abstract
Familial exudative vitreoretinopathy (FEVR) is a genetically heterogeneous 
retinal disorder characterized by abnormal vascularisation of the peripheral ret­
ina, often accompanied by retinal detachment. To date, mutations in four genes 
(FZD4, LRP5, NDP, and TSPAN12) have been shown to be causative for FEVR. 
In this study, we applied exome sequencing in two affected individuals o f a large 
Dutch pedigree segregating autosomal dominant FEVR, combined with concur­
rent genome-wide SNP linkage analysis in eight affected members. Bioinfor- 
matic analysis o f the exonic sequences revealed a p.H455Y missense change 
in ZNF408 as the most likely disease-causative variant. The linkage study also 
revealed cosegregation of the FEVR phenotype with a 42 Mb region on 11p11.2 
in which ZNF408 is located. Sequence analysis o f ZNF408 in nine other FEVR 
families revealed one additional family harbouring the same p.H455Y missense 
change. Functional assessment o f the wild type and mutant ZNF408 proteins in 
cellular transfection experiments showed that the mutant protein does not enter 
the nucleus where it is supposed to exert its function. Moreover, in co-transfec­
tion assays, it retains the wild-type protein in the cytoplasm due to putative di­
or multimerisation. These data strongly suggest that the p.H455Y mutation in 
ZNF408 causes adFEVR due to a dominant-negative disease mechanism. This 
study also underscores the importance o f combining exome sequencing with 
studies that provide positional information of the gene defect.
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Main text
Familial exudative vitreoretinopathy (FEVR) is a well-characterized devel­
opmental anomaly o f the retinal vasculature first described by Criswick and 
Schepens in 1969.1 The most prominent characteristics o f the disease result 
from the incomplete and aberrant vascularisation of the peripheral retina and/ 
or retinal blood vessel differentiation.2 The latter can lead to various complica­
tions, such as retinal neovascularization and exudates, vitreous hemorrhage, vit- 
reoretinal traction, ectopia o f the macula, retinal fold, and retinal detachment.3 
The clinical signs observed in patients can be diverse, ranging from hardly de­
tectable vascular anomalies in the peripheral retina in asymptomatic individuals 
to bilateral retinal detachments leading to blindness.
FEVR is genetically heterogeneous displaying all three forms o f inheritance
i.e. autosomal dominant (adFEVR, MIM# 133780), autosomal recessive (arFE- 
VR, MIM# 601813) or X-linked recessive (MlM# 305390), with autosomal 
dominant being the most common type o f inheritance.4-9 To date, mutations in 
genes encoding frizzled 4 (FZD4, located on 11q14.2 [MIM *604579), low- 
density lipoprotein 5 (LRP5, located on 11q13.2[MIM *603506]), TSpAN12 
(TSPAN12, located on 7q31.31 [MIM *613138]), and Norrin (NDP, located on 
Xp11.3 [MIM *300658]) have been shown to cause FEVR.4, 10-13
The proteins encoded by these genes participate in the Norrin/p-catenin path­
way. LRP5 and FZD4 act as coreceptors, whereas NDP is a ligand with strong 
affinity for FZD4.14 TSPAN12 is thought to act as a molecular switch, enhanc­
ing FZD4 oligomer clustering and multimerisation via binding to Norrin mul- 
timers.15 This molecular assembly is o f prime importance for the induction of 
the NDP/p-catenin signaling pathway, which, among others, orchestrates eye 
organogenesis and blood supply.7, 16-18 Several mouse models have been made 
that either have no or partially functional Fzd4, Lrp5, Tspan12 and Ndph (Nor­
rie disease pseudoglioma mouse homologue), in order to shed more light on 
the biochemical properties o f these proteins and understand the pathology of 
the associated diseases. These studies consistently have shown that all FEVR 
genes are expressed throughout development and when disrupted result in se­
vere developmental defects o f the superficial retinal vasculature and intraretinal 
capillary beds.14, 15, 19, 20
To unravel additional genetic causes underlying FEVR, we included FEVR 
patients and their relatives in our study. Informed consent was obtained from 
all participating individuals in adherence to the tenets o f the Declaration o f Hel­
sinki.
In 10 families with autosomal dominant FEVR, mutations in FZD4, LRP5, 
and TSPAN12 were excluded via sequence analysis o f all coding exons and in- 
tron-exon boundaries.3 In those families in which X-linked inheritance could 
not be excluded on the basis o f the pattern o f inheritance, mutations in NDP 
were excluded via sequence analysis. Subsequently, we applied an unbiased 
approach and sequenced the exomes (42 Mb of genomic sequencing targeting 
~18,000 genes) oftwo affected individuals (III:3 and V:2) from family W05-215
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(Figure 1A). Clinically, these two patients have no history o f premature birth, 
which often is associated with retinopathy o f prematurity, a phenotype closely 
resembling FEVR. They both show a peripheral avascular area, the most typi­
cal feature in FEVR, chorioretinal atrophy, aberrant patterning o f retinal blood 
vessels, retinal pigmentations but no retinal detachment or exudation (Figure 2).
Figure 1. Pedigrees of families W05-215 and W05-220 and overview of the genome- 
wide linkage and sequence analysis data.
A) Complete pedigree structure of family W05-215 that was selected for Illumina 
700K SNP genotyping analysis. Individuals of whom the clinical status is uncertain are 
depicted in gray. Eight affected members of family A, indicated with asterisks, were 
genotyped. M/+ indicates heterozygous carriers of the p.H455Y mutation, whereas +/+ 
indicates individuals with two wild-type alleles. All affected individuals in the family 
carry the respective causative mutations. Two healthy individuals carried the mutation, 
suggesting non-penetrance. B) Genome-wide LOD-score calculations, with the use of 
the700K SNP array genotyping data. The peak on chromosome 11 with A LOD-score 
of 2.68 is indicated by arrow. C) Pedigree structure of family W05-220. Two affected 
individuals in the family carry the respective causative mutations. The apparently unaf­
fected mutation carriers have not yet been clinically evaluated. D) Electropherograms of 
three affected individuals carrying the ZNF408 c.1363C>T mutation.
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Figure 2. Fundus photograph showing deformation in the retinal vasculature in 
patient V:2. Posterior pole of the left fundus in patient V:2 of family W05-215 who 
demonstrates “dragged” retinal blood vessels and a marked deformation of the vascular 
network at the optic nerve head.
We sequenced the exomes of two patients by using the SureSelect human 
exome enrichment kit Agilent, Santa Clara, CA, USA) in combination with one 
quarter o f a SOLiD sequencing slide (Life Technologies, Carlsbad, CA, USA). 
Colour space reads were mapped to the hg18 reference genome with SOLiD 
BioScope software version 1.1, which utilizes an iterative mapping approach. 
We obtained 3.1 Gb and 3.0 Gb o f sequence data per patient respectively. In 
total, 76% and 70% of bases originated from the targeted exome, resulting in a 
mean coverage o f 60- and 52-fold. Single-nucleotide variants were subsequent­
ly called by the DiBayes algorithm with conservative call stringency. At least 
ten reads are required to obtain a 99% probability o f having at least two reads 
containing the variant allele. More than 91% of the targeted exons were covered 
more than ten times. Small insertions and deletions were detected by using the 
SOLiD Small InDel Tool. Called SNP variants and indels were combined and 
annotated using a custom analysis pipeline.
On average, 12,967 genetic variants were identified per patient in the coding 
regions or the canonical dinucleotides o f the splice acceptor and donor sites, 
including 6,167 nonsynonymous changes (Table 1). A prioritization scheme was 
applied to identify the pathogenic mutation in each patient separately, similar 
to a recent study.21 We excluded known dbSNP130 variants as well as variants 
from our in-house variant database as these cannot explain a genetically domi­
nant disease, thereby reducing the number of candidates by more than 98%. 
This database consists o f data from in-house exome resequencing projects of 
patients with rare syndromes (548,103 variants), the 1000 Genomes Project, and 
published data from various studies (2,535,563 variants).22-24
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Table 1. Overview of all variants identified by 
exome sequencing in the two FEVR patients.
Patient 1 Patient 2 Mean
No. of genes with 
variants in both 
samples
Total variants called 23,375 24,000 23,687.5 6962
Exonic + SpliceSites (SS) (+/- 2 
nts intronic) variants 13,027 12,907 12,967 5129
Non-synonymous (NS) + SS 
variants + frameshifts 6,198 6,136 6,167 2783
Unknown SNP variants (db- 
SNP131) 589 517 553 134
Unknown SNP variants (in­
house database 327 297 312 38
The nucleotide changes with disease-causing potential after our expertise fil­
tering were 327 in patient III:3 and 297 in patient V:2 (Figure 1A), respectively. 
Under the assumption o f autosomal dominant inheritance in family W05-215, 
and the monogenic nature o f FEVR, we focused our attention only on those nu­
cleotides variants that were present in both affected members. Thirty-eight vari­
ants were selected, and based on evolutionary conservation scores,25 changes in 
five candidate genes were shortlisted as our prime candidates (Table 2).
Four concern missense changes i.e. p.H455Y in ZNF408, p.Y1442H in ATM, 
p.V698L in PCDHGC4 and p.G525Q in LY75, whereas in case of AKAP9 there 
is an in-frame addition o f an asparagine residue. Focusing on the relative func­
tion o f individual genes, ZNF408 is a transcription factor belonging to the class 
of C2H2 zinc finger proteins. ATM is a protein that belongs to the PI3/PI4-kinase 
family and serves as an important cell cycle checkpoint kinase. Mutations in 
ATM  are associated with ataxia telangiectasia, an autosomal recessive disorder 
characterised by progressive cerebellar ataxia.26 PCDHGC4 is a protocadherin 
molecule that plays a critical role in the establishment and function of specific 
cell-cell connections in the brain whereas LY75 and AKAP9 encode for a lym­
phocyte antigen and a regulatory subunit o f protein kinase A, respectively.
To obtain further positional information of the causative gene, eight affected 
individuals o f family W05-215 were genotyped on the Infinium II HumanLink- 
age-12 Panel (Illumina Human OmniExpress) that contains 733,202 SNP mark­
ers. Genome-wide linkage analysis via the GeneHunter 2.1r5 program in the 
easyLinkage v5.052beta software package14 revealed a 42 Mb genomic region 
on chromosome 11 suggestive for linkage (LOD score 2.68) (Figure 1B).
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Table 2. Overview of variants in candidate genes.
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11 46,683,189 C T 43 41.9 ZNF408 NM_024741 H Y 5.83
11 46,683,189 C T 38 63.2 ZNF408 NM_024741 H Y 5.83
11 107,665,626 T C 14 50 ATM NM_000051 Y H 4.98
11 107,665,626 T C 23 21.7 ATM NM_000051 Y H 4.98
5 140,847,016 G C 178 48.3 PCDHGC4 NM_031993 V L 3.58
5 140,847,016 G C 123 47.2 PCDHGC4 NM_031993 V L 3.58
2 160,443,420 C T 68 52.9 LY75 NM_002349 G E 2.17
2 160,443,420 C T 56 37.5 LY75 NM_002349 G E 2.17
7 91,490,117 - AAC 2 100 AKAP9 NM_005751 - N 2.05
7 91,490,117 - AAC 2 100 AKAP9 NM_005751 - N 2.05
Overview of variants in candidate genes from individual patients. Columns are from left 
to right: patient, chromosome (Chr), position of the variant (Position), reference allele on 
the plus strand (Ref), variant allele on the plus strand (Var), percentage of reads with the 
variant allele (% Var), gene name in which the variant is located (Gene), RefSeq gene id 
(Gene Id), reference amino acid, where “SS” indicates a canonical splice site (Ref aa), 
PhyloP log odds ratio for evolutionary conservation (PhyloP).
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When combining our prime candidate list from the exome sequencing data 
with the genome-wide linkage analysis, only the variant in ZNF408 appeared to 
be located within the linkage interval. This variant substitutes a tyrosine residue 
for a highly conserved histidine residue; and displays the highest PhyloP con­
servation score o f all selected variants (Table 2) o f all selected variants. ZNF408 
contains five exons, all o f which are protein coding, plus an alternative coding 
exon 1 for a different isoform. All exons o f ZNF408 were covered by sequence 
reads from the exome sequencing experiment. The missense variant that was de­
tected (c.1363C>T [p.H455Y]) is located in exon 5. This exon and the mutated 
nucleotide were on average covered in both samples by 41 unique sequence 
reads. In 21 o f the reads, the reference allele was detected, whereas in the other 
20 reads, the mutant allele was observed, clearly indicating that the mutation is 
present in a heterozygous state.
Conventional Sanger sequencing confirmed the mutation to be present in both 
affected members selected for exome sequencing o f W05-215 (Figure 1D). Fur­
thermore, the mutation was present in all relatives that were clearly affected 
with FEVR in family W05-215 (Figure 1A). The mutation was also present 
in two healthy individuals (Figure 1A: V:1 and V4), which suggests nonpen­
etrance, a phenomenon that is observed in up to 25% of individuals carrying 
mutations in FZD4, LRP5, NDP and TSPANI2 3 11
The p.H455Y variant was not detected in 220 control chromosomes. To de­
termine the prevalence o f ZNF408 mutations as a cause o f FEVR, we selected 
nine additional FEVR probands from unrelated families or sporadic cases, for 
sequence analysis o f the protein coding exons and flanking introns o f ZNF408. 
In one o f these nine families, the same p.H455Y change was detected to segre­
gate with the phenotype in a small family with two affected individuals (Figures 
1C, 1D). The ancestors o f these pedigrees originate from the same region in the 
Netherlands, strongly suggesting that the p.H455Y is a founder mutation.
Analysis with PSORT algorithms predicts that the protein localises to the 
nucleus. In addition, PROSITE algorithms predict the presence o f ten C2H2-type 
zinc finger binding domain signatures (Figure 3C). Extensive bioinformatic 
analysis including 4 software tools that assess putative pathogenicity of 
missense changes in human proteins (Project HOPE, PolyPhen, SIFT and Align 
GVGD) strongly suggest that the p.H455Y mutation in ZNF408 is located in 
a transcriptional regulation domain and that this missense change is probably 
damaging since the histidine is a 100% conserved amino acid (Figure 4) in the 
C2H2- type zinc finger binding domain. In addition, the wild-type histidine and 
the mutant tyrosine residue differ in size as the new mutant tyrosine is bigger 
and bears less hydrophobicity than histidine (Figure 3B). The wild-type residue 
is predicted to be buried in the core o f the protein where now the new mutant 
residue probably will not fit. Therefore, it is highly probable that the p.H455Y 
missense change modifies the structure o f the zinc finger as a whole entity, and 
consequently, the binding and activation of various target genes by ZNF408.
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In order to study the expression o f ZNF408 in various human eye tissues, 
quantitative qRT-PCR was performed according to previously published proto­
cols.27, 28 Although ZNF408 was expressed in all tissues tested, retinal expres­
sion is the highest among 11 human adult tissues/organs. It is expressed almost 
~30 times higher when compared with heart, placenta or liver (Figure 5). This 
expression pattern suggests that ZNF408 is present and probably possesses an 
important role in the adult retina.
h 2n -
SET domain Zinc finger cluster
Figure 3. Schematic representation and 3D modelling of ZNF408 and the p.H455Y 
missense mutation.
A) Overview of the protein in ribbon-presentation. B) Close-up of the mutation. The 
protein is coloured grey, the side chains of both the wild-type and the new mutant res­
idue are shown and coloured green and red respectively. C) Schematic overview of 
ZNF408 and its different domains.
In order to determine the effect o f the p.H455Y missense mutation on the sub­
cellular localisation ofZNF408, we created a N-terminally HA-tagged wild-type 
ZNF408 construct, ZNF408_R337P, which contains a non-synonymous sN p 
(p.R337P, rs36017347), and a ZNF408_H455Y mutant construct. In addition, 
we created eCFP labelled mutant constructs by using the mammalian expression 
vectors pcDNA3-HA/DEST and pcDNA3-eCFP/DEST respectively, that both 
contain a cytomegalovirus (CMV) promoter. Subsequently, COS-1 cells were 
transiently transfected by using Effectene (Qiagen, Hilden, Germany), accord­
ing to the manufacturer’s instructions. Forty-eight hrs after transfection, cells 
were washed with phosphate-buffered saline (PBS) and subsequently prepared 
for either immunolocalisation studies or western blot analysis.
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p .H455Y
I
Human ZNF4 0 8  AFARRPSLRLHRKTHQVPAAP 
C h im p  ZNF4 0 8  AFARRPSLRLHRKTHQVPAAP 
M a c a q u e  ZNF4 0 8  AFARRPSLRLHRKTHQVPTAP 
M o u s e  ZNF4 0 8  TFARRPSLRLHRKTHQMP|AP 
R a b b i t  ZNF4 0 8  AFARRPSLRLHRKTHQVPAAP 
D og ZNF4 0 8  AFARRPSLRLHRKTHQVPAAP 
C a t  ZNF4 0 8  AFARRPSLRLHRKTHQVPAAP
Cow ZNF4 0 8  AFARRPSLRLHRKTHQAAAAP
Figure 4. Sequence comparison of a num ber of vertebrate ZNF408 proteins. De­
picted are parts of ZNF408 proteins that harbour the mutated amino acid residue. The 
histidine residue at position 455 is completely conserved throughout vertebrate evo­
lution. Residues identical in all sequences are black on a white background, whereas 
similar amino acids are black on a light gray background. Nonconservative changes are 
indicated in white on a black background. GenBank numbers for ZNF408 amino acid 
alignment: Human, NP_079017.1; Chimp, XP_508399.1; Macaque, XP_001111210.1; 
Mouse, NP_001028623.1; Dog, XP_540750.2; Cat, NM_024741; Cow, XP_874718.2.
Figure 5. Relative expression of ZNF408  in human adult tissues.
Expression of ZNF408 was measured in heart, placenta, liver, lung, retina, brain, duode­
num, kidney, testis, spleen and bone marrow. Data denote the mean value on an arbitrary 
scale (y axis) representing expression relative to the housekeeping gene GUSB.
To detect the subcellular localization of the HA-tagged wild-type ZNF408, 
R337P and H455Y ZNF408, transiently transfected cells were fixed with 4% 
paraformaldehyde, incubated with primary anti-HA and secondary goat-anti- 
mouse Alexa580-labelled antibodies and mounted with Vectashield containing 
DAPI (Vector Laboratories Inc., Burlingame, CA). Images were taken with
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AxioImager Z1 upright fluorescent microscope, (Zeiss, Sliedrecht, the Nether­
lands) and processed with ApoTome slider module. To determine the number 
of cells expressing ZNF408 outside the nucleus, slides were blinded and 50 
cells of each transfected mutant were scored; each construct was transfected in 
duplicate.
Immunofluorescence analysis revealed that both the wild-type and SNP har­
bouring (p.R337P) ZNF408 are located almost exclusively in the cell nuclei. 
The c.1010C>G SNP resulting in p.R337P is present in 14/100 alleles in the 
Caucasian population. Interestingly the mutant (p.H455Y) ZNF408 protein was 
present mostly in the cytoplasm of the transfected cells (Figures 6A and 6B). 
The latter observations are consistent with a possible role for ZNF408 as a tran­
scriptional regulator and suggest that the p.H455Y mutation affects nuclear lo­
calisation o f the ZNF408 protein.
A DAPI HA Merge
Figure 6. Immunofluorescence analysis of transiently transfected HA-tagged wild­
type, SNP-containing, and m utant ZNF408 proteins. A) Representative examples 
are shown, in which expression of wild-type and p.R337R ZNF408 is observed inside 
the cell nuclei (indicated by arrows), whereas p.H455Y is expressed in the cytoplasm 
(indicated by arrows). Images are presented as DAPI (staining cell nuclei), anti-HA 
(detecting the transfected HA-tagged ZNF408 proteins), and merged pictures (DAPI in
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blue, HA-tagged ZNF408 in red). B) Quantification of the number of transfected cells 
expressing HA-tagged ZNF408 outside the nucleus. Slides were blinded and for each 
transfected construct in duplicate, 50 cells were evaluated. C) Western blot analysis of 
lysates of transfected cells stained with an anti-HA antibody. Tubulin levels are used for 
comparison.
Western blot analysis o f lysates o f transfected cells using an anti-HA antibody 
showed that the wild-type and mutant ZNF408 proteins were expressed as a 
single protein o f the expected molecular weight (Figure 6C) indicating that the 
staining observed in the immunocytochemical analysis is specifically derived 
from the tagged ZNF408 proteins. Based on the equal intensity o f the bands, 
there is no indication that the stability of the mutant ZNF408 differs from that 
of the wild type protein.
Zinc fingers are versatile DNA-recognition elements that comprise a class of 
regulatory proteins and participate in a variety o f cellular activities, such as em­
bryonic development and cellular differentiation. The zinc finger gene family 
belongs to one o f the biggest families o f transcription factors and can be divided 
into many subclasses based on the number and type o f zinc fingers they con- 
tain.29 Each finger constitutes a self-contained domain stabilised by a zinc (Zn) 
ion ligated to a pair o f cysteines and a pair o f histidines, in addition to an inner 
structural hydrophobic core. Although differential use o f the two residues gives 
rise to several types o f zinc fingers,30 the C2H2 finger has emerged as the most 
prevalent protein motif which characterises one o f the most abundant eukaryotic 
protein families that is found in 2% of all human genes.31, 32 Most C2H2 fingers 
appear to contribute to protein-DNA and protein-RNA interactions.30 However, 
they have also been implicated in protein-protein interactions: in general, the 
greater the number of finger domains, the higher the versatility and more fingers 
with specific affinity for different ligands in specific classes o f proteins e.g. 
class o f multiple-adjacent-C2H2 (maC2H2) finger proteins.33, 34 Moreover, C2H2 
zinc finger proteins containing a tandem repeat o f zinc finger motifs that can 
dimerise or homopolymerise through the co-ordinated action of specific zinc 
finger motifs. For example, consensus C2H2 zinc fingers have been shown to be 
responsible for selective homodimerisation of Ikaros family members35, 36 and/ 
or the contribution o f other domains in order to order to exert their function.36
ZNF408 is predicted to consist o f ten distinct zinc finger motifs arranged in 
a tandem array, located at the C-terminus o f the protein. The high number of 
those motifs suggests that ZNF408 possibly is a versatile molecule that may be 
involved in a wide range o f functions apart from high-affinity DNA binding. 
Next, we tested the possibility o f the mutant protein being able to affect the 
cellular localisation of the wild-type counterpart. We transiently co-transfected 
COS-1 cells with HA-tagged wild-type and mutant eCFP-ZNF408 constructs. 
Interestingly, whereas wild-type ZNF408 is almost exclusively expressed in the 
nucleus (Figures 7A-7F) when both constructs are introduced in the same cells, 
the wild-type ZNF408, in the presence o f the mutant protein, is predominantly 
retained in the cytoplasm (Figures 7G-7J).
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Figure 7. Wild-type ZNF408 is retained in the cytoplasm upon co-expression 
with m utant ZNF408.
A-C: Immunofluorescence analysis of transiently transfected HA-tagged wild-type 
ZNF408 proteins. Representative examples are shown, in which a number of cells show 
the presence of wild-type ZNF408 inside the cell nuclei (indicated by arrows). Images 
are presented as A) DAPI (staining cell nuclei), B) anti-HA (detecting the transfect­
ed HA-tagged ZNF408 proteins), and C) merged pictures (DAPI in blue, HA-tagged 
ZNF408 in red) D-F: Immunofluorescence analysis of transiently transfected eCFP- 
mutant ZNF408 proteins. Representative examples are shown, in which mutant ZNF408 
is located outside the cell nuclei (indicated by arrows). Images are presented as D) DAPI
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(staining cell nuclei), E) eCFP (detecting the transfected eCFP-ZNF408 mutant pro­
teins), and F) merged pictures (DAPI in blue, eCFP-tagged ZNF408 in green) G-J: Im­
munofluorescence analysis of transiently transfected HA-tagged wild-type and eCFP- 
mutant ZNF408 proteins. Representative examples are shown, in which wild-type and 
mutant ZNF408 are located outside the cell nuclei in a number of cells (indicated by 
arrows). Images are presented as G) DAPI (staining cell nuclei), H) eCFP (detecting the 
transfected eCFP-ZNF408 mutant proteins), I) anti-HA (detecting the transfected HA- 
tagged wild-type ZNF408 proteins), and J) merged pictures (DAPI in blue, HA-tagged 
ZNF408 in red, eCFP ZNF408 in green).
Thus far, adFEVR is caused mostly by loss-of-function mutations (haploinsuf- 
ficiency disease model) in genes encoding components o f the Norrin-p-catenin 
signaling network, i.e. FZD4, LRP5, NDP, and TSPAN12.37 These mutations 
perturb signaling initation, progression and subsequent p-catenin stabilisation 
and interaction with factors such as VEGF38 that drive retinal angiogenesis and 
vasculature formation.39 Moreover, mutations in the known FEVR genes seem 
to explain up to ~50% of all FEVR cases reported.12, 13, 18, 40, 41 The latter provides 
evidence that other FEVR genes exist and those are possibly to be found in 
components or regulators o f the Norrin-p-catenin signaling.
ZNF408 is a previously uncharacterised transcription factor that appears to 
be highly expressed in the retina. The p.H455Y variant that we found in two 
adFEVR families, affects a highly conserved amino acid that plays a key role 
in a zinc finger binding domain. Our cellular transfection studies show that the 
mutant protein does not enter the nucleus, where it is thought to exert its normal 
function. Moreover, it causes the wild-type protein to be retained in the cyto­
plasm, due to putative di- or multi- merisation, suggesting a possible dominant 
negative mode o f action of the mutant ZNF408. Even if  quite rare, a dominant 
negative disease mechanism has been previously described in FEVR, in which a 
truncated FZD4 protein oligomerises with wild-type FZ receptors trapping them 
in the endoplasmic reticulum.42 The role o f zinc finger proteins in processes reg­
ulating angiogenesis and/or modification o f the p-catenin-dependent transcrip­
tion activity is well documented.5, 43-47 Our data suggest that ZNF408 plays a role 
in p-catenin-based signaling network, which, when its routing to the nucleus 
is diminished, results in FEVR. Many questions however, remain on the exact 
functional identity o f this protein in the puzzle composing p-catenin signaling. 
Further experiments are required in order to unravel the hierarchical position of 
ZNF408 in the p-catenin signaling pathway. Identification o f the transcriptional 
targets o f ZNF408 could pinpoint new components underlying FEVR.
This study reveals not only the great potential but also the limitations of 
exome sequencing when applied in single individuals. It also stresses the im­
portance o f synergy between NGS and genome-wide linkage studies in disease 
gene identification. A single exome sequencing experiment o f an affected indi­
vidual can result in almost 24,000 nucleotide variants. After extensive bioinfor- 
matic analysis and prioritisation, which resulted in the exclusion of ~99% of all 
initially reported sequence variants, a mean o f 312 nucleotide changes remained 
that were concordant with an autosomal dominant disease model. By combin­
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ing sequencing data from the exomes o f two distantly related affected family 
members under the assumption of monogenic inheritance, the number of poten­
tial disease causing variants was almost 10-fold reduced. Still, to identify the 
culprit causal variant among the remaining shared nucleotide variants is a very 
demanding task. By combining genome-wide SNP linkage with sequence data 
from two exomes, we identified a single, unique disease causing-variant The 
identification of this variant in a second unrelated FEVR family corroborates the 
disease causing role o f the p.H455Y variant in ZNF408.
In summary, we have identified ZNF408 as a novel gene causative for autoso­
mal dominant FEVR. ZNF408 is only the fourth adFEVR gene and is mutated 
in two of the 10 families studied. Furthermore, we provide strong evidence for a 
dominant-negative disease mechanism underlying FEVR. Last, we highlight the 
successful combination o f exome sequencing with genome-wide SNP linkage 
analysis as a powerful approach to unravel mutations in novel genes that result 
in disease.
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Vitreoretinopathies
Our knowledge on the inherited vitreoretinopathies has expanded greatly over 
the past decade, especially through the identification o f the underlying genes. 
Vitreoretinopathies comprise a spectrum of eye disorders which may be con­
genital or acquired and include anomalies in the vitreous structure, e.g. optically 
empty vitreous, early onset cataract, retinal detachment, exudation and vasop- 
roliferation.
In this thesis, I studied and identified genetic defects in patients suffering from 
vitreoretinal degenerations, namely Wagner disease, FEVR, Norrie disease and 
Stickler syndrome.
Wagner disease model and VCAN
VCAN encodes versican, a large extracellular matrix proteoglycan with a 
maximal length o f 3396 amino acids and a molecural weight o f 370kDa,1,2 that 
consists of a core protein and glycosaminoglycan (GAG) side chains. Alterna­
tive pre-mRNA splicing gives rise to four isoforms of versican (V0, V1, V2, and 
V3), which vary by the presence or absence o f two glycosaminoglycan binding 
domains named aGAG and PGAG.3-5 Variant V0, that contains both the a- and 
PGAG binding domains,(encoded by exons 7 and 8 respectively), can bind to 17­
23 glycosaminoglycan (GAG) chains. Variant V1, containing the PGAG but not 
the aGAG domain, can bind 12-15 GAGs. Variant V2, that contains the aGAG 
but not the PGAG domain, can bind 5-8 GAGs, and variant V3, because it lacks 
both GAG domains, has no GAG attachment sites.6 All forms of versican share 
the remaining domains that include the amino-terminal globular domain (G1; 
which contains the hyaluronan-binding link modules), the carboxy-terminal G3 
domain which contains two EGF-like repeats, a complement-regulatory protein­
like repeat, and a C-type lectin domain. Both the N- and C- termini of versican 
serve as docking stations where multiple proteins, e.g. hyaluronan, fibrillin-1, 
tenascins, and heparan sulphate proteoglycans, can bind and aggregate.7-9
VCAN is expressed throughout the human body,10 but the presence o f the dif­
ferent isoforms and their relative abundance is determined in a tissue-specific 
manner. The latter suggests that the number of GAG chains and therefore the 
analogy between full-length versican and its different glycovariants may be a 
crucial parameter for the protein to exert a tissue-specific function. By virtue of 
their polyanionic nature, the chondroitin sulphate chains attached to the aGAG 
and PGAG domains o f versican are involved in wide a range o f functions.11,12 
They bind large amounts o f water, which are critical for maintenance o f revers- 
ibly compressible tissues. In addition, by altering the balance o f free water avail­
able to proteins, the GAG chains can also dynamically modulate protein-protein 
interactions, especially those involved in the establishment and/or maintenance 
of supramolecular structures.13-15
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Within the human eye, versican is expressed in the retina, the trabecular mesh- 
work, the ciliary muscle and the vitreous.3,16 Particularly in the vitreous body, 
a specialised type o f highly hydrated extracellular matrix composed of inter­
penetrating networks o f GAGs and collagen fibrils, versican is believed to be a 
fundamental factor o f maintaining structural integrity by the osmotic contribu­
tion o f GAGs.17-19
The six different point mutations in VCAN that have been associated with 
Wagner disease (Table 1)14,20-23 are all located in the highly conserved canonical 
splice sites o f exon 8. These mutations lead to aberrant mRNA splice products, 
and in the case o f V0 and V1, lack a small part o f exon 8 i.e. 39 nt (c.4004- 
1G>A, 4004-2A>G and c.4004-5T>A; chapter 2) and 21 nt (c.9265+1 G>A).14
Most interestingly, apart from the truncated V0 and V1 isoforms lacking 13 
amino acids, we were able to demonstrate that at least the intron 7 variants have 
an effect on the overall splicing regulation of the different versican isoforms, 
leading to preferential skipping of exon 8. Relative quantitation of the VCAN 
splice variants in our Wagner disease patients supports the previous notion, as 
the smaller V2 and V3 isoforms were upregulated and V0 and V1 are likely 
downregulated according to our hypothesis (chapter 2).
Both V2/V3 overexpression and/or reduced V0/V1 expression levels (50%- 
75% of normal) could underlie Wagner disease and ERVR though we favour 
the latter. In this scenario (Figure 1) we speculate that the overall quantity of 
all versican isoforms in the vitreous remains the same as there is a shift from 
V0/V1to V2/V3 upregulation. Nonetheless, due to this isoform imbalance, the 
absolute number o f GAGs is reduced. Given the potent regulatory role o f these 
sugar moieties, a change in their concentration could have a major impact on 
vitreous body homeostasis. For example, decreased interaction of versican with 
other extracellular matrix components and loss o f its electrostatic profile, that 
may be responsible for maintaining the spatial separation of the microfibrillar 
structures and the collagen fibers, could have an effect on the vitreous body.6,24 
The ultrastructural organisation o f the vitreous gel might become disturbed, ac­
celerating its liquefaction and finally manifesting in the "empty" vitreous ob­
served in Wagner patients.
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(A)
V C A N  pre-m R N A  (VO)
(B)
VCAN pre-m RNA (VO)
VO ^  ExonsjExonej Exon 7 | Exon 8 Exon 9 Exon 10 y
VO (A39 bp) ExonsjExonej Exon 7 |  ExonS Exon 9 Exon 10 y  
V2 /  ExonsjExonej Exon7 Exon9 Exon 1o| y
( C )
V C A N  pre-m R N A  (V1)
/  ExonsjExonej Exons Exon9 Exon 10 y
(D)
V C A N  pre-m R N A  (V1)
V1 ExonsjExonej Exon 8 Exon 9Exon 10 y
V1 {A39 bp) Exon5]Exone| Exons Exon9|Exon10 ,
V3 Exon 5 Exon sj Exon 9 Exon 10 y
Figure 1. Schematic demonstration of a putative disease model for Wagner disease.
A) Norm al splicing o f V C A N  pre-mRNA resulting in the V0 isoform. B) Mutations (hexa­
gon) in the splice acceptor splice site of exon 8 weakens its splicing potential. Therefore 
the splicing machinery is preferentially shifted towards the simultaneous selection (indi­
cated by dashed lines) o f an alternative splice site within exon 8 of V C A N  (dark grey bar) 
and/or complete skipping of exon 8 and selection of the canonical splice site o f exon 9. The 
latter generates overall reduced quantities of V0 with concomitant production of a trun­
cated version of V0 (A39 bp) and V2 isoforms. C) Normal splicing of V C A N  pre-mRNA 
resulting in the V1 isoform. D) Mutations (hexagon) in the splice acceptor splice site of 
exon 8 weakens its splicing potential. The latter as previously described (B) results in the 
overall downregulation of the wild-type V1 isoform and simultaneously in the generation 
o f a truncated version o f V1 (A39 bp) and wild-type V3 isoforms. *Based on RT-PCR data 
(chapter 2) it is not clear whether the wild type forms are transcribed in the presence of the 
splice-site changes.
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Table 1. VCAN pathologic variants causing Wagner disease and erosive vitreoretinopathy. 
(adapted from GENE Reviews "VCAN-Related Vitreoretinopathy"*)
Nucleotide change Effect on isoform distribution Reference
c.4004-1G>A (IVS 7 splice 
acceptor)
V 0|, V 1 |,V 2 |, V 3| Chapter 2
c.4004-2A>G (IVS 7 splice 
acceptor)
Not tested Miyamoto et al., 2005
c.4004-5T>C (IVS 7 splice 
acceptor)
V 0|, V 1 |,V 2 |, V 3| Chapter 2
c.4004-5T>A (IVS 7 splice 
acceptor)
V 0|, V 1 |,V 2 |, V 3| Chapter 2
c.9265+1G>A (IVS 8 splice 
donor)
Not tested Kloeckener-Gruissem et al., 2006 Mer­
edith et al., 2007
c.9265+1G>T (IVS 8 splice 
donor)
Not tested Ronan et al., 2009
*http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&part=wagner#wagner.
REF.kloeckenergruissem.2006.350)
While discussing the putative disease mechanism o f Wagner disease, it is also 
o f particular interest to consider that, without the splice site mutations in introns 
7 and 8, no other mutations have been identified in VCAN  s ORF or particularly 
in exons 7 and 8 that bear the GAG attachment domains. In mice, generation of 
hd f (heart defect) transgenic animals, that harbour an insertion in Vcan o f a lacZ 
reporter construct into the intron between exons 7 and 8, provided the first tool to 
explore the effects of versican deficiency in a model organism.25
Mice homozygous for the hd f'transgene die at 10.5-11 days post coitum as the 
absence o f versican results in severe cardiac defects and reduced size compared 
to wild-type littermates.25,26 In contrast, mice heterozygous for the hd f'transgene 
have no obvious phenotype and live to reproduction.26 The latter is not in agree­
ment with the human situation. Due to the absence o f reported heterozygous loss- 
of function mutations, we hypothesise that full haploinsufficiency o f VCAN is 
probably not tolerated and might lead to embryonic lethality. In addition, it is well 
known that the different versican isoforms are preferentially expressed in a high­
ly regulated manner in various tissues, influencing ECM function accordingly.
The importance o f these two processes is very neatly demonstrated by the gen­
eration o f V0/V2 specific knock-out and Adamts9 heterozygous mice, respec­
tively3,27 as exemplified below. The normal reproduction behaviour, litter size 
and lack o f Mendelian skewing in wild-type, heterozygous and homozygous V0/ 
V2 knock-out animals, showed that lethality of the hdftransgene is most probably 
caused by V1 deficiency. Moreover, haploinsufficiency o f Adamts9, a proteogly- 
canase that cleaves VCAN isoforms V0 and V1 (Glu441-A la442 bond) was shown 
to be associated with cardiac anomalies, adding evidence for the biological poten­
cy o f VCAN’s proteolytic fragments that result from certain isoforms.28-31 Last, 
adding to the complexity o f VCAN’s regulation and action, is the notion that 
specific isoforms may be, at least partially, functionally redundant. For example, 
V2 deficiency in mice causes no obvious phenotype even when focusing in the
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central nervous system where it is normally abundant. Lack o f versican V2 is 
suggested to be partially compensated in function by the action o f brevican.27
Considering the putative Wagner disease mechanism, coupled to the function­
al data extrapolated for VCAN function and regulation in mouse models, a few 
things can be deduced. The quantity and quality o f the different VCAN isoforms 
in the vitreous gel emphasise the role o f GAGs in providing the gel with its 
intrinsic structure, preventing the collapse o f the ECM components in a highly 
hydrated environment. This essential role o f VCAN in the eye and the nature 
of the pathogenic nucleotide variants that have been revealed, indicate the high 
plasticity in the expression pattern(s) o f the gene and its isoforms, which if  dis­
turbed is not tolerated, and leads to a disease phenotype.
Moreover, it is also o f particular interest to consider the involvement of other 
cis or trans-acting genetic elements that modulate the phenotypic expression in 
patients. One variant (c.4004-5T>C) has been proven to cause both Wagner dis­
ease and ERVR, the latter exhibiting a more severe phenotype. Furthermore, in 
a Chinese family with Wagner disease, although the causative sequence variant 
has yet to be identified, a high V2 and V3 upregulation was observed (chapter 
2).
Parameters such as natural variation in VCAN expression, presence o f particu­
lar intronic variants (with a special focus on intron 7) and/or polymorphisms, 
environmental factors and VCAN metabolism, especially in light o f the Ad- 
amts9+/- mouse model, may also play a key role in the phenotypic diversity of 
disease expression. Only recently, it was shown that VCAN expression can also 
be regulated by the action of microRNAs that act on the 3’ UTR of the gene e.g. 
miR199a, miR143,32, 33 or even within intronic regions (personal communica­
tion, A. Mukhopadhyay, New Delhi). Furthermore, polymorphisms in the VCAN 
promoter region or ORF have been implicated/associated with higher suscep­
tibility for intestinal gastric cancer and intracranial aneurisms (e.g. rs188703, 
rs160277, rs173686 and rs251124),34,35 illustrating the complex genetics of 
VCAN in health and disease.
Norrin/p-catenin signaling, FEVR and Norrie disease
The past few years have been accompanied by data implicating p-catenin sig­
naling and regulation in cell survival, differentiation, proliferation, and migra- 
tion.36-38 Particularly in the eye, it possesses a cardinal role during various stages 
of retinal development and field establishment, the maintenance o f retinal stem 
cell and neuronal specification and ocular blood vessel formation and architec­
ture. B-catenin is a molecule which acts as the merging point o f several signal­
ling pathways. Those pathways either upregulate or downregulate its expres­
sion, according to temporal and spatial needs, thereby constituting a complex 
network of events that determine the fate o f numerous cellular processes.39,40
The accumulation o f p-catenin in the cytoplasm is usually prevented by gene 
products that promote its degradation via phosphorylation and ubiquitin-medi- 
ated proteosomal degradation.41,42 This is a cellular mechanism that is normally
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interrupted by the canonical Wnt signaling. Wnts are a large family o f lipid- 
modified secreted glycoproteins that exert their signaling potential by binding 
to various membrane proteins. When they bind to one o f the multiple trans­
membrane frizzled (Fz) receptors and form a ternary complex with LRP5 and/ 
or LRP6 co-receptors, the signal is propagated from the cell surface to the cy­
toplasm where a large number of proteins is recruited or activated (e.g. Dishev­
eled, APC, Axin).43-46 Upon a series o f biochemical events (e.g. phosphorylation 
of Disheveled), those proteins interact with the cytosolic tails o f either frizzleds 
and/or LRPs resulting in the disassembly of the P-catenin destruction complex,47 
with subsequent accumulation of P-catenin in the cytoplasm. This causes the 
translocation of P-catenin to the nucleus, where it interacts with the TCF/LEF 
family o f transcription factors and activates the expression o f genes that are 
important for cell-fate decisions.48
Interestingly, FZD4 is a pleiotropic receptor that, in addition to Wnts, can 
also bind another ligand called Norrin, a protein with no discernable sequence 
similarity to Wnts. Norrin binding to FZD4 has the ability to act agonistically 
for the canonical signaling pathway inhibiting P-catenin phosphorylation and 
degradation, in an LRP5/6-dependent way.49 It is intriguing that among 10 dif­
ferent frizzleds, FZD4 is the only one that can bind Norrin.50
Adding to the complexity o f this non-WNT associated Norrin/p-catenin path­
way, TSPAN12 was recently identified as an additional membrane protein which 
is an essential part o f this complex.51 TSPAN12 is thought to act as a molecular 
switch, enhancing FZD4 oligomer clustering and multimerisation via binding to 
Norrin multimers. The latter is essential for activating the downstream signal­
ing cascade complemented by LRP5 that in turn regulates retinal vascular or­
ganisation and homeostasis, especially that o f blood vessels in the inner retinal 
layers.51 Finally, ZNF408, is a new and yet uncharacterised piece in the puzzle. 
The exact hierarchical position and regulatory potential as a transcription factor 
has yet to be determined. The central role and the biological importance o f the 
aforementioned molecules in retinal angio- and vasculogenesis is demonstrated 
by the fact that Fzd4, Lrp5, Ndph and Tspan12 “knockout” mutant mice in par­
allel with Tspan12/Lrp5 and Tspan12/Ndph trans-Heterozygotes show a highly 
similar hypovascularisation phenotype, indicating that these proteins are part of 
the same molecular pathway.51 Furthermore, particular heterozygous and likely 
loss-of-function mutations in FZD4, LRP5, NDP (chapter 4) and in the recently 
identified TSPAN12 (chapter 5) result in FEVR or, in case o f certain mutations 
in NDP, Norrie disease. These two diseases are largely characterised by failure 
of retinal angiogenesis and aberrant compensatory retinal neovascularisation, 
symptoms very similar to the phenotype observed in knock-out mice. Combin­
ing all the previous elements sheds light on and emphasises both the importance 
of the Norrin/P-catenin signalling pathway in retinal vascular development and 
its high sensitivity to gene dosage.52
FEVR is a genetically heterogeneous disease, as mutations in four genes 
roughly account for ~50% of all FEVR cases.53-56 In addition, the variable phe­
notypes observed between unrelated patients harbouring the same mutations or
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even between patients o f the same family, strongly suggest the presence and 
action o f modifying genes or epigenetic effects.
The Norrin/p-catenin pathway is quite a recent piece in the puzzle o f angio­
genic signaling. While its constituents acting in this pathway, and/or the mode 
of interaction of these proteins with their environment are currently being in­
vestigated, further functions are unravelled. We now know that the Norrin/p- 
catenin pathway is active throughout the course o f retinal vascular develop- 
ment49,52,57-60 rendering its components prime candidates not only for FEVR, but 
also for other angiopathies o f the retina.
Today’s technologic advances allow multiple strategies to be employed, which 
will not only aid the identification of the genetic defect(s) present in unsolved 
FEVR cases, but will also increase our understanding o f the disease’s molecular 
basis. The implementation of next generation sequencing (NGS) technologies 
by either sequencing all exons o f the genome (‘exome sequencing’) or o f a 
targeted chromosomal location when combined with linkage analysis data, has 
revolutionised genomics. Approaches requiring extensive and long-lasting dis­
ease candidate gene analyses together with ‘educated guesses’ on gene selection 
is progressively alleviated. Furthermore, screening of sporadic patients or small 
families with FEVR will, now more likely than ever before, contribute signifi­
cantly to identify candidate disease genes.
Despite the enormous development in molecular genetic tools, the identifica­
tion o f novel genes within loci associated with human genetic diseases is a very 
demanding task, because the critical region may typically contain hundreds of 
positional candidates. This was also our experience with the linkage studies per­
formed in the two large pedigrees harbouring mutations in TSPAN12 (chapter 5) 
and one additional family with a p.H455Y missense change in ZNF408 (chapter 
6). In case o f TSPAN12, linkage analysis resulted in a ~40 Mb region with more 
than 330 genes that were all sequenced with NGS, in addition to other genetic 
elements such as microRNAs, noncoding RNAs and highly conserved genomic 
regions. Our detailed bioinformatic analysis o f the NGS variants that prioritised 
TSPAN12 as the prime candidate coincided with its concurrent identification as a 
key player in regulating retinal vasculature.51 Moreover, in relation to ZNF408, 
exome sequencing resulted in almost 24,000 nucleotide variants. Extensive bio­
informatic analysis and prioritisation, resulted in the exclusion of ~99% of all 
initially reported sequencing variants leaving close to 300 with putative disease 
potential. Only after combining exome data with SNP linkage analysis were we 
able to pinpoint ZNF408 as the disease-causing gene.
A number of questions though still remain largely unanswered. Except for 
NDP and FZD4, none o f the other components (e.g. NDP and TSPAN12) have 
been shown to physically interact, and hence we are unaware about the complete 
mechanism of signal generation and transduction. Shedding light on the mecha­
nistic details o f a Norrin/p-catenin signaling network could dictate the way and 
the tools to be used e.g. protein-protein interaction studies, in order to identify 
new protein counterparts. Synergistic employment o f NGS, large mutagenesis
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projects in model organisms, biochemical assays and protein-protein interac­
tion analyses under the concept o f ‘systems biology’, will not only facilitate 
the identification of novel FEVR genes, but also deepens our knowledge on the 
molecular mechanisms underlying this disease.
Impact and future of next generation sequencing technology in basic 
research and disease diagnosis
Personalised genomics
The rate in which the discovery o f genes for genetic disorders increases, has 
strengthened the concept that genomic information will become an integral 
component o f personalised medicine and disease prevention.61,62 It is beyond 
doubt that personal genomics techniques will revolutionise predictive medicine 
as their applications will enable clinical scientists to apply individual tailor- 
made therapies.
One example is the area o f pharmacogenomics where genetic information ac­
quired on an individual basis could be used as a platform for appropriate and ef­
fective drug selection. In addition, genome-wide association studies are already 
in transit to a next era, in which they have the potential to identify and build 
individual risk profiles for several multifactorial conditions.
Reduction of cost (by at least two orders o f magnitude) together with the 
completion o f the 1000 human genomes project (http://www.1000genomes.org/ 
page.php) will enable us to overcome obstacles preventing a rapid high scale 
screening. Currently, technologic advances are ongoing and it is expected that 
the prices for NGS will further decrease.
However, whole genome and targeted exon sequencing still yields a large 
number of variants which shifts the interest and the main challenge to interpret 
variants in terms o f biological significance.63,64
The latter is also confirmed from our experience. Targeted sequencing o f the 
40.5 Mb locus in chromosome 7 in two large FEVR families (chapter 5) resulted 
in the detection o f a total o f 1915 variants. This number is devoid o f any deep in­
tronic changes that may be present, with the exception of WNT2 and WNT16. In 
addition, exome sequencing analysis in one FEVR family, with no mutations in 
the ORF of any of the four known FEVR genes, resulted in a staggering number 
of ~24,000 nucleotide variations. Even if  several methodologies were deployed 
in order to ‘filter’ those data (e.g. comparison with known polymorphisms), the 
amount o f sequence variants with suspected disease potential ranges between 
3-6% i.e. 700-1500 per patient tested. By either sequencing multiple affected 
individuals o f the same family, and/or linkage analysis and homozygosity map­
ping, pathologic sequence variants can be discriminated from the benign ones. 
If this is not possible, other approaches can be used such as cDNA expression 
profiling and functional assays in order to pinpoint the molecular genetic cause 
of a disease.
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Transcriptomics-Epigenetics
The regulation of gene expression and epigenetic controls, is crucial for un­
derstanding the interactions between genes and environment, the links between 
genotype and phenotype and the molecular functions o f cellular physiology. 
From the application of Northern blot and RT-PCR analysis used to identify 
the expression o f single genes, or assays o f limited potential (e.g. bisulphite 
sequencing) to study epigenetic modifications mostly on a local level (e.g. DNA 
methylation of single genes), NGS has tremendously upgraded research poten­
tial in the respective fields. The advances that we made using these modern 
technologies bring into focus unanswered questions concerning the disease 
mechanism of several vitreoretinopathies studied in this thesis, providing great 
promise to address them.
As previously discussed, Wagner disease is hypothesised to result from an 
abnormal imbalance o f the naturally occurring splice variants o f VCAN (chap­
ter 2). However, it is o f notice that this does not fully address the complete 
disease mechanism. In four families with Wagner disease we found suggestive 
segregation of VCAN variants with the disease (K.Nikopoulos, unpublished 
data). However, neither did we identify mutations in VCANs ORF and/or splice 
sites, nor any variation in the expression o f the different isoforms using mRNA 
qPCR. Moreover, FEVR but also other vitreoretinopathies, are developmentally 
heterogeneous disorders. Many parameters concerning their pathogenesis are 
unknown and even nowadays, clinical classification is rather difficult due the 
fact that no wide-spread clinical expertise exists for these ‘orphan diseases’ 
(Orphanet, http://www.orpha.net/consor/cgi-bin/index.php?lng=EN). Misdiag­
nosis is not uncommon, even between vitreoretinopathies exhibiting common 
pathologic features (i.e. Wagner disease and ocular Stickler syndrome).
With the aid o f NGS, coupled to existing or new methodologies in the areas 
of transcriptomics and epigenetics, we now have the potential to address several 
of these problems. One example o f particular interest is the single-molecule 
sequencing digital gene expression, or smsDGE, in relation to clinical entities 
such as Wagner disease. With this method, it is possible to not only unravel nov­
el previously uncharacterised gene transcripts e.g. novel isoforms, but also to 
achieve accurate mRNA transcript quantification. The effectiveness o f smsDGE 
is driven by the fact that only a single read is generated from each cDNA mol­
ecule, thereby maintaining an accurate representation of transcript distribution.
In our studies, in order to determine the expression levels for the different 
VCAN isoforms (chapter 2), we were only able to perform relative quantifica­
tion using a reference gene being the common denominator. Even if this ap­
proach was sensitive enough to detect the considerable V2 and V3 upregulation 
(1 to 2 orders o f magnitude), it was inconclusive for V0 and V1 due to their 
‘small’ (~20-40%) suspected decrease. Accurate measurements of the subtle 
quantitative differences o f V0 and/or V1 isoforms may explain the differences 
in clinical severity of Wagner disease and ERVR and as such be o f prognostic 
value for the patients.
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Chromatin immunoprécipitation followed by microarray hybridisation (ChlP- 
chip) allows detection o f DNA regions where a protein o f interest, usually a 
transcription factor, is bound.65 The introduction o f NGS facilitated the devel­
opment o f a new technique called ChIP-Seq, which detects histone modifica­
tion on a genome wide-scale66,67 together with the identification o f transcription 
factor binding sites at a base pair resolution. Furthermore, this new technology 
allows the identification o f novel DNA binding regions. Chip-Seq o f ZNF408 
may reveal the position of this transcription factor in the P-catenin pathway and 
possibly may unveil other adFEVR candidate disease genes.
Furthermore, among the plethora o f NGS applications, both in transcriptomics 
and epigenetics, is the profiling o f small non-coding RNAs e.g. (tRNA, rRNA, 
miRNA and siRNAs) which can be combined with data reporting on multigene 
DNA methylation and histone modifications, respectively. All those analyses 
provide an actual insight on both spatial and temporal transcription regulation 
of target genes, building detailed ‘regulation profiles’ per gene and per indi­
vidual patient. Their implementation in daily routine will also provide answers 
concerning the disease mechanism underlying Wagner disease in the families 
where no quantitative differences are observed between versican’s different 
splice variants (chapter 2).
Finally, the role o f CNVs, genomic structural re-arrangements and individual 
intergenic/intronic variants, is largely unexplored or with very few reports on 
literature about their contribution to human disease in general, and/or vitreo- 
retinopathies in particular. Currently, gene identification analysis (paired-end 
method) within large-scale transcriptome sequencing projects has been used to 
detect genomic rearrangements and gene fusions together with genomic regions 
that result in abnormal mRNA expression e.g. pseudogenes.68,69 This can poten­
tially lead to the disease causing variants e.g. heterozygous deletions o f known 
or novel genes (partially or as a whole), that standard sequence analysis would 
have missed. In addition, intronic variants could explain the natural variation in 
expression o f human genes that may also play a role in disease severity i.e. full 
or partial disease penetrance o f the same nucleotide variant in different patients.
NGS and diagnostics
During this thesis study, NGS is, despite its enormous potential, primarily 
being used in a research oriented set up to aid disease gene identification. The 
technology at its conception has been developed for large scale genomics ap­
plications. Currently it is further adapted towards DNA diagnostic applications, 
however the challenge lies in meeting specific quality criteria that include 1) 
high throughput for all selected regions (2) high sensitivity to detect and inter­
pret all types o f variants (e.g. missense changes and/or copy number variations) 
(3) the need for only small amounts o f sample material (4) high reliability and 
(5) cost-effectiveness.70
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Quality
Currently there are a number of concerns about NGS technology and its ca­
pacity to be readily used under clinical parameters. Till now, there is a lack of 
definitive criteria that enable accurate detection of sequencing errors from real 
sequence changes. Growing experience and development o f the technology has 
shown that the latter largely depends on the level o f sequence coverage. Despite 
the knowledge that high coverage o f a specific location allows accurate nucleo­
tide calls, there are however no formal guidelines indicating a ‘golden standard’ 
to confidently establish a heterozygous call.
Cost effectiveness
As with any new technology, the initial costs necessary to set up a massive­
ly parallel sequencing platform are high. Commercially available instruments 
cost $400,000-$1,350,000 each, for instance Roche 454 GL FLX Titanium 
~$700,000.
In addition to that, there are two major legs o f expenses. One lies in the use 
of sequencing consumables. Current estimations vary and are very dynamic as 
the technology is rapidly evolving. However, as a rule o f thumb the amount of 
money required for a single run is approximately $7700 (whole genome se­
quencing/454 sequencer series).71 In today’s diagnostic setup, whole genome 
approaches are not being used. Targeted screening of specific gene disease 
groups, genes or even exons makes the use o f NGS generally not affordable. 
An option to optimise throughput and quality while decreasing the cost of NGS 
is to enable innovative solutions such as sequencing enrichment. This method 
has been successful on a large number o f target regions with the 454 FLX Se­
quencer.72 The latter could also be used by analysing multiple samples from dif­
ferent individuals during the same application (machine run), either by separat­
ing them physically or by adding short oligonucleotide adapters as ‘‘barcodes”, 
and running the samples as a pool. This is already being tested and reduces the 
price tag per sample.73,74
The other leg includes ‘hidden’ costs arising with the use o f such an infra­
structure such as data storage, transfer and bioinformatic analysis. It is also of 
note that many diagnostic laboratories have staff with the technical expertise to 
perform the high-throughput sequencing but they don’t possess the necessary 
investment in bioinformatic infrastructure and personnel with programming ex­
pertise. The bioinformatic challenges are mostly solved by the use o f core facili­
ties that retain data on their servers, access to analysis software and consultation 
with bioinformatic experts. Additionally, cloud computing has been suggested 
as an alternate affordable approach for data analysis, enabling wider access to 
these new technologies.75
Ethical issues
It is a fact that NGS technology is rapidly advancing and undoubtedly it is a 
matter o f time until it becomes common practise in clinical molecular genet­
ics. However, the enormity o f large DNA sequence or whole-genome datasets,
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brings many ethical challenges76 into a major focus which strictly speaking may 
not be entirely unique to NGS, but have already sparkled a very vibrant debate.
Actually, its key component involves the analysis, storing and reporting of 
data. Our current knowledge on interpretation o f the different variations found 
in large genomic portions o f our DNA is not infinite but steadily evolving. That 
brings into question whether for example the reference lab which undertook the 
analysis has the obligation to report all the sequence variants found, or if there 
is obligation to re-analyse the data and to provide updated interpretations as new 
knowledge regarding significance becomes available.
In addition to the previous, and focusing on the fact that our understanding of 
the exact role o f sequence variants is exhaustible, the acquisition o f informed 
consent becomes challenging. Especially in an environment where socio-polit­
ical and economical parameters are dynamic, for example the way how results 
are integrated into someone’s medical record is also a daunting task when it 
comes to privacy and protection of data.
Modifier alleles and phenotypic heterogeneity
As already mentioned, phenotypic variability in vitreoretinopathies is a preva­
lent phenomenon. This heterogeneity in clinical presentation is not only limited 
to this group o f diseases, but has been extensively reported in retinal dystrophies 
caused by mutations in the same gene. Taking that one step further, genotype- 
phenotype correlations even if  largely desired both for prognostic and thera­
peutic reasons, are not easy to establish, due to the high inter- and intra familial 
variability o f vitreoretinopathy patients with mutations in the causative genes. 
This phenotypic plethora can be attributed to allelic heterogeneity, environmen­
tal or other collateral factors e.g. lifestyle, and/or most interestingly epistatic 
parameters e.g. modifier alleles.
Inherited chorioretinal dystrophies are a group of disorders that show a high 
degree o f clinical assortment. The PRPH2/peripherin gene is a very good ex­
ample to demonstrate the concept o f allelic heterogeneity. Although some mu­
tations cause autosomal dominant retinitis pigmentosa,77 others are associated 
with macular dystrophy or patterned pigment dystrophy o f the fovea78-80,80 and 
retinitis punctata albescens,81 as the mutations in this gene seem to affect both 
rods and cones.
Along the same line, we know that certain heterozygous mutations in LRP5 
can result in FEVR, whereas others do not and when combined with a second 
mutation in the same gene result in OPPG (chapter 4). Furthermore, mutations 
in NDP can result either in Norrie Desease or the X-linked form of FEVR.
As described in chapter 4 and previously found elsewhere,82 ~15-25% of in­
dividuals carrying a FEVR-associated mutation, show minimal or no disease 
phenotype. This is a particularly interesting topic to study, since the same muta­
tion, in the same family causes different effects. Excluding allelic heterogeneity 
and obvious environmental factors, this phenotypic diversity can be potentially 
connected with the action o f modifier genes. A modifier gene is an inherited
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genetic variation which leads to a qualitative or quantitative difference in any 
aspect o f the disease phenotype.83 An example o f a model o f the ‘protective’ role 
that a modifier gene can exert in an autosomal dominant disease, lowering dis­
ease penetrance, is given in Figure 2. Here, all heterozygous mutation carriers 
reach the threshold for disease manifestation and therefore the disease is said to 
be fully penentrant. However, with the action of a modifier gene, a fraction of 
the heterozygous mutation carriers are “protected” as the threshold for disease 
manifestation has shifted.
Modifier alleles have been described in a large number of human diseases such 
as cystic fibrosis and P-thalassaemia.84,85 Yet, it also includes disorders with an 
ocular phenotype such as Joubert syndrome or Bardet-Biedl syndrome, where, 
heterozygous mutations in BBS1, BBS2, or BBS6 genes correlate with a more 
severe phenotype in patients with biallelic mutations at a second BBS locus.86-91
Figure 2. Example of the protective role exerted from the action of a modifier gene.
This model illustrates how a modifier gene can affect disease penetrance in an autosomal 
dominant disease by offering a “protective” role to individuals that are heterozygous for 
a given mutation. The solid curves and lines of this diagram show the distribution of 
disease phenotype (based on severity) in a given number of individuals. The vertical 
dashed line shows the phenotypic threshold for disease manifestation without the ac­
tion of modifier genes whereas the solid vertical line shows the phenotypic threshold 
for disease manifestation with action of modifier genes. By moving the threshold (from 
left arrow ‘old’ to right arrow “new”), some mutant heterozygotes are no longer affected 
(area indicated by dotted background) therefore reducing disease penetrance.
+/+; denotes individuals with two copies of the wild type allele
+/-; denotes individuals with one copy of the wild type allele and one copy of the mutant
allele.
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Notably, even in the case o f FEVR, reports exist that are suggestive of the 
presence o f modifier alleles. Qin and colleagues describe an example in which 
two patients with FEVR harbour the same FZD4 missense change.92 The more 
severely affected patient carries a second inconclusive variant in the same gene 
i.e. p.H69R. This missense change was previously shown to segregate with the 
disease.93 In addition, a reported factor V mutation was found to co-segregate 
with a FZD4 mutation in a patient suggesting the putative action o f a modifier 
and a digenic form of inheritance.94
For disorders inherited in a Mendelian fashion, a single gene plays the pre­
dominant role in the development o f a disease phenotype. However, with the 
implementation o f novel sequencing and bioinformatic technologies, a new 
spectrum of genetic information is currently being unravelled at unprecedented 
rates. The key now lies in the interpretation of the available data. The latter 
will probably explain the pluralism in disease potential o f the same or similar 
sequence variants, especially in the context of the overall genomic make up of 
an individual. A clear example o f that is the creation of ‘congenic mice’ in which 
the same mutation elicits a different phenotype in animals with different genetic 
backgrounds. Even more interesting is the fact that the same mutation causes 
both Wagner disease and ERVR (chapter 2). The latter obviously highlights the 
complexity underlying the elucidation of the molecular causes o f vitreoretinop- 
athies and other monogenic disorders. However, at the same time it dictates the 
course to be followed for the development o f personalised medicine and tailor- 
made therapeutic approaches that will significantly improve patient care.
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Development of targeted molecular therapeutic strategies for vitreo- 
retinopathies.
Vitreoretinopathies cover a broad spectrum of phenotypic features, display­
ing genetic heterogeneity and, except for Norrie disease and X-linked FEVR 
due to NDP mutations, are mostly inherited in an autosomal dominant manner. 
Inherent heterogeneity poses a great challenge to develop effective treatments 
for all patients. Yet, various promising therapeutic agents are currently being 
employed and evaluated, that either directly target the genetic defect, with a 
prospect to alleviate it, or indirectly by targeting other components o f the dis­
ease mechanism in an effort to counterbalance putative pathologic conditions.
Assays targeting the primary genetic defect
Gene therapy
The eye is one o f the most suitable organs for gene therapy. Amongst many 
reasons, it is highly compartmentalised, easily accessible and allows local ap­
plication of therapeutic agents with reduced risk o f systemic effects.95,96 In ad­
dition, the effects o f treatment can be monitored by a variety o f non-invasive 
examinations with minimal discomfort. There are several subtypes o f genetic 
therapy. In gene augmentation therapy, a normal copy o f the defective gene is 
added to the affected tissue.
Gene therapy is a twofold process. First, a gene must be cloned or engineered, 
and second it has to be delivered to a target tissue o f choice in order to exert its 
function. Usually the procedure includes the delivery o f a construct which is 
performed by means o f a vector that will target the defective gene with an aim 
of reconstituting its function. Vectors can be either viral e.g. recombinant adeno- 
associated viruses (rAAVs), or lentiviruses, or non-viral e.g. liposomes and/or 
nanoparticles.
Two critical parameters for the success o f any gene therapeutic approach is 
the selection of the most suitable vector and the delivery method for the target 
of choice. Generally, the preferred ‘vehicles’ o f gene delivery are recombinant 
adenoviruses and rAAVs. High efficiency o f in vivo gene transfer to numerous 
cell types, development o f a large arsenal o f viral capsids with different tro- 
pisms and low innate/inflammatory responses to viral particles, have made these 
vectors highly attractive. Delivery o f the vectors in the eye can be performed by 
intravitreous, subretinal, periocular and systemic injections.
Gene therapy has been particularly promising in cases o f patients with in­
herited retinal dystrophy, as it has proven to be effective in LCA patients with 
defects in the RPE. RPE65 gene augmentation therapy led to modest improve­
ments in visual function, even in patients in advanced stages o f the disease.97-100 
Nonetheless, even if  this is a promising and powerful tool, its long-term efficacy 
is still being monitored.101
Gene therapy is far from becoming the holy grail for the cure o f genetic dis­
eases. A number of issues still exist that need to be addressed before this ap­
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proach becomes a frequently used method in clinical practise. A particularly 
common and widespread risk is that the vectors used to carry genetic material 
to target cells, might set off an immune response. This greatly decreases success 
in curing any type o f disease. Moreover, the longevity o f the therapy itself, i.e. 
constant expression o f the newly introduced DNA construct , is a very critical 
prerequisite for its success.
AAVs seem to bypass the aforementioned problems, but there are more issues 
that need to considered. Even if  AAVs are very versatile tools, the currently 
available serotypes can only accommodate inserts o f up to ~5 kb. Immediately, 
this is prohibitive for many diseases e.g. Wagner disease, as certain isoforms of 
VCAN consist of more than 10 kb of cDNA. Moreover, the nature o f the defec­
tive protein poses a challenge to gene therapy efficacy. Heterozygous carriers 
of mutations in RPE65 do not demonstrate disease pathology. RPE65 has an 
enzymatic action, and therefore only a small proportion o f the normal enzymatic 
activity might be sufficient to restore retinal function. For other proteins, their 
correct action (or function) may depend on strictly defined expression levels. 
Genes that have a role in eye development may also be less suitable for this 
approach.
One additional point to be addressed concerning gene therapy is the existence 
of animal models that could be used in order to evaluate and assess the efficacy 
of a therapeutic approach in pre-clinical studies. Data from these studies are 
crucial for the effective translation of gene therapy to the clinic.
Last and most important, gene augmentation as a strategy is highly individu­
alised and as o f now, has its own limited therapeutic niche. Constructs have to 
be made individually, for each disease gene/mutation. Furthermore, selection of 
the vector needs to be highly specific as different vectors target different ana­
tomic elements in the eye, and expression of the construct needs to be within 
limits that render the approach effective but not toxic.
“Read- through” strategies
Small-molecule drugs have been developed that when administered introduce 
a conformational change in the mRNA and allow the ribosome to insert an ami­
no acid at a UGA, UAG, or UAA premature stop codon during translation.102,103 
Such nonsense mutation suppression therapy is selective for premature stop co­
dons relative to normal termination codons, at the 3 ’ end of the gene, presum­
ably because the geometry o f the mRNA at these sites is different.103,104 Drugs 
that induce suppression o f these nonsense mutations result in an increase in the 
read-through o f the premature stop signal and production of full-length protein. 
The drug PTC124 has been shown to suppress nonsense mutations and is able 
to enter several tissues throughout the human body by systemic administration. 
Thus far, PTC124 has been proven to have beneficial effects in animal models 
and in patients suffering from cystic fibrosis and Duchenne muscular dystro­
phy restoring full length protein expression up to 20-30% compared to normal 
physiological values.103,105-109 This approach has not yet been tested in patients 
suffering from vitreoretinopathies as safety issues, and in light o f the develop­
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mental nature o f the diseases, its suitability are under question.110 Moreover, 
as PTC124 is orally delivered it is not certain if  and in what concentrations it 
reaches the eye. Therefore the challenge apart from the efficacy of the specific 
drug lies in the design/application o f an ocular drug delivery system that will 
be o f convenience to the patient and will successfully deliver the therapeutic 
agent to its target site within the eye.
‘Antisense’ approaches
A different approach involves therapeutic “exon skipping”. In this way, the 
exon in which a nucleotide aberration e.g. nonsense mutations or frameshift 
changes are located, can be skipped and therefore not translated. Studies of 
rare, dystrophin-positive “revertant” fibres in some DMD patients first indi­
cated that this might be a feasible therapeutic approach.111 With this method, 
a short, specific antisense oligonucleotide molecule is administered. The oli­
gonucleotide binds to a homologous target region of mRNA in an exon that 
contains the mutation and alters splicing by excluding the faulty exon to be 
spliced out and translated. This AON treatment does not generate a wild-type 
transcript, albeit a truncated gene product that might retain many critical func­
tions, minimising or even eliminating biological consequences.
Application of the AON treatment has also some pitfalls. This method will 
only be successful if  the exon that is skipped does not encode a functionally 
or structurally crucial part o f the protein and for instance could be useful in 
proteins that possess similar and redundant motifs that could compensate for 
individual motif loss(es). All in all, this strategy, despite its limitations holds 
great promise and is currently being explored in human clinical trials112,113 with 
potential to also be applied in patients with vitreoretinopathies e.g. LRP5 and 
FEVR.
Possible therapeutic applications for vitreoretinopathies
In chapter 3 we described the identification of two nonsense mutations in 
COL9A1 in two families with autosomal recessive Stickler syndrome. Patients 
carrying two copies o f the p.R295X and p.R507X nonsense changes in princi­
ple could be very good candidates for either PTC124 or AON treatment. Proof 
of concept studies have been conducted in mouse models o f dystrophic epider­
molysis bullosa, a disease caused by mutations in another collagen molecule
i.e. COL7A1. Goto and colleagues114 designed AON molecules to induce skip­
ping o f a targeted exon (exon 70) containing a premature termination codon 
mutation. That resulted in restoration o f the open reading frame, partial expres­
sion o f COL7A1 and a mild rescue o f the mutant phenotype in mice.
In addition an example for the use o f antisense RNA technology to not only 
cause exon skipping or gene silencing, would be redirecting pre-mRNA splic­
ing. In three families with Wagner disease who harbour two splice site changes 
at the 3’ end o f VCAN  s intron 7 (c.4004-1G>A, c.4004-5T>A), we identified 
an aberrant 39 nucleotide deletion in mRNA isoforms V0 and V1 due to the ac­
tivation o f an alternative splice site in exon 8 (chapter 2). Antisense-mediated 
splicing reprogramming could be used in order to block any alternative splicing
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site, routing splicing back to its normal pattern (Figure 3). Even if we are not 
sure about the pathogenic nature o f the truncation of 13 amino-acids from V0 
and/or V1, stereochemical changes in VCAN and their contribution in the dis­
ease severity cannot be ruled out. Therefore, enhancement o f the normal splic­
ing mechanism for V0 and V1 could possibly lead to a milder phenotype easing 
patients from some o f the disease symptoms.
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X  * ,
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AU" ¥ -//
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VCAN mRNA
< r
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VCAN pre-mRNA (VO)
VCAN mRNA
Figure 3. Schematic demonstration of antisense-mediated splicing modulation in 
VCAN pre-mRNA. A) Mutations in the normal splice-acceptor site of exon 8 result in 
the selection of an alternative splice site within exon 8 of VCAN (dark-grey bar). The 
latter results in the generation of both normal and truncated V0 transcripts. B) Antisense 
oligonucleotide (AON) blocking of the alternative splice site in exon 8 of VCAN could 
enhance the generation of the normal V0 transcript.
Finally it is of interest that 20%-30% of all FEVR and Norrie disease causing 
mutations in FZD4, LRP5 and/or NDP are truncating mutations that lead to the 
introduction of premature nonsense codons (chapter 4). PTC124 administration 
in that fraction o f patients would, in principle, be applicable. However, it is pos­
sible that even if  the nonsense mutation would be “out o f context”, the errone­
ous inclusion of an amino acid in its position could potentially have the same 
effect as a missense change depending on its protein topology. Furthermore, 
the small number of exons in FZD4 (2 exons) and NDP (3 exons) would render 
therapeutic exon skipping not applicable for these genes.
Overall, even if  a large number of gene therapeutic approaches are being 
tested, they seem to have their own limited disease ‘niche’ in which they indi­
vidually can be deployed. By the same token, in case o f developmental diseases 
such as vitreoretinopathies, any effective treatment would require very early 
intervention so as to minimise and prohibit structural deterioration of tissues
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(e.g. retina) that is impossible to reverse. In conclusion, gene therapy does not 
seem to be generally applicable in vitreoretinopathies but, despite financial con­
straints has potential for progressive forms of inherited retinal dystrophies.
Assays targeting the secondary effects of the disease mechanism.
Stem cells
Stem cells, both embryonic and adult, are attracting much interest as a pro­
spective therapeutic approach to tackle ocular pathologies. Much attention has 
been given in technologies that particularly identify stem cells and introduce 
them into the tissue/organ o f choice. Therapeutic applications o f stem cells 
or research trials have been largely directed to two major directions. The first 
includes their use, in correcting structural anomalies in the ocular tissues, i.e. 
retinal degeneration, re-establishing functionality o f synaptic connections be­
tween retinal cell types. The second is to utilise them as “genetically corrected” 
vehicles that either will repair/replace the gene in question or release biologi­
cal agents that will adverse the disease pathology minimising possible immune 
responses. Paradigms of such methodologies include the application o f autolo­
gous bone marrow- or cord blood-derived stem cells in order to reconstruct 
damaged retina.115
Antisense RNA technology
A different and elegant approach to minimise consequences o f a genetic dis­
ease without targeting the primary defect is the introduction of RNA-modulat- 
ing elements that act at the level o f transcription of the target gene.116
This tool is particularly flexible offering several advantages, in that RNA in­
terfering elements are small and generally fit into any viral capsids and there is 
no direct interference with protein expression levels that could trigger toxicity.
Such an example could be defects in ocular angiogenesis and neovascularisa- 
tion, causing severe loss o f vision. This largely occurs in a spectrum of ocular 
disorders including FEVR and Norrie disease. One o f the underlying causes 
of vision loss is the increased vascular permeability leading to retinal oedema, 
vascular fragility, resulting in haemorrhage or fibrovascular proliferation, with 
tractional and rhegmatogenous retinal detachment. Pro- and anti-angiogenic 
factors regulate an “angiogenic switch,” which when turned on, leads to the 
pathogenesis o f the above ocular diseases.
Although neovascularisation tends to occur at a relatively late stage in the 
course o f many ocular disorders, it is an attractive target for therapeutic inter­
vention, since it represents a final common pathway in processes that are multi­
factorial in aetiology and is the event that typically leads directly to visual loss. 
Identification o f these angiogenesis regulators has enabled the development of 
novel therapeutic approaches in which antisense RNA targets important junc­
tion molecules such as vascular endothelial growth factor (VEGF) and VEGF 
receptors e.g. PEDF.117
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Peptide factors
Last in the spectrum of therapeutic agents used or that could potentially be ad­
ministered to minimise the consequences o f vitreoretinopathies is the employ­
ment o f peptide factors with a major if not exclusive focus on neovascularisa- 
tion. VEGF is recognised as pivotal molecule in pathological angiogenesis and 
vascular permeability and its functional blockade is used as a central therapeutic 
approach. Macugen® (pegaptanib for injection; OSI-Eyetech Pharmaceuticals, 
Long Island), an aptamer,118, 119 Lucentis® (ranibizumab for injection; Genen- 
tech, San Francisco), a FAB fragment derived from a humanized monoclonal 
antibody120 and Avastin®, (Bevacizumab; Genentech, San Francisco) a VEGF- 
A function-blocking antibody, that is approved for the treatment o f colorectal 
cancer,121 are three o f the major pharmaceutical agents used or currently under 
clinical trials, in order to prevent neovessel growth in the retina.
Conclusion
Hereditary vitreoretinopathies are a clinically diverse group of disorders. 
Knowledge o f the molecular aetiology for these diseases has greatly expanded 
over the past decade.
Advances in molecular genetics leading to the identification of novel disease 
genes has enabled a better definition and re-assessment o f the clinical criteria 
that even define specific vitreoretinopathies. The latter has greatly improved 
diagnostics and patient clinical management. Especially with the current boom 
in next generation sequencing technologies and promising advances made in 
the area o f treatment, both in terms of new chemical substances tested or gene 
therapy, a new era in alleviating blindness may be about to begin.
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Summary
Vitreoretinopathies are a diverse group of eye disorders, primarily charac­
terised by degeneration of the vitreous body. Due to their high phenotypic and 
genetic heterogeneity, many o f the causative genes are still unknown and many 
patients remain mis- or even undiagnosed, in the presence o f minimal pheno­
types. The aim of this thesis was to elucidate the genetic basis and gain insights 
of the molecular mechanisms underlying this group o f ophthalmic diseases. By 
doing that, we intended to contribute to improved diagnostics and subsequent 
counseling of patients and their families suffering from vitreoretinopathies. The 
latter may enable better prophylaxis or treatment in selected cases.
To this end, we dived into the molecular pathology o f vitreoretinopathies and 
we used both classical and high-throughput microarray-based approaches (SNP 
arrays) to identify genomic regions (loci) that segregate with inherited diseases. 
Although linkage analysis enables the identification of such genetic loci, those 
are often large regions that contain numerous genes, hampering a fast identifica­
tion o f the underlying gene defect. We therefore used Sanger and next genera­
tion sequencing (NGS) technology to identify the causative disease genes. Work 
described in this thesis reveals that combining linkage data with either classical 
sequencing or NGS technologies, is a powerful method that facilitates the iden­
tification of several remaining disease genes.
In chapter 2, we investigated the role o f VCAN/CSPG2, in seven families with 
Wagner disease and in a family with erosive vitreoretinopathy (ERVR). VCAN 
encodes four major isoforms (V0-V3), three o f which contain glycosaminogly- 
can (GAG) domains and thereby constitute proteoglycans. These multifunc­
tional proteins are believed to contribute to vitreous homeostasis due to their 
intrinsic negative charge. Sequence analysis o f the open reading frame (ORF) 
including 50 bp of flanking intronic sequences o f VCAN, revealed three differ­
ent sequence variants (c.4004-5T>C, c.4004-5T>A, c.4004-1G>A) at the splice 
junction between intron 7 and exon 8. RNA analysis showed the variable activa­
tion o f a cryptic splice site which results in an in-frame 39-nt deletion o f exon 8 
(V0 and V l), and a consistent increase o f the V2 (>40-fold) and V3 (>10-fold) 
splice variants, in all patients with intron 7 splice site sequence changes. The 
conspicuous clustering o f sequence variants in the splice acceptor site o f intron 
7 and the consistent upregulation of the V2 and V3 mRNA isoforms, lead us to 
believe that V0 and/or V l reduction underlies Wagner disease and ERVR. This 
imbalance might have an effect in the overall reduction of the sugar moieties at­
tached to VCAN and thus to the negative charge. This could lead to the collapse 
of the vitreous body, a hallmark of Wagner and ERVR.
Chapter 3 describes two families with autosomal recessive Stickler syndrome 
harboring mutations in COL9A1. Extensive clinical investigation of the families 
included patient evaluation for dysmorphic features as well as ophthalmologic, 
audiologic and radiologic abnormalities. Molecular testing was performed by 
genotype and/or haplotype analysis using SNP arrays and/or polymorphic simple 
sequence repeat markers, followed by direct sequencing o f the COL9A1 ORF.
- 219 -
Chapter -8-
This analysis identified a novel homozygous COL9A1 mutation (p.R507X) in 
two affected Turkish sisters and a previously reported mutation (p.R295X) in a 
Moroccan boy. Moreover, it revealed that distinct vitreous changes and exuda­
tive detachment, reported as a new finding in Stickler syndrome, may enable 
better recognition o f patients likely to carry mutations in COL9A1, despite the 
extensive phenotypic overlap between the different subtypes o f this disease.
In chapter 4, we report 21 novel variants for FZD4, LRP5 and NDP in FEVR 
and Norrie disease patients, and discuss the putative functional consequences of 
those variants in gene function. FZD4, LRP5 and NDP are part of the Wnt sig­
naling network that plays a pivotal role in fundamental aspects o f development, 
including cell fate specification, proliferation, and survival. A comprehensive 
overview o f all mutations in the aforementioned genes is presented together 
with a synopsis o f functional assessments performed in animal models, that 
were found to cause marked alterations in retinal vascular development similar 
to FEVR and Norrie disease as seen in humans.
In chapter 5, we describe the use o f genetic linkage and NGS analysis which 
led to the identification of TSPAN12 as a new gene causative for adFEVR. In 
two sizeable Dutch pedigrees with autosomal dominant FEVR harbouring no 
mutations in the ORF of the known FEVR genes, genome-wide SNP analysis 
revealed a new adFEVR locus o f ~40 Mb on chromosome 7. Moreover, mic­
rosatellite marker analysis suggested similar at risk haplotypes in patients of 
both families. In order to pinpoint the causative disease gene among 338 genes 
present in the 40 Mb linkage interval, we applied targeted NGS in a proband of 
one of the families. Bioinformatic analysis o f the sequence data revealed three 
candidate disease variants. One of these variants was an alanine-to-proline sub­
stitution in the transmembrane 4 superfamily member 12 protein, encoded by 
TSPAN12. Parallel to our study, functional data provided by others implicated 
this protein to regulate the development o f retinal vasculature. Subsequent se­
quence analysis o f TSPAN12 in 11 FEVR families revealed two mutations seg­
regating in five o f them. The p.A237P variant was also shown to be a founder 
mutation in the Netherlands. By identifying TSPAN12 we were among the first 
groups to demonstrate the power o f targeted NGS technology in disease gene 
identification.
In chapter 6, we report the identification of ZNF408 as a strong candidate gene 
for adFEVR by combining linkage analysis and exome sequencing. ZNF408 is 
the fourth autosomal gene described to be causative for FEVR and is mutated 
in two of the 10 families studied. Exome sequencing o f two affected individuals 
combined with genome wide SNP linkage analysis in eight affected members of 
a large Dutch family resulted in the selection of a p.H455Y missense change in 
ZNF408 as the top candidate disease variant. Functional assessment o f the wild 
type and mutant ZNF408 protein in a series o f cellular transfection experiments 
showed that the mutant protein does not enter the nucleus where it is supposed 
to exert its function. Moreover, in co-transfection assays, it causes the wild-type 
protein to be retained in the cytoplasm due to putative di- or multimerisation. 
The latter suggests a possible dominant- negative disease mechanism underly­
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ing the effect o f the p.H455Y mutation. Moreover, this is the first description of 
a putative dominant-negative disease model for FEVR.
In chapter 7, the findings o f the work described in this thesis are discussed 
and implications for both scientists and patients are presented. Disease gene 
identification in patients suffering from vitreoretinopathies is important not only 
because it provides a better understanding o f disease etiology but also more 
accurate and earlier diagnostics for patients. This is o f prime importance for 
identifying mutation carriers before disease occurs. Frequent eye examinations 
may detect retinal detachment at an early stage which will maximise treatment 
outcome. Currently, the area o f genetic screening technologies is advancing at 
unprecedented rates. Sequencing of large targeted loci containing hundreds of 
genes, or even of all exons o f the entire genome, results in thousands o f se­
quence variants identified in each individual. The challenge now lies in effec­
tively combining NGS platforms with other tools e.g. linkage analysis, identity- 
by-descent mapping, bioinformatic analysis and functional characterisation, in 
order to better interpret and discriminate the disease causing variants.
In conclusion, the studies described in this thesis have led to significant new 
insights into the molecular genetics basis o f vitreoretinopathies.
- 221 -
Chapter -8-
Samenvatting
Vitreoretinopathieën vormen een diverse groep van oogaandoeningen, voor­
namelijk gekenmerkt door degeneratie van het glasachtig lichaam. Vanwege 
hun hoge fenotypische en genetische heterogeniteit, zijn veel van de oorzake­
lijke genen nog onbekend. Hierdoor worden veel patiënten, ondanks de aan­
wezigheid van subtiele oogheelkundige afwijkingen, verkeerd, o f zelfs niet ge­
diagnosticeerd. Het doel van dit proefschrift was om inzichten te verwerven in 
de moleculair genetische mechanismen die ten grondslag liggen aan deze groep 
van oogheelkundige aandoeningen. Hiermee willen wij bijdragen aan een betere 
diagnose en de daarop volgende begeleiding van vitreoretinopathie patiënten en 
hun familieleden. Dit laatste kan resulteren in een betere profylaxe o f behandel­
ing in geselecteerde patiënten.
Voor de lokalisatie van de genetische oorzaken hebben wij zowel klassieke als 
grootschalige microarray-gebaseerde benaderingen (SNP arrays) gebruikt. Stan­
daard koppelingsonderzoek resulteert vaak in één o f enkele grote genomische 
gebieden met een groot aantal genen, waardoor een snelle identificatie van het 
oorzakelijke gen niet mogelijk is. We hebben daarom Sanger en next genera­
tion sequencing (NGS) technologie gebruikt om de oorzakelijke ziektegenen te 
identificeren. Uit onze studies blijkt dat het combineren van positionele infor­
matie (uit koppelings- o f homozygotie-onderzoek) met klassieke sequencing of 
NGS technologieën, een krachtige methode is om de oorzakelijke ziektegenen 
te identificeren.
In hoofdstuk 2 hebben we de rol van VCAN/CSPG2 onderzocht in zeven 
gezinnen met de ziekte van Wagner, en in een gezin met erosieve vitreoretinopa- 
thie (ERVR). Het VCAN gen bevat de code voor vier grote isovormen (V0-V3), 
waarvan er drie glycosaminoglycaan (GAG) domeinen bevatten en daarmee 
proteoglycanen vormen. Deze multifunctionele eiwitten worden geacht om bij 
te dragen tot de glasvocht homeostase vanwege hun intrinsieke negatieve la­
ding. Sequentie analyse van het open leesraam (ORF), waaronder 50 bp van de 
flankerende intronische sequenties van VCAN, liet drie verschillende varianten 
zien (c.4004-5T>C, c.4004-5T>A, c.4004-1G>A) in de splice site tussen intron
7 en exon 8. RNA-analyse toonde de variabele activering aan van een cryptische 
splice site die resulteert in een in-frame 39-nt deletie van exon 8 (in V0 en V1), 
en een consistente stijging van de V2 (> 40-voudig) en V3 (> 10-voudig) splice 
varianten, bij alle patiënten met intron 7 splice site defecten. De opvallende 
clustering van sequentievarianten in de splice acceptor site van intron 7 en de 
consistente toename van de V2 en V3 mRNA isovormen, doen vermoeden dat 
V0 en / o f V1 vermindering ten grondslag ligt aan de ziekte van Wagner en 
aan ERVR. Deze onevenwichtigheid kan resulteren in een vermindering van de 
suiker-groepen aan VCAN en dus de negatieve lading. Dit kan leiden tot een 
vroegtijdige ineenstorting (vervloeing) van het glasachtig lichaam, een kenmerk 
van zowel de ziekte van Wagner als ERVR.
Hoofdstuk 3 beschrijft twee families met autosomaal recessief Stickler-syn- 
droom die mutaties dragen in het COL9A1 gen. Uitgebreid klinisch onderzoek
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van de gezinnen omvatte de evaluatie van dysmorfe kenmerken alsmede het 
opsporen van oogheelkundige, audiologische en radiologische afwijkingen. Na 
een positionele analyse middels SNP arrays en hoog-polymorfe DNA markers, 
gevolgd door directe sequentiebepaling van het COL9A1 ORF, zijn we erin 
geslaagd om een homozygote COL9A1 mutatie (p.R507X) in twee aangedane 
Turkse zussen te detecteren, alsmede een reeds eerder gerapporteerde muta­
tie (p.R295X) in een Marokkaanse jongen. Bovendien werden verschillende 
glasvocht afwijkingen en exsudatieve netvliesloslating gevonden in deze vorm 
van het Stickler-syndroom, waardoor de herkenning van patiënten met COL9A1 
mutaties zou kunnen worden vergemakkelijkt ondanks de grote fenotypische 
overlap tussen de verschillende subtypes van deze ziekte.
In hoofdstuk 4 hebben we 21 nieuwe varianten in FZD4, LRP5 en NDP geï­
dentificeerd in patiënten met de ziekte FEVR en de ziekte van Norrie, en hebben 
we de mogelijke functionele gevolgen van deze varianten op de functie van de 
eiwitten besproken. FZD4, LRP5 en NDP zijn onderdeel van het Wnt-signaler- 
ings netwerk, dat een centrale rol speelt in de fundamentele aspecten van de cel 
ontwikkeling, inclusief cel-identiteit specificatie, -proliferatie en -overleving. 
Bovendien presenteren we een uitgebreide samenvatting van alle mutaties in 
de bovengenoemde genen, samen met een overzicht van de functionele studies 
die zijn verricht in proefdieren, die model staan voor de afwijkingen in retinale 
vasculaire ontwikkeling zoals die ook in patiënten met de ziekte FEVR en de 
ziekte van Norrie aanwezig zijn.
In hoofdstuk 5 beschrijven we het gebruik van genetisch koppelingsonder- 
zoek en NGS-analyse die samen hebben geleid tot de identificatie van TSPAN12 
als een nieuw gen voor adFEVR. In twee grote Nederlandse families met au­
tosomaal dominante FEVR waarin geen mutaties in het ORF van de bekende 
FEVR genen waren geïdentificeerd, vonden wij na genoom-wijde SNP-analyse 
een nieuw adFEVR locus van ~40 Mb op chromosoom 7. Microsatelliet mark­
er analyse toonde vervolgens aan dat beide families een identiek segment op 
chromosoom 7 bevatten met daarin waarschijnlijk hetzelfde gendefect. Om het 
ziektegen te lokaliseren tussen de 338 aanwezige genen in het 40 Mb locus, is 
er ‘targeted’ NGS uitgevoerd op een proband van één van de families. Bioin­
formatica analyse van de sequentie data onthulden drie varianten die verant­
woordelijk zouden kunnen zijn voor de ziekte. Eén van deze varianten was een 
missense verandering van alanine naar proline in het transmembraan 4 super­
familie member 12 eiwit, gecodeerd door TSPAN12. Parallel aan onze studie, 
lieten functionele data in andere studies zien dat dit eiwit betrokken is bij de 
regulatie van de ontwikkeling van de bloedvatvorming in het netvlies. Sequentie 
analyse van TSPAN12 in 11 FEVR families toonde twee mutaties aan, die sa­
men verantwoordelijk waren voor de ziekte in vijf families. De p.A237P vari­
ant bleek een ‘founder’ mutatie te zijn in Nederland. Met het identificeren van 
TSPAN12 waren wij één van de eerste groepen die de kracht van ‘targeted’ NGS 
technologie hebben aangetoond bij het identificeren van ziektegenen.
In hoofdstuk 6 beschrijven wij de identificatie van ZNF408 als een sterk kan­
didaat gen voor adFEVR door het combineren van koppelingsonderzoek en
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exome sequencing. ZNF408 is het vierde autosomale ziektegen dat wordt be­
schreven voor FEVR, en is gemuteerd in twee van de tien door ons bestudeerde 
families. Exome sequencing van twee aangedane personen gecombineerd met 
genoom-wijde SNP linkage analyses in acht aangedane leden van een grote 
Nederlandse familie resulteerde in het vinden van een missense verandering 
(p.H455Y) in ZNF408 als de meest waarschijnlijke variant als oorzaak van de 
ziekte. Functionele studies van het wildtype en mutant ZNF408 eiwit in een 
reeks van cellulaire transfectie experimenten toonden aan dat het mutante eiwit 
de celkern niet binnendringt waar het normaliter zijn vermeende functie uit­
voert. Daarnaast werd in co-transfectie-assays van zowel mutant als wildtype 
ZNF408 eiwit, het wildtype eiwit in het cytoplasma ‘vastgehouden’, mogelijk 
als gevolg van binding van het mutant ZNF408 aan het wild-type ZNF408 ei­
wit. Dit laatste suggereert een mogelijk dominant-negatief ziekte mechanisme 
dat ten grondslag ligt aan de werking van de p.H455Y mutatie. Hiermee is dit 
de eerste beschrijving van zulk een dominant-negatief ziektemodel voor FEVR.
In hoofdstuk 7 van dit proefschrift worden de bevindingen en de implicaties 
van ons werk besproken, voor zowel wetenschappers als patiënten. Ziektegen 
identificatie in patiënten die lijden aan vitreoretinopathies is niet alleen belan­
grijk omdat het zorgt voor een beter begrip van het ontstaan van ziekten, maar 
ook voor een nauwkeurigere en vroegere diagnose voor patiënten. Dit is van 
groot belang voor het identificeren van mutatiedragers voordat de ziekte zich 
openbaart. Frequent oogonderzoek kan netvliesloslating in een vroeg stadium 
detecteren, waardoor het maximale uit de behandeling wordt gehaald. De mo­
gelijkheden van genetische studies nemen in een ongekend tempo toe. Sequentie 
analyse van delen van het humane genoom met daarin honderden genen, of zelfs 
van alle exonen van het hele genoom, resulteert in duizenden sequentievarianten 
die in elk individu geïdentificeerd worden. Voor het selecteren van de oorzake­
lijke mutaties te midden van het groot aantal niet-oorzakelijke varianten ligt nu 
de uitdaging om NGS-technologie te combineren met andere methoden zoals 
koppelingsonderzoek, homozygotie analyse, bioinformatica analyse en functio­
nele karakterisering.
Concluderend hebben de studies beschreven in dit proefschrift geleid tot be­
langrijke nieuwe inzichten in de moleculair genetische basis van vitreoretino- 
pathieën.
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Abbreviations
A Adenine (DNA/RNA)
A Alanine (Ala) (amino acid)
AAV Adeno-associated virus
AD Anno Domini
Ad Autosomal dominant
ADAMTS9 A Disintegrin And Mettaloproteinase with Thrombospondin
APC Adenomatous polyposis coli
ar Autosomal recessive
ASMA Alpha-smooth muscle actin
ATP Adenosine-5'-triphosphate
BBS Bardet-Biedl syndrome
BC Before Christ
BMI Bone mass index
bp Base pair
C Cytosine (DNA/RNA)
C Cysteine (Cys) (amino acid)
CCD Charge coupled device
cDNA Complementrary deoxyribonucleic acid
CF Cystic fibrosis
cM centiMorgan
CNV Copy number variation
CSPG2 Chondoitin sulphate proteoglycan 2
D Aspartic acid (Asp) (amino acid)
dp Deeper plexus
DMD Duchenne muscular dystrophy
DNA Deoxyribonucleic acid
E Glutamic acid (Glu) (amino acid)
EBV Epstein-Barr virus
ECM Extracellular matrix
EDTA Ethylenediaminetetraacetic acid
ERG Electroretinogram
EGF Epidermal growth factor
ERVR Erosive vitreoretinopathy
F Phenylalanine (Phe) (amino acid)
FAG Fluorescence angiography
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FEVR Familial exudative vitreoretinopathy
Fz Frizzled
FZD Frizzled homolog
FZD4 Frizzled homolog 4
G Guanine (DNA/RNA)
G Glycine (Gly) (amino acid)
GABA Gamma-aminobutyric acid
GAG Glycosaminoglycan
GCL Ganglion cell layer
H Histidine (His) (amino acid)
HBM High bone mass trait
hdf Heart defect
hv Hyaloid vasculature
Hz Hertz
I Isoleucine (Ile (amino acid)
ILM Internal limiting membrane
INL Inner nuclear layer
IVS Intervening sequence
ISCEV International Society for Electrophysiology o f Vision
K Lysine (Lys) (amino acid)
kDa Kilo Dalton
L Leucine (Leu) (amino acid)
lacZ Lactose Z
LCA Leber congenital amaurausis
LDL Low-density lipoprotein
LEF Lymphoid enhancer-binding factor
LOD Logarithm of odds
LRPs Low density lipoprotein receptor-related proteins
LRP5 Low density lipoprotein receptor-related protein 5
LRP6 Low density lipoprotein receptor-related protein 6
M Methionine (Met) (amino acid)
Mb Megabase
mg milligram
ml milliliter
MIM Mendelian inheritance in man
miR MicroRNA
mm Millimetre
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M-MLV Moloney murine leukemia virus reverse transcriptase
mRNA Messenger ribonucleic acid
miRNA Micro ribonucleic acid
N Asparagine (Asn) (amino acid)
nt Nucleotide
ND Norrie disease
NDP Norrie disease pseudoglioma
NGS Next generations sequencing
NMD Nonsense mediated decay
OCT Optical coherence tomography
OMIM Online Mendelian inheritance in man
ONL Outer nuclear layer
OPL Outer plexiform layer
OS Outer segments
OPPG Osteoporosis-Pseudoglioma syndrome
P Proline (Pro) (amino acid)
p. Protein
PBS Phosphate buffered saline
PEDF Pigment epithelium-derived factor
PCR Polymerase chain reaction
PHPV Persistent foetal vasculature syndrome
PTC Premature termination codon
Q Glutamine (Gln) (amino acid)
qPCR Quantitative polymerase chain reaction
R Arginine (Arg) (amino acid)
rAAV Recombinant adeno-associated virus
rAd Recombinant adenovirus
RRD Rhegmatogenous retinal detachment
ROP Retinopathy of prematurity
RNA Ribonucleic acid
RT-PCR Reverse transcription polymerase chain reaction
RPE Retinal pigment epithelium
RPE65 Retinal pigment epithelium-specific protein 65kDa
rRNA Ribosomal ribonucleic acid
S Serine (Ser) (amino acid)
siRNA Small interfering ribonucleic acid
smsDGE Single-molecule sequencing digital gene expression
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SNP Single nucleotide polymorphism
SSR Single sequence repeat
STL1 Stickler type 1
STL2 Stickler type 2
STL3 Stickler type 3
T Thymine (DNA/RNA)
T Threonine (Thr) (amino acid)
TCF Transcription factor
tRNA Transfer ribonucleic acid
TSPAN12 Tetraspanin 12
TSPAN Tetraspanin
U Uracil (RNA)
UTR Untranslated region
V Valine (Val) (amino acid)
VA Visual acuity
VCAN Versican
VEGF Vascular endothelial growth factor
W Tryptophan (Trp) (amino acid)
WNT Wingless-type MMTV integration site family
WNT2 Wingless-type MMTV integration site family, member 2
WNT16 Wingless-type MMTV integration site family, member 16
wt Wild type
X Stop
xl X-linked
Y Tyrosine 
ZNF Zinc finger 
ZNF408 Zinc finger 408 
^g microgram
^l microliter
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